

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number  
**WO 01/57226 A1**(51) International Patent Classification<sup>7</sup>: **C12N 15/62**,  
C07K 16/28, 16/46, C12N 15/13, 15/63, 5/10, A61K  
39/395, A61P 9/10, 19/02, 31/18, 37/06Siobhan [IE/GB]; 39 Dorset Mews, Finchley, London  
N3 2BN (GB). **O'KEEFE, Theresa** [US/US]; 61 Parkers  
Lane, Waltham, MA 02453 (US).

(21) International Application Number: PCT/US01/03537

(74) Agents: **TREANNIE, Lisa, M.** et al.; Hamilton, Brook,  
Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA  
02421 (US).

(22) International Filing Date: 2 February 2001 (02.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/497,625 3 February 2000 (03.02.2000) US(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 09/497,625 (CIP)  
Filed on 3 February 2000 (03.02.2000)(71) Applicant (for all designated States except US): **MIL-  
LENNIUM PHARMACEUTICALS, INC.** [US/US]; 75  
Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LAROSA, Gregory,  
J.** [US/US]; 325 Woodward Street, Newton, MA 02468  
(US). **HORVATH, Christopher** [US/US]; 209 Plain  
street, Taunton, MA 02780 (US). **NEWMAN, Walter**  
[US/US]; 3 Durham Street, No. 3, Boston, MA 02115  
(US). **JONES, S., Tarran** [GB/GB]; 1 Christ Church Cres-  
cent, Radlett, Hertfordshire WD7 8AG (GB). **O'BRIEN,**(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR

(57) Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor (2) (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

**WO 01/57226 A1**

## HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR

### RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Application Serial No. 09/497,625, filed February 3, 2000, which is a continuation-in-part of U.S. Application Serial No. 09/359,193, filed July 22, 1999, which is a continuation-in-part of U.S. Application Serial No. 09/121,781, filed July 23, 1998, the entire teachings of all of which are incorporated herein by reference.

### BACKGROUND OF THE INVENTION

Over the past several years a growing family of leukocyte chemoattractant/activating factors, termed chemokines, has been described (Oppenheim, J.J. *et al.*, *Annu. Rev. Immunol.*, 9:617-648 (1991); Schall and Bacon, *Curr. Opin. Immunol.*, 6:865-873 (1994); Baggiolini, M., *et al.*, *Adv. Immunol.*, 55:97-179 (1994)). Members of this family are produced and secreted by many cell types in response to early inflammatory mediators such as IL-1 $\beta$  or TNF $\alpha$ . The chemokine superfamily comprises two main branches: the  $\alpha$ -chemokines (or CXC chemokines) and the  $\beta$ -chemokines (CC chemokines). The  $\alpha$ -chemokine branch includes proteins such as IL-8, neutrophil activating peptide-2 (NAP-2), melanoma growth stimulatory activity (MGSA/gro or GRO $\alpha$ ), and ENA-78, each of which have attracting and activating effects predominantly on neutrophils. The members of the  $\beta$ -chemokine branch affect other cell types such as monocytes, lymphocytes, basophils, and eosinophils (Oppenheim, J.J. *et al.*, *Annu. Rev. Immunol.*, 9:617-648 (1991); Baggiolini, M., *et al.*, *Adv. Immunol.*, 55:97-179 (1994); Miller and Krangel,

- Crit. Rev. Immunol.*, 12:17-46 (1992); Jose, P.J., *et al.*, *J. Exp. Med.*, 179:881-118 (1994); Ponath, P.D., *et al.*, *J. Clin. Invest.*, 97:604-612 (1996)), and include proteins such as monocyte chemotactic proteins 1-4 (MCP-1, MCP-2, MCP-3, and MCP-4), RANTES, and macrophage inflammatory proteins (MIP-1 $\alpha$ , MIP-1 $\beta$ ).
- 5 Recently a new class of membrane-bound chemokines designated CX3C chemokines has been identified (Bazan, J.F., *et al.*, *Nature* 385:640-644 (1997)). Chemokines can mediate a range of pro-inflammatory effects on leukocytes, such as triggering of chemotaxis, degranulation, synthesis of lipid mediators, and integrin activation (Oppenheim, J.J. *et al.*, *Annu. Rev. Immunol.*, 9:617-648 (1991);
- 10 Baggiolini, M., *et al.*, *Adv. Immunol.*, 55:97-179 (1994); Miller, M.D. and Krangel, M.S., *Crit. Rev. Immunol.*, 12:17-46 (1992)). Lately, certain  $\beta$ -chemokines have been shown to suppress HIV-1 infection of human T cell lines *in vitro* (Cocchi, F., *et al.*, *Science (Wash. DC)*, 270:1811-1815 (1995)).

- Chemokines bind to 7 transmembrane spanning (7TMS) G protein-coupled
- 15 receptors (Murphy, P.M., *Annu. Rev. Immunol.*, 12:593-633 (1994)). Some known receptors for the CC or  $\beta$  chemokines include CCR1, which binds MIP-1 $\alpha$  and RANTES (Neote, K., *et al.*, *Cell*, 72:415-425 (1993); Gao, J.L., *J. Exp. Med.*, 177:1421-1427 (1993)); CCR2, which binds chemokines including MCP-1, MCP-2, MCP-3 and MCP-4 (Charo, I.F., *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:2752-2756
- 20 (1994); Myers, S.J., *et al.*, *J. Biol. Chem.*, 270:5786-5792 (1995); Gong *et al.*, *J. Biol. Chem.* 272:11682-11685 (1997); Garcia-Zepeda *et al.*, *J. Immunol.* 157:5613-5626 (1996)); CCR3, which binds chemokines including eotaxin, RANTES and MCP-3 (Ponath, P.D., *et al.*, *J. Exp. Med.*, 183:2437-2448 (1996)); CCR4, which has been found to signal in response to MCP-1, MIP-1 $\alpha$ , and RANTES (Power,
- 25 C.A., *et al.*, *J. Biol. Chem.*, 270:19495-19500 (1995)); and CCR5, which has been shown to signal in response to MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES (Boring, L., *et al.*, *J. Biol. Chem.*, 271 (13):7551-7558 (1996); Raport, C.J., *J. Biol. Chem.*, 271:17161-17166 (1996); and Samson, M. *et al.*, *Biochemistry*, 35:3362-3367 (1996)).

- CCR2 is expressed on the surface of several leukocyte subsets, and appears
- 30 to be expressed in two slightly different forms (CCR2a and CCR2b) due to alternative splicing of the mRNA encoding the carboxy-terminal region (Charo *et al.*, *Proc. Natl. Acad. Sci. USA* 91:2752-2756 (1994)). MCP-1 acts upon monocytes,

lymphocytes and basophils, inducing chemotaxis, granule release, respiratory burst and histamine and cytokine release. Studies have suggested that MCP-1 is implicated in the pathology of diseases such as rheumatoid arthritis, atherosclerosis, granulomatous diseases and multiple sclerosis (Koch, *J. Clin. Invest.* 90:772-79 (1992); Hosaka *et al.*, *Clin. Exp. Immunol.* 97:451-457 (1994); Schwartz *et al.*, *Am. J. Cardiol.* 71(6):9B-14B (1993); Schimmer *et al.*, *J. Immunol.* 160:1466-1471 (1998); Flory *et al.*, *Lab. Invest.* 69:396-404 (1993); Gong *et al.*, *J. Exp. Med.* 186:131-137 (1997)). Additionally, CCR2 can act as a co-receptor for HIV (Connor *et al.*, *J. Exp. Med.* 185:621-628 (1997)). Thus, CCR2 receptor antagonists may represent a new class of important therapeutic agents.

#### SUMMARY OF THE INVENTION

The present invention relates to an antibody (immunoglobulin) or functional fragment thereof (e.g., an antigen-binding fragment) which binds to a mammalian CC-chemokine receptor 2 (also referred to as CCR2, CKR-2, MCP-1RA or MCP-1RB) or portion of the receptor (anti-CCR2). In one embodiment, the antibody of the present invention or fragment thereof has specificity for human or rhesus CCR2 or a portion thereof. In another embodiment, the antibody or fragment of the invention blocks binding of a ligand (e.g., MCP-1, MCP-2, MCP-3, MCP-4) to the receptor and inhibits function associated with binding of the ligand to the receptor (e.g., leukocyte trafficking). For example, as described herein, antibodies and fragments thereof of the present invention which bind human or rhesus CCR2 or a portion thereof, can block binding of a chemokine (e.g., MCP-1, MCP-2, MCP-3, MCP-4) to the receptor and inhibit function associated with binding of the chemokine to the receptor. In one embodiment, the antibody is monoclonal antibody (mAb) LS132.1D9 (1D9) or an antibody which can compete with 1D9 for binding to human CCR2 or a portion of human CCR2. Functional fragments of the foregoing antibodies are also envisioned.

In another embodiment, the antibody or functional fragment of the present invention binds human CCR2 or a portion thereof, and inhibits human immunodeficiency virus (HIV) binding to the receptor, thereby inhibiting function associated with binding of HIV to the receptor (e.g., HIV antigen release and



infectivity). In one embodiment, the antibody is monoclonal antibody 1D9 or an antibody which can compete with 1D9 for binding to human CCR2 or a portion of human CCR2.

The present invention also relates to an antibody or functional fragment thereof (e.g., an antigen-binding fragment) which binds to a mammalian CCR2 or portion of the receptor and provides increased fluorescent staining intensity of CCR2 or compositions comprising CCR2 relative to other anti-CCR2 antibodies. In one embodiment, the antibody is monoclonal antibody 1D9 or LS132.8G2 (8G2) or an antibody which can compete with 1D9 or 8G2 for binding to human CCR2 or a portion of human CCR2.

The present invention also relates to a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2, said immunoglobulin comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region of the gamma type). In one embodiment, the humanized immunoglobulin or fragment thereof described herein can compete with 1D9 for binding to CCR2. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin is derived from monoclonal antibody 1D9 (e.g., an immunoglobulin comprising the variable regions of the light and heavy chains as shown in Figure 7 (SEQ ID NO: 9) and Figure 8 (SEQ ID NO: 10), respectively).

For example, the humanized immunoglobulin or antigen-binding fragment thereof can comprise an antigen binding region comprising at least one complementarity determining region (CDR) of nonhuman origin, and a framework region (FR) derived from a human framework region. In one aspect, the humanized immunoglobulin having binding specificity for CCR2 comprises a light chain comprising at least one CDR derived from an antibody of nonhuman origin which binds CCR2 and a FR derived from a light chain of human origin (e.g., from HF-21/28), and a heavy chain comprising a CDR derived from an antibody of nonhuman origin which binds CCR2 and a FR derived from a heavy chain of human origin (e.g., from 4B4'CL). In another aspect, the light chain comprises three CDRs

derived from the light chain of the 1D9 antibody, and the heavy chain comprises three CDRs derived from the heavy chain of the 1D9 antibody.

The present invention also relates to humanized immunoglobulin light chains and antigen-binding fragments thereof (e.g., comprising CDR1, CDR2 and CDR3 of  
5 the light chain of the 1D9 antibody, and a human light chain FR), and to humanized immunoglobulin heavy chains and antigen-binding fragments thereof (e.g., comprising CDR1, CDR2 and CDR3 of the heavy chain of the 1D9 antibody, and a human heavy chain FR). In a preferred embodiment, the invention relates to humanized heavy and light chains described herein (e.g., a humanized light chain  
10 comprising the variable region of the light chain shown in Figure 7 (SEQ ID NO: 9), a humanized heavy chain comprising the variable region of the heavy chain shown in Figure 8 (SEQ ID NO: 10). Also encompassed are humanized immunoglobulins comprising one or more humanized light and/or heavy chains.

The subject invention also relates to a humanized immunoglobulin or  
15 antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain and a light chain, wherein said light chain comprises at least one complementarity determining region derived from murine monoclonal antibody 1D9 and a framework region derived from the light chain of human antibody HF-21/28, and wherein said heavy chain comprises at least one complementarity determining  
20 region derived from murine monoclonal antibody 1D9 and a framework region derived from the heavy chain of human antibody 4B4'CL. In one embodiment, the light chain comprises three complementarity determining regions derived from the light chain of the 1D9 antibody, and the heavy chain comprises three complementarity determining regions derived from the heavy chain of the 1D9  
25 antibody. In another embodiment, the complementarity determining regions derived from the light chain of 1D9 are amino acids 24-39 of SEQ ID NO: 9, amino acids 55-61 of SEQ ID NO: 9 and amino acids 94-102 of SEQ ID NO: 9, and the complementarity determining regions derived from the heavy chain of 1D9 are amino acids 31-35 of SEQ ID NO: 10, amino acids 50-68 of SEQ ID NO: 10 and  
30 amino acids 101-106 of SEQ ID NO: 10.

The invention further relates to a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a light

chain and a complementary heavy chain, wherein said light chain comprises a variable region comprising SEQ ID NO: 12. The invention also relates to a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain and a complementary light chain, wherein said heavy chain comprises a variable region comprising SEQ ID NO: 17. In a preferred embodiment, the invention relates to a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain and a light chain, wherein said light chain comprises a variable region comprising SEQ ID NO: 12, and wherein said heavy chain comprises a variable region comprising SEQ ID NO: 17. In one embodiment, the humanized immunoglobulin or antigen-binding fragment can compete with murine antibody 1D9 for binding to CCR2. In a further embodiment, the humanized immunoglobulin or antigen-binding fragment inhibits binding of a ligand to CCR2.

The invention further relates to isolated nucleic acid molecules comprising a nucleic acid sequence which encodes a humanized immunoglobulin of the present invention (e.g., a single chain antibody), as well as to isolated nucleic acid molecules comprising a sequence which encodes a humanized immunoglobulin light chain (e.g., comprising nucleotides 52-390 of SEQ ID NO: 95) or heavy chain (e.g., comprising nucleotides 58-411 of SEQ ID NO: 96) of the present invention. For example, the present invention provides a gene (e.g., a fused gene) encoding a humanized immunoglobulin light or heavy chain comprising a first nucleic acid sequence encoding an antigen binding region derived from murine 1D9 monoclonal antibody; and a second nucleic acid sequence encoding at least a portion of a constant region of an immunoglobulin of human origin.

The present invention further relates to a construct comprising a nucleic acid molecule encoding a humanized immunoglobulin having binding specificity for CCR2 or a chain of such an immunoglobulin. For example, an expression vector comprising a gene (e.g., a fused gene) encoding a humanized immunoglobulin light chain, comprising a nucleotide sequence encoding a CDR derived from a light chain of a nonhuman antibody having binding specificity for CCR2, and a framework region derived from a light chain of human origin, is provided. An expression vector comprising a gene encoding a humanized immunoglobulin heavy chain,

comprising a nucleotide sequence encoding a CDR derived from a heavy chain of a nonhuman antibody having binding specificity for CCR2, and a framework region derived from a heavy chain of human origin is another example of such a construct.

The present invention also relates to a host cell comprising a nucleic acid molecule of the present invention, including one or more constructs comprising a nucleic acid molecule of the present invention. In one embodiment, the invention relates to a host cell comprising a first recombinant nucleic acid encoding a humanized immunoglobulin light chain, and a second recombinant nucleic acid encoding a humanized immunoglobulin heavy chain, said first nucleic acid comprising a nucleotide sequence encoding a CDR derived from the light chain of murine 1D9 antibody and a framework region derived from a light chain of human origin; and said second nucleic acid comprising a nucleotide sequence encoding a CDR derived from the heavy chain of murine 1D9 antibody and a framework region derived from a heavy chain of human origin.

The present invention also provides a method of preparing a humanized immunoglobulin comprising maintaining a host cell of the present invention under conditions appropriate for expression of a humanized immunoglobulin, whereby a humanized immunoglobulin chain(s) is expressed and a humanized immunoglobulin is produced. The method can further comprise the step of isolating the humanized immunoglobulin.

The humanized immunoglobulins of the present invention can be less immunogenic than their murine or other nonhuman counterparts. Thus, the humanized immunoglobulins described herein can be used as therapeutic agents in humans, for example to control lymphocyte homing to mucosal lymphoid tissue, thereby, reducing inflammatory responses.

The invention further relates to a humanized immunoglobulin of the present invention for use in diagnosis or therapy (including prophylaxis). In one embodiment, the invention relates to a humanized immunoglobulin of the present invention for use in the treatment of diseases associated with leukocyte infiltration of tissues, for example, in the treatment of inflammatory diseases, autoimmune diseases, graft rejection, HIV infection and monocyte-mediated disorders such as atherosclerosis.

In another aspect, the invention relates to use of a humanized immunoglobulin of the present invention for the manufacture of a medicament for the treatment of diseases associated with leukocyte infiltration of tissues, for example, in the treatment of inflammatory diseases, autoimmune diseases,  
5 monocyte-mediated disorders such as atherosclerosis, graft rejection, or HIV infection.

The present invention further relates to a method of inhibiting the interaction of a cell bearing mammalian (e.g., human, non-human primate or murine) CCR2 with a ligand thereof, comprising contacting the cell with an effective amount of an  
10 antibody or functional fragment thereof which binds to a mammalian CCR2 or a portion of CCR2. Suitable cells include granulocytes, leukocytes, such as monocytes, macrophages, basophils and eosinophils, mast cells, and lymphocytes including T cells (e.g., CD8+ cells, CD4+ cells, CD25+ cells, CD45RO+ cells), and other cells expressing CCR2 such as a recombinant cell expressing CCR2 (e.g.,  
15 transfected cells). In a particular embodiment, the antibody is 1D9 or an antibody which can compete with 1D9 for binding to human CCR2 or a portion of human CCR2.

Another embodiment of the invention relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a chemokine, comprising  
20 contacting said cell with an effective amount of an antibody or functional fragment thereof which binds to CCR2 or a portion of said receptor. In one embodiment of the method, the antibody or functional fragment thereof is any one or more of 1D9, an antigen-binding fragment of 1D9 or an antibody or fragment thereof having an epitopic specificity which is the same as or similar to that of 1D9. Furthermore, the  
25 invention relates to a method of inhibiting a function associated with binding of a chemokine to CCR2, comprising administering an effective amount of an antibody or functional fragment thereof which binds to a mammalian CCR2 protein or a portion of said receptor. In one aspect of the method, the antibody or functional fragment thereof is any one or more of 1D9, an antigen-binding fragment of 1D9 or  
30 an antibody or fragment thereof having an epitopic specificity which is the same as or similar to that of 1D9.

Another aspect of the invention is a method of identifying expression of a mammalian CCR2 or portion of the receptor by a cell. According to the method, a composition comprising a cell or fraction thereof (e.g., a membrane fraction) is contacted with an antibody or functional fragment thereof (e.g., 1D9 or 8G2) which  
5 binds to a mammalian CCR2 protein or portion of the receptor under conditions appropriate for binding of the antibody thereto, and the formation of a complex between said antibody or fragment and said protein or portion thereof is detected. Detection of the complex, directly or indirectly, indicates the presence of the receptor on the cell. The present invention also relates to a kit for use in detecting  
10 the presence of CCR2 or a portion thereof in a biological sample, comprising an antibody or functional fragment thereof which binds to a mammalian CC-chemokine receptor 2 or a portion of said receptor, and one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or fragment and said protein or portion thereof.

15 Also encompassed by the present invention are methods of identifying additional ligands or other substances which bind a mammalian CCR2 protein, including inhibitors and/or promoters of mammalian CCR2 function. For example, agents having the same or a similar binding specificity as that of an antibody of the present invention or functional fragment thereof can be identified by a competition  
20 assay with said antibody or fragment. Thus, the present invention also encompasses methods of identifying ligands or other substances which bind the CCR2 receptor, including inhibitors (e.g., antagonists) or promoters (e.g., agonists) of receptor function. In one embodiment, cells which naturally express CCR2 receptor protein or suitable host cells which have been engineered to express a CCR2 receptor or  
25 variant encoded by a nucleic acid introduced into said cells are used in an assay to identify and assess the efficacy of ligands, inhibitors or promoters of receptor function. Such cells are also useful in assessing the function of the expressed receptor protein or polypeptide.

Thus, the invention also relates to a method of detecting or identifying an  
30 agent which binds a mammalian CCR2 or ligand binding variant thereof, comprising combining an agent to be tested, an antibody or antigen-binding fragment of the present invention (e.g., monoclonal antibody 1D9, an antibody having an epitopic

specificity which is the same as or similar to that of 1D9, antigen-binding fragments of 1D9, monoclonal antibody 8G2, an antibody having an epitopic specificity which is the same as or similar to that of 8G2, and antigen-binding fragments of 8G2) and a composition comprising a mammalian CCR2 protein or a ligand binding variant thereof. The foregoing components can be combined under conditions suitable for binding of the antibody or antigen-binding fragment to mammalian CCR2 protein or a ligand binding variant thereof, and binding of the antibody or fragment to the mammalian CCR2 protein or ligand binding variant is detected or measured, either directly or indirectly, according to methods described herein or other suitable methods. A decrease in the amount of complex formed relative to a suitable control (e.g., in the absence of the agent to be tested) is indicative that the agent binds said receptor or variant. The composition comprising a mammalian CCR2 protein or a ligand binding variant thereof can be a membrane fraction of a cell bearing recombinant CCR2 protein or ligand binding variant thereof. The antibody or fragment thereof can be labeled with a label such as a radioisotope, spin label, antigen label, enzyme label, fluorescent group and chemiluminescent group. These and similar assays can be used to detect agents, including ligands (e.g., chemokines which interact with CCR2) or other substances, including inhibitors or promoters of receptor function, which can bind CCR2 and compete with the antibodies described herein for binding to the receptor.

According to the present invention, ligands, inhibitors or promoters of receptor function can be identified in a suitable assay, and further assessed for therapeutic effect. Inhibitors of receptor function can be used to inhibit (reduce or prevent) receptor activity, and ligands and/or promoters can be used to induce (trigger or enhance) normal receptor function where indicated. The present invention also provides a method of treating inflammatory diseases, autoimmune diseases, atherosclerosis, and graft rejection, or HIV infection, comprising administering an inhibitor of receptor function (e.g., chemokine binding or HIV binding) to an individual (e.g., a mammal, such as a human). The present invention further provides a method of stimulating receptor function by administering a novel ligand or promoter to an individual, providing a new approach to selective

stimulation of leukocyte function, which is useful, for example, in the treatment of infectious diseases and cancer.

Another aspect of the invention relates to a method of inhibiting HIV infection of a cell which expresses a mammalian CCR2 or portion thereof,  
5 comprising contacting the cell with an effective amount of an antibody or functional fragment thereof which binds to a mammalian CCR2 or portion of the receptor and inhibits HIV binding and infection. In a particular embodiment of the invention, the antibody or functional fragment thereof is any of 1D9, an antibody having an epitopic specificity which is the same as or similar to that of 1D9, an antibody which  
10 can compete with 1D9 for binding to human CCR2, and antigen-binding fragments thereof.

Also encompassed by the present invention is a method of inhibiting (e.g., treating) HIV in a patient, comprising administering to the patient an effective amount of an antibody or functional fragment thereof which binds to a mammalian  
15 CCR2 or a portion of said receptor and inhibits HIV binding to the CCR2 receptor. The anti-CCR2 antibody or fragment can be administered alone or in combination with one or more additional therapeutic agents, e.g., one or more antibodies which bind a co-receptor for HIV infection and inhibit binding to said co-receptor, such as an anti-CCR3, anti-CCR5, and/or anti-CXCR4 antibody.

20 Another aspect of the invention also relates to a method of preventing or inhibiting HIV infection in an individual, comprising administering to the individual an effective amount of an antibody or functional fragment thereof which binds to CCR2 and inhibits HIV binding to CCR2. According to the method, preventing HIV infection includes treatment in order to prevent (reduce or eliminate) infection  
25 of new cells in an infected individual or in order to prevent infection in an individual who may be, may have been or has been exposed to HIV. For example, individuals such as an HIV infected individual, a fetus of an HIV infected female, or a health care worker can be treated according to the method of the present invention.

The present invention also encompasses a method of inhibiting leukocyte  
30 trafficking in a patient, comprising administering to the patient an effective amount of an antibody or functional fragment thereof which binds to a mammalian CCR2 or



-12-

portion of said receptor and inhibits function associated with binding of a ligand to the receptor.

The present invention also relates to a method of inhibiting or treating CCR2-mediated disorders, such as inflammatory disorders, comprising  
5 administering to a patient an effective amount of an antibody or functional fragment thereof which binds to a mammalian CCR2 or portion of said receptor and inhibits CCR2-mediated function. For example, the invention relates to a method of inhibiting or treating stenosis or restenosis of the vasculature comprising  
10 administering to a patient an effective amount of an antibody or functional fragment thereof which binds to a mammalian CCR2 or portion of said receptor and inhibits CCR2-mediated function.

The present invention further relates to an antibody or fragment thereof as described herein (e.g., monoclonal antibody 1D9 or an antigen-binding fragment thereof) for use in therapy (including prophylaxis) or diagnosis, and to the use of  
15 such an antibody or fragment for the manufacture of a medicament for the treatment of a CCR2-mediated disorder, or other disease or inflammatory condition as described herein.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a fluorescence activated cell scanning (FACS) histogram profile  
20 illustrating that mAbs 1D9 and 8G2 stain CCR2 transfectants but not CCR5 or CCR1 transfectants. L1/2 (also referred to herein as L1.2) murine pre-B lymphoma host cells were transfected with CCR2, CCR5 and CCR1 as indicated, and stained with antibodies with different receptor specificities. Staining was analyzed by flow cytometry.

25 Figure 2 is a FACS dot plot showing expression of CCR2 on most monocytes, a subpopulation of lymphocytes and a small subset of granulocytes. Whole blood cells were stained with one of three anti-CCR2 mAbs (5A11, generated using a peptide consisting of the first 32 amino acids of the CCR2 amino-terminus as an immunogen, and 1D9 and 8G2 generated as described herein using CCR2b  
30 L1/2 cell transfectants as the immunogen). Staining was analyzed by flow cytometry, and the lymphocyte, granulocyte and monocyte populations were gated

using the forward and side light scatter. The X-axis represents forward light scatter (a measure of cell size), and the Y-axis fluorescence intensity of staining for CCR2. The level of negative control staining is indicated by a line.

Figure 3 is a FACS dot plot showing that mAb 1D9 stains an IgE positive population in peripheral blood (basophils) using two-color staining for IgE and CCR2. Whole blood cells were first stained with either a negative control antibody (anti-Flag), anti-CCR2 antibody 1D9, or an anti-CXCR1 antibody, as indicated, and detected by an anti-mouse-FITC conjugate. A second staining was done using either PBS or a biotinylated antibody specific for IgE or CD16, as indicated, and detected with a streptavidin-phycoerythrin. Staining was analyzed by flow cytometry.

Figure 4 illustrates that mAb 1D9 inhibits [ $^{125}$ I]MCP-1 binding to THP-1 cell membranes. 3.0  $\mu$ g of THP-1 membrane protein was incubated with 0.1 nM [ $^{125}$ I]MCP-1 in the presence of various concentrations of 1D9 or the isotype-matched anti-CXCR3 antibody 1C6. The amount of bound tracer was determined by separation of free from bound by filtration and scintillation counting. The data was analyzed to determine the IC<sub>50</sub> value by non-linear regression using a 4-parameter logistic equation with KaleidaGraph software.

Figure 5 illustrates that mAb 1D9 inhibits [ $^{125}$ I]MCP-1 binding to fresh human PBMC. Freshly isolated peripheral blood mononuclear cells (500,000) were incubated with 0.1 nM [ $^{125}$ I]MCP-1 in the presence of various concentrations of 1D9 or the isotype-matched anti-CXCR3 antibody 1C6. The amount of bound tracer was determined by separation of free from bound by filtration and scintillation counting. The data was analyzed to determine the IC<sub>50</sub> value as for Figure 4.

Figures 6A and 6B are graphs demonstrating that mAb 1D9 inhibits MCP-1-induced chemotaxis, but not RANTES-induced chemotaxis, of fresh PBMC. Figure 6A shows the results of chemotaxis assays of PBMC to 10 nM MCP-1 with no antibody, or 0.1 or 10  $\mu$ g/ml of 1D9 or nonspecific murine IgG2a. The spontaneous nonspecific migration is also indicated. Figure 6B shows the results of chemotaxis assays of PBMC to 10 nM RANTES with no antibody, 10  $\mu$ g/ml 1D9 or 10  $\mu$ g/ml nonspecific murine IgG2a. The spontaneous nonspecific migration in the absence of RANTES is also indicated.

Figure 7 shows the amino acid sequence (SEQ ID NO: 9) of the kappa light chain variable region of the murine 1D9 antibody. The CDRs are highlighted in bold.

Figure 8 shows the amino acid sequence (SEQ ID NO: 10) of the heavy chain variable region of the murine 1D9 antibody. The CDRs are highlighted in bold.

Figure 9 illustrates the canonical classes of CDRs in the murine 1D9 V<sub>K</sub> region. "Chothia Canonical Classes" indicates where the canonical classes as defined by Chothia and his colleagues (Chothia and Lesk, *J. Mol. Biol.* 197:901 (1987); Chothia *et al.*, *Nature* 34:877 (1989); Tramontano *et al.*, *J. Mol. Biol.* 215:175 (1990); and Chothia *et al.*, *J. Mol. Biol.* 227:799 (1992)) were used, while "Martin Canonical Classes" signifies where the canonical classes defined by Martin and Thornton (Martin and Thornton, *J. Mol. Biol.* 263:800 (1996)) were used. FR residues are highlighted in bold.

Figure 10 illustrates the canonical classes of CDRs in the murine 1D9 V<sub>H</sub> region. "Chothia Canonical Classes" indicates where the canonical classes as defined by Chothia and his colleagues (Chothia and Lesk, *J. Mol. Biol.* 197:901 (1987); Chothia *et al.*, *Nature* 34:877 (1989); Tramontano *et al.*, *J. Mol. Biol.* 215:175 (1990); and Chothia *et al.*, *J. Mol. Biol.* 227:799 (1992)) were used, while "Martin Canonical Classes" signifies where the canonical classes defined by Martin and Thornton (Martin and Thornton, *J. Mol. Biol.* 263:800 (1996)) were used. FR residues are highlighted in bold.

Figure 11 shows the amino acid sequences of various versions of the humanised 1D9 V<sub>K</sub> region (SEQ ID NOS: 12-15 and 107, respectively). Where the 1D9 V<sub>K</sub> region residues (SEQ ID NO: 9) and the human HF-21/28 V<sub>K</sub> region (SEQ ID NO: 11) sequences match a dot [.] is shown. Where no amino acid is present at a specific residue position a dash [-] is shown. Where an amino acid in the HF-21/28 FRs is changed in the humanised 1D9 V<sub>K</sub> region, it is highlighted in bold. The CDRs are described by the use of nomenclature [=L1=]. The numbering used is according to Kabat *et al.*, *Sequences of proteins of immunological interest*, Fifth edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991).

Figure 12 shows the amino acid sequences of various versions of the humanised 1D9 V<sub>H</sub> region (SEQ ID NOS: 17-20, respectively). Where the 1D9 V<sub>H</sub> region residues (SEQ ID NO: 10) and the human 4B4'CL V<sub>H</sub> region sequences (SEQ ID NO: 16) match a dot [.] is shown. Where no amino acid is present at a specific residue position a dash [-] is shown. Where an amino acid in the 4B4'CL is changed in the humanised 1D9 V<sub>H</sub> region, it is highlighted in bold. The CDRs are described by the use of nomenclature [=H1=], while [-----] denotes part of the H1 structure loop. The numbering used is according to Kabat *et al.*, *Sequences of proteins of immunological interest*, Fifth edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991).

Figure 13 shows a comparison of a portion of the murine 1D9 V<sub>K</sub> region (SEQ ID NO: 21) with mouse germline V<sub>K</sub> gene sequences (SEQ ID NOS: 22-33, respectively). "Identical residues" represents the number of identical residues in a mouse germline V<sub>K</sub> region to the murine 1D9 V<sub>K</sub> region. Where the 1D9 V<sub>K</sub> region sequence and the mouse germline V<sub>K</sub> region sequences match a dot [.] is shown. Where no amino acid is present at a specific residue position a dash [-] is shown.

Figure 14 shows a comparison of a portion of the murine 1D9 V<sub>H</sub> region (SEQ ID NO: 34) with mouse germline V<sub>H</sub> gene sequences (SEQ ID NOS: 35-53, respectively). "Identical residues" represents the number of identical residues in a mouse germline V<sub>H</sub> region to the murine 1D9 V<sub>H</sub> region. Where the 1D9 V<sub>H</sub> region sequence and the mouse germline V<sub>H</sub> region sequences match a dot [.] is shown. Where no amino acid is present at a specific residue position a dash [-] is shown.

Figure 15 shows a comparison of the murine 1D9 V<sub>K</sub> region (SEQ ID NO: 9) with the most homologous seventeen human V<sub>K</sub> amino acid sequences (SEQ ID NOS: 54-70, respectively). "ID" represents the percentage identity of the human V<sub>K</sub> sequences to the murine 1D9 V<sub>K</sub> region. Where the 1D9 V<sub>K</sub> region residues and the human V<sub>K</sub> region sequences match a dot [.] is shown. Where no amino acid is present at a specific residue position a dash [-] is shown. "S" indicates amino acid positions on the surface of the F<sub>V</sub> domain. "C" indicates residues located within the core of the F<sub>V</sub> domain. Residues within 5 Å of a CDR are defined using capital letters, while those located further away are described with a lower case letter. The CDRs themselves are described by the use of the nomenclature ==L1==. "v"

denotes the Vernier residues (Foote and Winter, *J. Mol. Biol.* 224:487 (1992)) located in the FRs. Those residues in the human  $V_K$  region sequences which are underlined differ from their closest human  $V_K$  germline gene. The numbering used is as according to Kabat *et al.*, *Sequences of proteins of immunological interest*,  
 5 Fifth edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991).

Figure 16 shows a comparison of the murine 1D9  $V_K$  region with the most homologous seventeen human  $V_K$  amino acid sequences. "ID" indicates the percentage identity of the human  $V_K$  sequence to the murine 1D9  $V_K$  region.  
 10 "Surface" indicates the number of identical residues on the surface. "Core" indicates the number of identical residues within the core of the  $F_V$  domain. "CDR" indicates the number of identical residues within the CDRs. "FR" indicates the number of identical residues within the FRs. "FR Surface" indicates the number of identical residues which are surface exposed. "FR Core" indicates the number of  
 15 identical residues which are located within the core of the  $F_V$  domain. "FR Near CDR" represents the number of identical residues amongst the FR amino acids within 5 Å of a CDR. "Vernier" indicates the number of identical residues amongst the 14 Vernier amino acids (Foote and Winter, *J. Mol. Biol.* 224:487 (1992)). " $V_K$ " indicates the number of identical residues within the  $V_K$  gene. "J Chain" indicates  
 20 the number of identical residues within the J chain gene. "L1 Len" to "L3 Len" defines the number of residues in each CDR, while "L1 Class" to "L3 Class" describes the canonical class of the CDR according to Martin and Thornton (Martin and Thornton, *J. Mol. Biol.* 263:800 (1996)).

Figures 17A-17B show a comparison of the murine 1D9  $V_H$  region (SEQ ID  
 25 NO: 10) with the most homologous 24 human  $V_H$  amino acid sequences (SEQ ID NOS: 71-94, respectively). "ID" represents the percentage identity of the human  $V_H$  sequences to the murine 1D9  $V_H$  region. Where the 1D9  $V_H$  region residues and the human  $V_H$  region sequences match a dot [.] is shown. Where no amino acid is present at a specific residue position a dash [-] is shown. "S" indicates amino acid  
 30 positions on the surface of the  $F_V$  domain. "C" indicates residues located within the core of the  $F_V$  domain. Residues within 5 Å of a CDR are defined using capital letters, while those located farther away are described with a lower case letter. The

CDRs themselves are described by the use of the nomenclature == H1==. "v" denotes the Vernier residues (Foote and Winter, *J. Mol. Biol.* 224:487 (1992)) located in the FRs. Those residues in the human V<sub>H</sub> region sequences which are underlined differ from their closest human V<sub>H</sub> germline gene. The numbering used is as according to Kabat *et al.*, *Sequences of proteins of immunological interest*, Fifth edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991).

Figures 18A-18B show a comparison of the murine 1D9 V<sub>H</sub> region with the most homologous 24 human V<sub>H</sub> amino acid sequences. "ID" indicates percentage identity of the human V<sub>H</sub> sequence to the murine 1D9 V<sub>H</sub> region. "All" indicates the number of identical residues in the whole of the human V<sub>H</sub> region when compared to the whole of the murine 1D9 V<sub>H</sub> region. "Surface" indicates the number of identical residues on the surface. "Core" indicates the number of identical residues within the core of the F<sub>V</sub> domain. "CDR" indicates the number of identical residues within the CDRs. "FR" indicates the number of identical residues within the FRs. "FR Surface" indicates the number of identical residues which are surface exposed. "FR Core" indicates the number of identical residues which are located within the core of the F<sub>V</sub> domain. "FR Near CDR" represents the number of identical residues amongst the FR amino acids within 5Å of a CDR. "Vernier" indicates the number of identical residues amongst the 14 Vernier amino acids (Foote and Winter, *J. Mol. Biol.* 224:487 (1992)). "V<sub>H</sub>" indicates the number of identical residues within the V<sub>H</sub> gene. "J Chain" indicates the number of identical residues within the J chain gene. "H1 Size" to "H3 Size" define the number of residues in each CDR, while "H1 Class" and "H2 Class" describe the canonical class of the CDR according to Martin and Thornton, (*J. Mol. Biol.* 263:800 (1996)).

Figures 19A-19C show the alignment of amino acid sequences leading to the design of the first (1D9RK<sub>A</sub>) and second (1D9RK<sub>B</sub>) humanised versions of the 1D9 antibody kappa light chain variable region. Amino acids identical to the mouse 1D9 at a particular residue position in column 7 are not shown; "--" indicates no amino acid is located at this residue position. Boldface type indicates positions in FRs and CDRs where the human amino acid residue was replaced by the corresponding mouse residue. "Δ" indicates the numbering of changes in the human FRs of

1D9RK<sub>A</sub>. "Mouse 1D9 V<sub>K</sub>" indicates the amino acid sequence of the V<sub>K</sub> region from the murine 1D9 kappa light chain variable region. "Mouse κ-II" indicates the consensus sequence of mouse V<sub>K</sub> regions from Kabat subgroup κ-II. "Human κ-II" indicates the consensus sequence of human V<sub>K</sub> regions from Kabat subgroup κ-II.

5 "HF-21/28" indicates the amino acid sequence of the light chain variable region from the human HF-21/28 antibody (Chastagner *et al.*, *Gene* 101(2):305-6 (1991)). The number in parenthesis (005056) is the Kabat database ID number. "Surface or Core" indicates the position of the amino acid in relation to the rest of the residues in both chains of the antibody variable regions. Residues within 5Å of a CDR are

10 defined using capital letters. "1D9RK<sub>A</sub>" indicates the amino acid sequence of the first version of the humanised 1D9 V<sub>K</sub> region. "1D9RK<sub>B</sub>" indicates the amino acid sequence of the second version of the humanised 1D9 V<sub>K</sub> region.

Figures 20A-20C show the alignment of amino acid sequences leading to the design of the first (1D9RH<sub>A</sub>) and second (1D9RK<sub>B</sub>) humanised human versions of

15 the 1D9 antibody kappa light chain variable region. Amino acids identical to the mouse 1D9 at a particular residue position in column 7 are not shown. "-" indicates that no amino acid is located at this residue position. Boldface type indicates positions in the FRs and CDRs where the human amino acid residue was replaced by the corresponding mouse residue. "Δ" indicates the numbering of changes in the

20 human FRs of 1D9RH<sub>A</sub>. "Mouse 1D9 V<sub>H</sub>" indicates the amino acid sequence of the V<sub>H</sub> region from the murine 1D9 heavy chain variable region. "Mouse IIIc" indicates the consensus sequence of mouse V<sub>H</sub> regions from Kabat subgroup IIIc. "Human III" indicates the consensus sequence of human V<sub>H</sub> regions from Kabat subgroup III. "4B4'CL" indicates the amino acid sequence of the heavy chain variable region

25 from the human 4B4'CL antibody (Sanz *et al.*, *Journal of Immunology* 142:883 (1989)). The number in parenthesis (000490) is the Kabat database ID number. "Surface or Core" indicates the position of the amino acid in relation to the rest of the residues in both chains of the antibody variable regions. Residues within 5Å of a CDR are defined using capital letters. "1D9RH<sub>A</sub>" indicates the amino acid

30 sequence of the first version of the humanised 1D9 V<sub>H</sub> region. "1D9RH<sub>B</sub>" indicates the amino acid sequence of the second version of the humanised 1D9 V<sub>H</sub> region.

Figure 21 shows the nucleotide sequence, complement and encoded amino acid sequence of the murine antibody 1D9 heavy chain variable region. The leader sequence and a portion of the constant region are also shown. The illustrated nucleotide sequence is SEQ ID NO: 96, the complementary sequence is SEQ ID NO: 99, and the amino acid sequence is SEQ ID NO: 100.

Figure 22 shows the nucleotide sequence, complement and encoded amino acid sequence of the murine antibody 1D9 kappa light chain variable region. The leader sequence and a portion of the constant region are also shown. The illustrated nucleotide sequence is SEQ ID NO: 95, the complementary sequence is SEQ ID NO: 101, and the amino acid sequence is SEQ ID NO: 102.

Figure 23 shows the nucleotide sequence of the humanized heavy chain 1D9RH<sub>A</sub>. The indicated enzyme sites were added for cloning into the vector pLKTOK41. The vector also has human leader and constant regions. The illustrated nucleotide sequence is SEQ ID NO: 97, the complementary sequence is SEQ ID NO: 103, and the amino acid sequence is SEQ ID NO: 104.

Figure 24 shows the nucleotide sequence of the humanized light chain 1D9RK<sub>A</sub>. The indicated enzyme sites were added for cloning into the vector pLKTOK41. The vector also has human leader and constant regions. The bracketed Y indicates a residue which changes to aspartate when cloned into the Eco RV cloning site of pLKTOK41. The illustrated nucleotide sequence is SEQ ID NO: 98, the complementary sequence is SEQ ID NO: 105, and the amino acid sequence is SEQ ID NO: 106.

Figure 25 illustrates a comparison of the abilities of murine mAb 1D9 and a humanized version of mAb 1D9 (heavy chain of 1D9RH<sub>A</sub>V<sub>H</sub>, light chain of 1D9RK<sub>A</sub>V<sub>L</sub>) to inhibit the binding of [<sup>125</sup>I]-MCP-1 to whole THP-1 cells. Data points for murine 1D9 (mus-1D9) are shown as closed triangles. Data points for the humanized version of 1D9 (hum-1D9) are shown as closed squares.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to an antibody (anti-CCR2) or functional fragment thereof which binds mammalian CC-chemokine receptor 2 (CCR2, CKR-2, MCP-1RA or MCP-1RB) or a portion of CCR2. In one embodiment, the



antibody has specificity for human or rhesus CCR2 or portion thereof. In one embodiment, the antibodies (immunoglobulins) are raised against an isolated and/or recombinant mammalian CCR2 or portion thereof (e.g., peptide) or against a host cell which expresses mammalian CCR2. In a preferred embodiment, the antibodies

5 specifically bind human CCR2 receptor(s) (e.g., CCR2a and/or CCR2b) or a portion thereof, and in a particularly preferred embodiment the antibodies have specificity for a naturally occurring or endogenous human CCR2. As used herein, "CC-chemokine receptor 2" ("CCR2") refers to CC-chemokine receptor 2a and/or CC-chemokine receptor 2b. Antibodies or functional fragments thereof which can

10 inhibit one or more functions characteristic of a mammalian CCR2, such as a binding activity (e.g., ligand, inhibitor and/or promoter binding), a signaling activity (e.g., activation of a mammalian G protein, induction of a rapid and transient increase in the concentration of cytosolic free calcium  $[Ca^{2+}]_i$ ), and/or stimulation of a cellular response (e.g., stimulation of chemotaxis, exocytosis or inflammatory

15 mediator release by leukocytes, integrin activation) are also encompassed by the present invention, such as an antibody which can inhibit binding of a ligand (i.e., one or more ligands) to CCR2 and/or one or more functions mediated by CCR2 in response to a ligand. For example, in one aspect, the antibodies or functional fragments thereof can inhibit (reduce or prevent) the interaction of receptor with a

20 natural ligand, such as MCP-1, MCP-2, MCP-3 and/or MCP-4. In another aspect, an antibody or functional fragment thereof that binds to CCR2 can inhibit binding of MCP-1, MCP-2, MCP-3 and/or MCP-4 and/or HIV to mammalian CCR2 (e.g., human CCR2, non-human primate CCR2, murine CCR2). The antibodies or functional fragments thereof of the present invention can inhibit functions mediated

25 by human CCR2, including leukocyte trafficking, HIV entry into a cell, T cell activation, inflammatory mediator release and/or leukocyte degranulation. Preferably, the antibodies or fragments can bind CCR2 with an affinity of at least about  $0.1 \times 10^{-9}$  M, preferably at least about  $1 \times 10^{-9}$  M, and more preferably at least about  $3 \times 10^{-9}$  M. In a particular embodiment, antibodies or functional fragments

30 thereof demonstrate inhibition of chemokine-induced (e.g., MCP-1-induced) chemotaxis of cells (e.g., PBMC) at less than about 150  $\mu$ g/ml, preferably less than

about 100 µg/ml, more preferably less than about 50 µg/ml, and even more preferably less than about 20 µg/ml.

In a further embodiment of the invention, the antibodies or functional fragments thereof of the invention can inhibit binding of a CCR2 ligand (e.g., a chemokine) to CCR2 with an IC<sub>50</sub> of less than about 1.0 µg/ml, preferably less than about 0.05 µg/ml, and more preferably less than about 0.005 µg/ml.

Murine monoclonal antibodies specific for CCR2, designated 1D9 and 8G2, were produced as described herein. In a preferred embodiment, the antibodies of the present invention bind human CCR2, and have an epitopic specificity which is the same as or similar to that of murine 1D9 or 8G2 antibody described herein.

Antibodies with an epitopic specificity which is the same as or similar to that of murine 1D9 monoclonal antibody can be identified by their ability to compete with murine 1D9 monoclonal antibody for binding to human CCR2 (e.g., to cells bearing human CCR2, such as transfectants bearing CCR2, CD8+ cells, CD4+ cells, CDR45RO+ cells, CD25+ cells, monocytes, dendritic cells, macrophages and basophils). Similarly, antibodies with an epitopic specificity which is the same as or similar to that of murine 8G2 monoclonal antibody can be identified by their ability to compete with murine 8G2 monoclonal antibody for binding to human CCR2.

Using receptor chimeras (Rucker *et al.*, *Cell* 87:437-446 (1996)), the binding site of mAbs 1D9 and 8G2 has been mapped to the amino-terminal domain of human CC-chemokine receptor 2, specifically to an epitope comprising from about amino acid 1 to about amino acid 30 of the protein. Using these or other suitable techniques, antibodies having an epitopic specificity which is the same as or similar to that of an antibody of the present invention can be identified. mAbs 1D9 and 8G2 have epitopic specificity for the amino-terminal domain of the CCR2 receptor, e.g., from about amino acid number 1 to about amino acid number 30 of the receptor protein. Thus, the invention pertains to an antibody or functional portion thereof which binds to the amino-terminal domain or portion thereof of mammalian CC-chemokine receptor 2, and particularly to an epitope comprising from about amino acid 1 to about amino acid 30 of mammalian CC-chemokine receptor 2.

The invention also relates to a bispecific antibody, or functional fragment thereof (e.g., F(ab')<sub>2</sub>), which has the same or similar epitopic specificity as at least

-22-

two of the antibodies described herein (see, e.g., U.S. Patent No. 5,141,736 (Iwasa *et al.*), U.S. Patent Nos. 4,444,878, 5,292,668, 5,523,210 (all to Paulus *et al.*) and U.S. Patent No. 5,496,549 (Yamazaki *et al.*). For example, a bispecific antibody of the present invention can have the same or similar epitopic specificity as mAb 1D9 and  
5 8G2, e.g., binds the amino terminal domain, or portion thereof, of mammalian CCR2 protein.

Hybridoma cell lines producing antibodies according to the present invention were deposited on July 17, 1998, on behalf of LeukoSite, Inc., 215 First Street, Cambridge, MA 02142, U.S.A. (now Millennium Pharmaceuticals, Inc., 75 Sidney  
10 Street, Cambridge, MA 02139, U.S.A.), at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110, U.S.A., under Accession Nos. HB-12549 (1D9) and HB-12550 (8G2). The present invention also pertains to the hybridoma cell lines deposited under ATCC Accession No. HB-12549 and ATCC Accession No. HB-12550, as well as to the monoclonal antibodies produced  
15 by the hybridoma cell lines deposited under ATCC Accession Nos. HB-12549 and HB-12550.

The antibodies of the present invention can be polyclonal or monoclonal, and the term "antibody" is intended to encompass both polyclonal and monoclonal antibodies. Furthermore, it is understood that methods described herein which  
20 utilize 8G2 can also utilize functional fragments (e.g., antigen-binding fragments) of 8G2, antibodies which have the same or similar epitopic specificity as 8G2, and combinations thereof, optionally in combination with antibodies or fragments having an epitopic specificity which is not the same as or similar to 8G2; similarly, methods described as utilizing 1D9 can also utilize functional fragments of 1D9, antibodies  
25 which have the same or similar epitopic specificity as 1D9, and combinations thereof, optionally in combination with antibodies or fragments having an epitopic specificity which is not the same as or similar to 1D9. Antibodies of the present invention can be raised against an appropriate immunogen, such as isolated and/or recombinant mammalian CCR2 protein or portion thereof, or synthetic molecules,  
30 such as synthetic peptides. In a preferred embodiment, cells which express receptor, such as transfected cells, can be used as immunogens or in a screen for antibody which binds receptor.

The antibodies of the present invention, and fragments thereof, are useful in therapeutic, diagnostic and research applications as described herein. The present invention encompasses an antibody or functional portion thereof of the present invention (e.g., mAb 1D9 or 8G2, or antigen-binding fragments thereof) for use in  
5 therapy (including prophylaxis) or diagnosis (e.g., of particular diseases or conditions as described herein), and use of such antibodies or functional portions thereof for the manufacture of a medicament for use in treatment of diseases or conditions as described herein.

Preparation of immunizing antigen, and polyclonal and monoclonal antibody  
10 production can be performed as described herein, or using other suitable techniques. A variety of methods have been described (see e.g., Kohler *et al.*, *Nature*, 256: 495-497 (1975) and *Eur. J. Immunol.* 6: 511-519 (1976); Milstein *et al.*, *Nature* 266: 550-552 (1977); Koprowski *et al.*, U.S. Patent No. 4,172,124; Harlow, E. and D. Lane, 1988, *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory:  
15 Cold Spring Harbor, NY); *Current Protocols In Molecular Biology*, Vol. 2 (Supplement 27, Summer '94), Ausubel, F.M. *et al.*, Eds., (John Wiley & Sons: New York, NY), Chapter 11, (1991)). Generally, a hybridoma can be produced by fusing a suitable immortal cell line (e.g., a myeloma cell line such as SP2/0) with antibody producing cells. The antibody producing cell, preferably those of the spleen or  
20 lymph nodes, are obtained from animals immunized with the antigen of interest. The fused cells (hybridomas) can be isolated using selective culture conditions, and cloned by limiting dilution. Cells which produce antibodies with the desired binding properties can be selected by a suitable assay (e.g., ELISA).

Other suitable methods of producing or isolating antibodies which bind  
25 CCR2, including human or artificial antibodies, can be used, including, for example, methods which select recombinant antibody (e.g., single chain Fv or Fab) from a library, or which rely upon immunization of transgenic animals (e.g., mice) capable of producing a repertoire of human antibodies (see e.g., Jakobovits *et al.*, *Proc. Natl. Acad. Sci. USA*, 90: 2551-2555 (1993); Jakobovits *et al.*, *Nature*, 362: 255-258  
30 (1993); Lonberg *et al.*, U.S. Patent No. 5,545,806; Surani *et al.*, U.S. Patent No. 5,545,807).

Single chain antibodies, and chimeric, humanized or primatized (CDR-grafted) antibodies, as well as chimeric or CDR-grafted single chain antibodies, and the like, comprising portions derived from different species, are also encompassed by the present invention and the term "antibody". The various portions of these antibodies can be joined together chemically by conventional techniques, or can be prepared as a contiguous protein using genetic engineering techniques. For example, nucleic acids encoding a chimeric or humanized chain can be expressed to produce a contiguous protein. See, e.g., Cabilly *et al.*, U.S. Patent No. 4,816,567; Cabilly *et al.*, European Patent No. 0,125,023 B1; Boss *et al.*, U.S. Patent No. 4,816,397; Boss *et al.*, European Patent No. 0,120,694 B1; Neuberger, M.S. *et al.*, WO 86/01533; Neuberger, M.S. *et al.*, European Patent No. 0,194,276 B1; Winter, U.S. Patent No. 5,225,539; Winter, European Patent No. 0,239,400 B1; and Queen *et al.*, U.S. Patent Nos. 5,585,089, 5,698,761 and 5,698,762. See also, Newman, R. *et al.*, *BioTechnology*, 10: 1455-1460 (1992), regarding primatized antibody, and Ladner *et al.*, U.S. Patent No. 4,946,778 and Bird, R.E. *et al.*, *Science*, 242: 423-426 (1988)) regarding single chain antibodies.

In addition, functional fragments of antibodies, including fragments of chimeric, humanized, primatized or single chain antibodies, can also be produced. Functional fragments of the foregoing antibodies retain at least one binding function and/or modulation function of the full-length antibody from which they are derived. Preferred functional fragments retain an antigen-binding function of a corresponding full-length antibody (e.g., the ability to bind a mammalian CCR2). Particularly preferred functional fragments retain the ability to inhibit one or more functions characteristic of a mammalian CCR2, such as a binding activity, a signaling activity, and/or stimulation of a cellular response. For example, in one embodiment, a functional fragment can inhibit the interaction of CCR2 with one or more of its ligands (e.g., MCP-1, MCP-2, MCP-3 and/or MCP-4) and/or can inhibit one or more receptor-mediated functions, such as leukocyte trafficking, HIV entry into cells, T cell activation, inflammatory mediator release and/or leukocyte degranulation.

For example, antibody fragments capable of binding to a mammalian CCR2 receptor or portion thereof, including, but not limited to, Fv, Fab, Fab' and F(ab')<sub>2</sub> fragments are encompassed by the invention. Such fragments can be produced by

enzymatic cleavage or by recombinant techniques, for example. For instance, papain or pepsin cleavage can generate Fab or F(ab')<sub>2</sub> fragments, respectively. Antibodies can also be produced in a variety of truncated forms using antibody genes in which one or more stop codons has been introduced upstream of the natural  
5 stop site. For example, a chimeric gene encoding a F(ab')<sub>2</sub> heavy chain portion can be designed to include DNA sequences encoding the CH<sub>1</sub> domain and hinge region of the heavy chain.

The present invention relates to a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2, comprising an  
10 antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region or portion thereof). In one embodiment, the humanized immunoglobulin includes an antigen binding region of nonhuman origin which binds CCR2 and a constant region derived from a human constant region. In another  
15 embodiment, the humanized immunoglobulin which binds CCR2 comprises a complementarity determining region of nonhuman origin and a variable framework region of human origin, and optionally, a constant region of human origin. For example, the humanized immunoglobulin can comprise a heavy chain and a light chain, wherein the light chain comprises a complementarity determining region  
20 derived from an antibody of nonhuman origin which binds CCR2 and a framework region derived from a light chain of human origin, and the heavy chain comprises a complementarity determining region derived from an antibody of nonhuman origin which binds CCR2 and a framework region derived from a heavy chain of human origin.

25 In one embodiment, the humanized immunoglobulin can compete with murine 1D9 or 8G2 monoclonal antibody for binding to human CCR2. In a preferred embodiment, the antigen-binding region of the humanized immunoglobulin (a) is derived from 1D9 monoclonal antibody (e.g., as in a humanized immunoglobulin comprising CDR1, CDR2 and CDR3 of the 1D9 light  
30 chain and/or CDR1, CDR2 and CDR3 of the 1D9 heavy chain) or (b) is derived from 8G2 monoclonal antibody (e.g., as in a humanized immunoglobulin comprising CDR1, CDR2 and CDR3 of the 8G2 light chain and/or CDR1, CDR2

and CDR3 of the 8G2 heavy chain). Chimeric or CDR-grafted single chain antibodies are also encompassed by the term humanized immunoglobulin.

The present invention also relates to a humanized immunoglobulin light chain or antigen-binding fragment thereof or a humanized immunoglobulin heavy chain or antigen-binding fragment thereof. In one embodiment, the invention relates to a humanized light chain comprising a light chain CDR (i.e., one or more CDRs) of nonhuman origin and a human light chain framework region. In another embodiment, the present invention relates to a humanized immunoglobulin heavy chain comprising a heavy chain CDR (i.e., one or more CDRs) of nonhuman origin and a human heavy chain framework region. The CDRs can be derived from a nonhuman immunoglobulin.

Naturally occurring immunoglobulins have a common core structure in which two identical light chains (about 24 kD) and two identical heavy chains (about 55 or 70 kD) form a tetramer. The amino-terminal portion of each chain is known as the variable (V) region and can be distinguished from the more conserved constant (C) regions of the remainder of each chain. Within the variable region of the light chain is a C-terminal portion known as the J region. Within the variable region of the heavy chain, there is a D region in addition to the J region. Most of the amino acid sequence variation in immunoglobulins is confined to three separate locations in the V regions known as hypervariable regions or complementarity determining regions (CDRs) which are directly involved in antigen binding. Proceeding from the amino-terminus, these regions are designated CDR1, CDR2 and CDR3, respectively. The CDRs are held in place by more conserved framework regions (FRs). Proceeding from the amino-terminus, these regions are designated FR1, FR2, FR3, and FR4, respectively. The locations of CDR and FR regions and a numbering system have been defined by Kabat *et al.* (Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991)).

Human immunoglobulins can be divided into classes and subclasses, depending on the isotype of the heavy chain. The classes include IgG, IgM, IgA, IgD and IgE, in which the heavy chains are of the gamma ( $\gamma$ ), mu ( $\mu$ ), alpha ( $\alpha$ ), delta ( $\delta$ ) or epsilon ( $\epsilon$ ) type, respectively. Subclasses include IgG1, IgG2, IgG3,

- IgG4, IgA1 and IgA2, in which the heavy chains are of the  $\gamma 1$ ,  $\gamma 2$ ,  $\gamma 3$ ,  $\gamma 4$ ,  $\alpha 1$  and  $\alpha 2$  type, respectively. Human immunoglobulin molecules of a selected class or subclass may contain either a kappa ( $\kappa$ ) or lambda ( $\lambda$ ) light chain. See e.g., *Cellular and Molecular Immunology*, Wonsiewicz, M.J., Ed., Chapter 45, pp. 41-50, W. B. Saunders Co, Philadelphia, PA (1991); Nisonoff, A., *Introduction to Molecular Immunology*, 2nd Ed., Chapter 4, pp. 45-65, Sinauer Associates, Inc., Sunderland, MA (1984).

The term "immunoglobulin" as used herein includes whole antibodies and biologically functional fragments thereof. Such biologically functional fragments retain at least one antigen-binding function of a corresponding full-length antibody (e.g., specificity for CCR2 of antibody 1D9), and preferably, retain the ability to inhibit the interaction of CCR2 with one or more of its ligands (e.g., HIV, MCP-1, MCP-2, MCP-3, MCP-4). Examples of biologically functional antibody fragments which can be used include fragments capable of binding to CCR2, such as single chain antibodies, Fv, Fab, Fab' and F(ab')<sub>2</sub> fragments. Such fragments can be produced by enzymatic cleavage or by recombinant techniques. For instance, papain or pepsin cleavage can be used to generate Fab or F(ab')<sub>2</sub> fragments, respectively. Antibodies can also be produced in a variety of truncated forms using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site. For example, a chimeric gene encoding the heavy chain of an F(ab')<sub>2</sub> fragment can be designed to include DNA sequences encoding the CH<sub>1</sub> domain and hinge region of the heavy chain. As used herein, an antigen-binding fragment of a humanized immunoglobulin heavy or light chain is intended to mean a fragment which binds to an antigen when paired with a complementary chain. That is, an antigen-binding fragment of a humanized light chain will bind to an antigen when paired with a heavy chain (e.g., murine, chimeric, humanized) comprising a variable region, and an antigen-binding fragment of a humanized heavy chain will bind to an antigen when paired with a light chain (e.g., murine, chimeric, humanized) comprising a variable region.

The term "humanized immunoglobulin" as used herein refers to an immunoglobulin comprising portions of immunoglobulins of different origin, wherein at least one portion is of human origin. For example, the humanized



antibody can comprise portions derived from an immunoglobulin of nonhuman origin with the requisite specificity, such as a mouse, and from immunoglobulin sequences of human origin (e.g., chimeric immunoglobulin), joined together chemically by conventional techniques (e.g., synthetic) or prepared as a contiguous polypeptide using genetic engineering techniques (e.g., DNA encoding the protein portions of the chimeric antibody can be expressed to produce a contiguous polypeptide chain). Another example of a humanized immunoglobulin of the present invention is an immunoglobulin containing one or more immunoglobulin chains comprising a CDR derived from an antibody of nonhuman origin and a framework region derived from a light and/or heavy chain of human origin (e.g., CDR-grafted antibodies with or without framework changes). Chimeric or CDR-grafted single chain antibodies are also encompassed by the term humanized immunoglobulin. See, e.g., Cabilly *et al.*, U.S. Patent No. 4,816,567; Cabilly *et al.*, European Patent No. 0,125,023 B1; Boss *et al.*, U.S. Patent No. 4,816,397; Boss *et al.*, European Patent No. 0,120,694 B1; Neuberger, M.S. *et al.*, WO 86/01533; Neuberger, M.S. *et al.*, European Patent No. 0,194,276 B1; Winter, U.S. Patent No. 5,225,539; Winter, European Patent No. 0,239,400 B1; Padlan, E.A. *et al.*, European Patent Application No. 0,519,596 A1. See also, Ladner *et al.*, U.S. Patent No. 4,946,778; Huston, U.S. Patent No. 5,476,786; and Bird, R.E. *et al.*, *Science*, 242: 423-426 (1988)), regarding single chain antibodies.

For example, humanized immunoglobulins can be produced using synthetic and/or recombinant nucleic acids to prepare genes (e.g., cDNA) encoding the desired humanized chain. For example, nucleic acid (e.g., DNA) sequences coding for humanized variable regions can be constructed using PCR mutagenesis methods to alter DNA sequences encoding a human or humanized chain, such as a DNA template from a previously humanized variable region (see e.g., Kamman, M., *et al.*, *Nucl. Acids Res.*, 17: 5404 (1989)); Sato, K., *et al.*, *Cancer Research*, 53: 851-856 (1993); Daugherty, B.L. *et al.*, *Nucleic Acids Res.*, 19(9): 2471-2476 (1991); and Lewis, A.P. and J.S. Crowe, *Gene*, 101: 297-302 (1991)). Using these or other suitable methods, variants can also be readily produced. In one embodiment, cloned variable regions can be mutagenized, and sequences encoding variants with the

desired specificity can be selected (e.g., from a phage library; see e.g., Krebber *et al.*, U.S. 5,514,548; Hoogenboom *et al.*, WO 93/06213, published April 1, 1993)).

The antigen binding region of the humanized immunoglobulin (the nonhuman portion) can be derived from an immunoglobulin of nonhuman origin (referred to as a donor immunoglobulin) having binding specificity for CCR2. For example, a suitable antigen binding region can be derived from the murine monoclonal antibody 1D9. Other sources include CCR2-specific antibodies obtained from nonhuman sources, such as rodent (e.g., mouse, rat), rabbit, pig goat or non-human primate (e.g., monkey). Additionally, other polyclonal or monoclonal antibodies, such as antibodies which bind to the same or similar epitope as the 1D9 antibody, can be made (e.g., Kohler *et al.*, *Nature*, 256:495-497 (1975); Harlow *et al.*, 1988, *Antibodies: A Laboratory Manual*, (Cold Spring Harbor, NY); and *Current Protocols in Molecular Biology*, Vol. 2 (Supplement 27, Summer '94), Ausubel *et al.*, Eds. (John Wiley & Sons: New York, NY), Chapter 11 (1991)).

For example, antibodies can be raised against an appropriate immunogen in a suitable mammal (e.g., a mouse, rat, rabbit or sheep). Cells bearing CCR2, membrane fractions containing CCR2, and immunogenic fragments of CCR2 are examples of suitable immunogens. Antibody-producing cells (e.g., a lymphocyte) can be isolated from, for example, the lymph nodes or spleen of an immunized animal. The cells can then be fused to a suitable immortalized cell (e.g., a myeloma cell line), thereby forming a hybridoma. Fused cells can be isolated employing selective culturing techniques. Cells which produce antibodies with the desired specificity can be selected by a suitable assay (e.g., ELISA). Immunoglobulins of nonhuman origin having binding specificity for CCR2 can also be obtained from antibody libraries (e.g., a phage library comprising nonhuman Fab molecules).

In one embodiment, the antigen binding region of the humanized immunoglobulin comprises a CDR of nonhuman origin. In this embodiment, the humanized immunoglobulin having binding specificity for CCR2 comprises at least one CDR of nonhuman origin. For example, CDRs can be derived from the light and heavy chain variable regions of immunoglobulins of nonhuman origin, such that a humanized immunoglobulin includes substantially heavy chain CDR1, CDR2 and/or CDR3, and/or light chain CDR1, CDR2 and/or CDR3, from one or more

immunoglobulins of nonhuman origin, and the resulting humanized immunoglobulin has binding specificity for CCR2. Preferably, all three CDRs of a selected chain are substantially the same as the CDRs of the corresponding chain of a donor, and more preferably, all three CDRs of the light and heavy chains are substantially the same as the CDRs of the corresponding donor chain. In one embodiment, the invention relates to an immunoglobulin having binding specificity for CCR2 comprising a humanized light chain or antigen-binding fragment thereof comprising CDR1, CDR2 and CDR3 of the light chain of the 1D9 antibody and a heavy chain, e.g., a human heavy chain. The invention also includes an immunoglobulin having binding specificity for CCR2 comprising a humanized heavy chain or antigen-binding fragment thereof comprising CDR1, CDR2 and CDR3 of the heavy chain of the 1D9 antibody and a light chain, e.g., a human light chain.

The invention also relates to an immunoglobulin having binding specificity for CCR2 comprising a light chain and a heavy chain, wherein the light chain comprises at least 1 CDR of an antibody of non-human origin (e.g., 1D9) and framework and constant regions of human origin (e.g., SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO: 107), and wherein the heavy chain comprises a variable region of non-human origin (e.g., from 1D9) and a constant region of human origin. The invention also provides antigen-binding fragments of these immunoglobulins. The invention also relates to an immunoglobulin having binding specificity for CCR2 comprising a light chain and a heavy chain, wherein the light chain comprises a variable chain of non-human origin (e.g., from 1D9) and a constant region of human origin, and wherein the heavy chain comprises at least 1 CDR of an antibody of non-human origin (e.g., 1D9) and framework and constant regions of human origin (e.g., SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO:19 and SEQ ID NO: 20). The invention also provides antigen-binding fragments of these immunoglobulins.

The portion of the humanized immunoglobulin or immunoglobulin chain which is of human origin (the human portion) can be derived from any suitable human immunoglobulin or immunoglobulin chain. For example, a human constant region or portion thereof, if present, can be derived from the  $\kappa$  or  $\lambda$  light chains, and/or the  $\gamma$  (e.g.,  $\gamma 1$ ,  $\gamma 2$ ,  $\gamma 3$ ,  $\gamma 4$ ),  $\mu$ ,  $\alpha$  (e.g.,  $\alpha 1$ ,  $\alpha 2$ ),  $\delta$  or  $\epsilon$  heavy chains of

human antibodies, including allelic variants. A particular constant region (e.g., IgG1), variant or portions thereof can be selected in order to tailor effector function. For example, a mutated constant region (variant) can be incorporated into a fusion protein to minimize binding to Fc receptors and/or ability to fix complement (see  
5 e.g., Example 3; see also, Winter *et al.*, GB 2,209,757 B; Morrison *et al.*, WO 89/07142; Morgan *et al.*, WO 94/29351, December 22, 1994).

If present, human framework regions (e.g., of the light chain variable region) are preferably derived from a human antibody variable region having sequence similarity to the analogous or equivalent region (e.g., light chain variable region) of  
10 the antigen binding region donor. Other sources of framework regions for portions of human origin of a humanized immunoglobulin include human variable consensus sequences (see, e.g., Kettleborough, C.A. *et al.*, *Protein Engineering* 4:773-783 (1991); Carter *et al.*, WO 94/04679, published March 3, 1994)). For example, the sequence of the antibody or variable region used to obtain the nonhuman portion can  
15 be compared to human sequences as described in Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, Fifth Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991). In a particularly preferred embodiment, the framework regions of a humanized immunoglobulin chain are derived from a human variable region having at least about 60% overall sequence  
20 identity, preferably at least about 70% overall sequence identity and more preferably at least about 85% overall sequence identity, with the variable region of the nonhuman donor (e.g., murine antibody 1D9). A human portion can also be derived from a human antibody having at least about 65% sequence identity, and preferably at least about 70% sequence identity, within the particular portion (e.g., FR) being  
25 used, when compared to the equivalent portion (e.g., FR) of the nonhuman donor.

In one embodiment, the humanized immunoglobulin comprises at least one of the framework regions (FR) derived from one or more chains of an antibody of human origin. Thus, the FR can include a FR1 and/or FR2 and/or FR3 and/or FR4 derived from one or more antibodies of human origin. Preferably, the human  
30 portion of a selected humanized chain includes FR1, FR2, FR3 and FR4 derived from a variable region of human origin (e.g., from a human immunoglobulin chain, from a human consensus sequence).

The immunoglobulin portions of nonhuman and human origin for use in the present invention have sequences identical to immunoglobulins or immunoglobulin portions from which they are derived or to variants thereof. Such variants include mutants differing by the addition, deletion, or substitution of one or more residues.

5 As indicated above, the CDRs which are of nonhuman origin are substantially the same as in the nonhuman donor, and preferably are identical to the CDRs of the nonhuman donor. As described in Example 2, changes in the framework region, such as those which substitute a residue of the framework region of human origin with a residue from the corresponding position of the donor, can be made. One or  
10 more mutations in the framework region can be made, including deletions, insertions and substitutions of one or more amino acids. Several such substitutions are described in the design of humanized 1D9 antibodies in Example 2. For a selected humanized antibody or chain, framework mutations can be designed as described herein. Preferably, the humanized immunoglobulins can bind CCR2 with an affinity  
15 similar to or better than that of the nonhuman donor. Variants can be produced by a variety of suitable methods, including mutagenesis of nonhuman donor or acceptor human chains.

The humanized immunoglobulins of the present invention have binding specificity for human CCR2. In a preferred embodiment, the humanized  
20 immunoglobulin of the present invention has at least one functional characteristic of murine antibody 1D9, such as binding function (e.g., having specificity for CCR2, having the same or similar epitopic specificity), and/or inhibitory function (e.g., the ability to inhibit CCR2-dependent function *in vitro* and/or *in vivo*, such as the ability to inhibit the binding of a cell bearing CCR2 to a ligand thereof (e.g., a chemokine)).  
25 Thus, preferred humanized immunoglobulins can have the binding specificity of the murine antibody 1D9, the epitopic specificity of murine antibody 1D9 (e.g., can compete with murine 1D9, a chimeric 1D9 antibody, or humanized 1D9 for binding to CCR2 (e.g., on a cell bearing CCR2)), and/or inhibitory function of murine antibody 1D9.

30 The binding function of a humanized immunoglobulin having binding specificity for CCR2 can be detected by standard immunological methods, for example using assays which monitor formation of a complex between humanized

immunoglobulin and CCR2 (e.g., a membrane fraction comprising CCR2, on a cell bearing CCR2, human cell line or recombinant host cell comprising nucleic acid encoding CCR2 which expresses CCR2). Binding and/or adhesion assays or other suitable methods can also be used in procedures for the identification and/or  
5 isolation of humanized immunoglobulins (e.g., from a library) with the requisite specificity (e.g., an assay which monitors adhesion between a cell bearing CCR2 and a ligand thereof (e.g., HIV, MCP-1, MCP-2, MCP-3, MCP-4), or other suitable methods.

The immunoglobulin portions of nonhuman and human origin for use in the  
10 present invention include light chains, heavy chains and portions of light and heavy chains. These immunoglobulin portions can be obtained or derived from immunoglobulins (e.g., by *de novo* synthesis of a portion), or nucleic acid molecules encoding an immunoglobulin or chain thereof having the desired property (e.g., binding CCR2, sequence similarity) can be produced and expressed. Humanized  
15 immunoglobulins comprising the desired portions (e.g., antigen binding region, CDR, FR, C region) of human and nonhuman origin can be produced using synthetic and/or recombinant nucleic acids to prepare genes (e.g., cDNA) encoding the desired humanized chain. To prepare a portion of a chain, one or more stop codons can be introduced at the desired position. For example, nucleic acid (e.g.,  
20 DNA) sequences coding for newly designed humanized variable regions can be constructed using PCR mutagenesis methods to alter existing DNA sequences (see e.g., Kamman, M., *et al.*, *Nucl. Acids Res.* 17:5404 (1989)). PCR primers coding for the new CDRs can be hybridized to a DNA template of a previously humanized variable region which is based on the same, or a very similar, human variable region  
25 (Sato, K., *et al.*, *Cancer Research* 53:851-856 (1993)). If a similar DNA sequence is not available for use as a template, a nucleic acid comprising a sequence encoding a variable region sequence can be constructed from synthetic oligonucleotides (see e.g., Kolbinger, F., *Protein Engineering* 8:971-980 (1993)). A sequence encoding a signal peptide can also be incorporated into the nucleic acid (e.g., on synthesis, upon  
30 insertion into a vector). If the natural signal peptide sequence is unavailable, a signal peptide sequence from another antibody can be used (see, e.g., Kettleborough, C.A., *Protein Engineering* 4:773-783 (1991)). Using these methods, methods

described herein or other suitable methods, variants can be readily produced. In one embodiment, cloned variable regions can be mutagenized, and sequences encoding variants with the desired specificity can be selected (e.g., from a phage library; see e.g., Krebber *et al.*, U.S. 5,514,548; Hoogenboom *et al.*, WO 93/06213, published 5 April 1, 1993)).

The invention relates to a humanized immunoglobulin light chain or antigen-binding fragment thereof, said light chain or antigen-binding fragment thereof having an amino acid sequence comprising at least a functional portion of the light chain variable region amino acid sequence of SEQ ID NO: 9. In a preferred 10 embodiment, the amino acid sequence comprises at least one, preferably two, and more preferably three of the CDRs of SEQ ID NO: 9. The invention also relates to a humanized immunoglobulin heavy chain or antigen-binding fragment thereof, said heavy chain or antigen-binding fragment thereof having an amino acid sequence comprising at least a functional portion of the heavy chain variable region amino 15 acid sequence shown in SEQ ID NO: 10. In a preferred embodiment, the amino acid sequence comprises at least one, preferably two, and more preferably three of the CDRs of SEQ ID NO: 10. It is noted that all murine sequences described herein are derived from *Mus musculus*.

According to one embodiment of the invention, a humanized 20 immunoglobulin light chain or antigen-binding fragment thereof having binding specificity for CCR2 can comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 107. According to another embodiment of the invention, a humanized immunoglobulin heavy chain or antigen-binding fragment thereof having 25 binding specificity for CCR2 can comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20. In a particular embodiment, a humanized immunoglobulin of the invention can comprise both a light chain or antigen-binding fragment thereof having binding specificity for CCR2, comprising an amino acid sequence selected 30 from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 107, and a heavy chain or antigen-binding fragment thereof having binding specificity for CCR2 comprising an amino acid

sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.

In one embodiment, the invention relates to a humanized immunoglobulin having binding specificity for CCR2 comprising a light chain comprising the amino acid sequence of SEQ ID NO: 12 and a complementary heavy chain, or an antigen-binding fragment of said humanized immunoglobulin having binding specificity for CCR2. In another embodiment, the invention relates to a humanized immunoglobulin having binding specificity for CCR2 comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 17 and a complementary light chain, or an antigen-binding fragment of said humanized immunoglobulin having binding specificity for CCR2. A complementary light or heavy chain is one which is capable of associating with a selected heavy or light, respectively, chain, resulting in the ability of an immunoglobulin comprising said complementary heavy and light chains to have binding specificity for CCR2. In a preferred embodiment, the invention relates to a humanized immunoglobulin having binding specificity for CCR2 comprising a light chain comprising the amino acid sequence of SEQ ID NO: 12 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, or an antigen-binding fragment of said humanized immunoglobulin having binding specificity for CCR2.

In an alternative embodiment, a humanized immunoglobulin of the invention comprises both a light chain comprising the amino acid sequence of SEQ ID NO: 12 and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, or an antigen-binding fragment of said immunoglobulin having binding specificity for CCR2. In a further embodiment, a humanized immunoglobulin of the invention comprises both a light chain comprising the amino acid sequence of SEQ ID NO: 13 and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, or an antigen-binding fragment of said immunoglobulin having binding specificity for CCR2. In an additional embodiment, a humanized immunoglobulin of the invention comprises both a light chain comprising the amino acid sequence of SEQ ID NO: 14 and a heavy chain comprising an amino acid sequence selected from the group consisting



of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, or an antigen-binding fragment of said immunoglobulin having binding specificity for CCR2. In another embodiment, a humanized immunoglobulin of the invention comprises both a light chain comprising the amino acid sequence of SEQ ID NO: 15  
5 and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, or an antigen-binding fragment of said immunoglobulin having binding specificity for CCR2. In an alternative embodiment, a humanized immunoglobulin of the invention comprises both a light chain comprising the amino acid sequence of  
10 SEQ ID NO: 107 and a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, or an antigen-binding fragment of said immunoglobulin having binding specificity for CCR2.

In another embodiment, a humanized immunoglobulin of the invention  
15 comprises both a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 107 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 17, or an antigen-binding fragment of said immunoglobulin having binding specificity for CCR2. In an alternate embodiment, a humanized immunoglobulin of the  
20 invention comprises both a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 107 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 18, or an antigen-binding fragment of said immunoglobulin having binding specificity for CCR2. In a further embodiment, a  
25 humanized immunoglobulin of the invention comprises both a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 107 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 19, or an antigen-binding fragment of said immunoglobulin having binding specificity for  
30 CCR2. In an additional embodiment, a humanized immunoglobulin of the invention comprises both a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO:

15 and SEQ ID NO: 107 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 20, or an antigen-binding fragment of said immunoglobulin having binding specificity for CCR2.

5 In one embodiment, the humanized immunoglobulin light chain or antigen-binding fragment thereof having binding specificity for CCR2 can be encoded by a nucleic acid molecule comprising SEQ ID NO: 98. In another embodiment, the humanized immunoglobulin heavy chain or antigen-binding fragment thereof having binding specificity for CCR2 can be encoded by a nucleic acid molecule comprising SEQ ID NO: 97.

10 The invention also relates to a chimeric immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a light chain variable region of nonhuman origin and a human constant region (e.g., a light chain constant region). The invention further relates to a chimeric immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a  
15 heavy chain variable region of nonhuman origin and a human constant region (e.g., a heavy chain constant region). In another embodiment, the chimeric immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprises a light chain variable chain region of nonhuman origin and a heavy chain variable region of nonhuman origin and further comprises a human constant region (e.g., a  
20 human light chain constant region and/or a human heavy chain constant region).

### **Nucleic Acids and Constructs**

The present invention also relates to isolated and/or recombinant (including, e.g., essentially pure) nucleic acid molecules comprising nucleic acid sequences which encode a humanized immunoglobulin or humanized immunoglobulin light or  
25 heavy chain of the present invention.

Nucleic acid molecules referred to herein as "isolated" are nucleic acid molecules which have been separated away from the nucleic acids of the genomic DNA or cellular RNA of their source of origin (e.g., as it exists in cells or in a mixture of nucleic acids such as a library), and include nucleic acid molecules  
30 obtained by methods described herein or other suitable methods, including essentially pure nucleic acid molecules, nucleic acid molecules produced by

chemical synthesis, by combinations of biological and chemical methods, and recombinant nucleic acid molecules which are isolated (see e.g., Daugherty, B.L. *et al.*, *Nucleic Acids Res.*, 19(9): 2471-2476 (1991); Lewis, A.P. and J.S. Crowe, *Gene*, 101: 297-302 (1991)).

5           Nucleic acid molecules referred to herein as "recombinant" are nucleic acid molecules which have been produced by recombinant DNA methodology, including those nucleic acid molecules that are generated by procedures which rely upon a method of artificial recombination, such as the polymerase chain reaction (PCR) and/or cloning into a vector using restriction enzymes. "Recombinant" nucleic acid  
10 molecules are also those that result from recombination events that occur through the natural mechanisms of cells, but are selected for after the introduction to the cells of nucleic acids designed to allow and make probable a desired recombination event.

          The present invention also relates more specifically to isolated and/or recombinant nucleic acid molecules comprising a nucleotide sequence which  
15 encodes a humanized 1D9 immunoglobulin (i.e., a humanized immunoglobulin of the present invention in which the nonhuman portion is derived from the murine monoclonal antibody 1D9) or chain thereof. In one embodiment, the light chain comprises three complementarity determining regions derived from the light chain of the 1D9 antibody, and the heavy chain comprises three complementarity  
20 determining regions derived from the heavy chain of the 1D9 antibody. Such nucleic acid molecules include, for example, (a) a nucleic acid molecule comprising a sequence which encodes a polypeptide comprising the amino acid sequence of the heavy chain variable region of a humanized 1D9 immunoglobulin (e.g., heavy chain variable region of Figures 8 and 21) (e.g., nucleotides 58-411 of SEQ ID NO: 96);  
25 (b) a nucleic acid molecule comprising a sequence which encodes a polypeptide comprising the amino acid sequence of the light chain variable region of a humanized 1D9 immunoglobulin (e.g., light chain variable region of Figures 7 and 22) (e.g., nucleotides 52-390 of SEQ ID NO: 95); (c) a nucleic acid molecule comprising a sequence which encodes at least a functional portion of the light or  
30 heavy chain variable region of a humanized 1D9 immunoglobulin (e.g., a portion sufficient for antigen binding of a humanized immunoglobulin which comprises said chain). Due to the degeneracy of the genetic code, a variety of nucleic acids can be

made which encode a selected polypeptide. In one embodiment, the nucleic acid comprises the nucleotide sequence of the variable region as set forth or substantially as set forth in Figure 21 or as set forth or substantially as set forth in Figure 22, including double or single-stranded polynucleotides. (Although various figures may illustrate polypeptides which are larger than the variable region (i.e., include a signal peptide coding sequence or a portion of a constant region coding sequence), reference to the variable region of a particular figure is meant to include the variable region portion of the sequence shown). Isolated and/or recombinant nucleic acid molecules meeting these criteria can comprise nucleic acid molecules encoding sequences identical to sequences of humanized 1D9 antibody or variants thereof as discussed above.

Nucleic acid molecules of the present invention can be used in the production of humanized immunoglobulins having binding specificity for CCR2. For example, a nucleic acid molecule (e.g., DNA) encoding a humanized immunoglobulin of the present invention can be incorporated into a suitable construct (e.g., a vector) for further manipulation of sequences or for production of the encoded polypeptide in suitable host cells.

### Targeting Molecules

The invention also relates to targeting molecules which can effectuate the interaction of a CCR2-expressing cell with a target cell. The targeting molecule includes a first binding moiety which can bind mammalian CCR2, and a second binding moiety which can bind a molecule expressed on the surface of a target cell. Preferred target cells include tumor cells and virus infected cells. A variety of molecules which are expressed at higher levels or uniquely on tumor cells (e.g., tumor antigens, such as Lewis Y, HER-2/neu, disialoganglioside G3, carcinoembryonic antigen, CD30) and/or virus infected cells (e.g., viral antigens, such as influenza virus hemagglutinin, Epstein-Barr virus LMP-1, hepatitis C virus E2 glycoprotein, HIV gp160, HIV gp 120) are known in the art. The targeting molecule can contain any suitable binding second moiety which binds to a molecule expressed on a desired target cell (see, for example Ring, U.S. Patent No. 5,948,647, the entire teachings of which are incorporated herein by reference). Suitable binding

moieties include, for example, proteins and peptides (including post-translationally modified forms e.g., glycosylated, phosphorylated, lipidated), sugars, lipids, peptidomimetics, small organic molecules, nucleic acids and other agents which bind mammalian CCR2 or a molecule expressed on the surface of a target cell.

- 5 Suitable binding moieties can be identified using any suitable method, such as the binding assays described herein.

In a preferred embodiment, the first binding moiety can be, for example, a humanized immunoglobulin of the invention which binds mammalian CCR2 or antigen-binding fragment thereof (e.g., Fab, Fv, Fab', F(ab)'<sub>2</sub>). The second binding  
10 moiety can be, for example, an antibody (e.g., a second humanized immunoglobulin) or antigen-binding fragment thereof which binds to a molecule expressed on the target cell or antigen binding fragment thereof. Where the targeting molecule comprises a first binding moiety which is a humanized anti-CCR2 immunoglobulin or antigen-binding fragment thereof, it is preferred that the humanized anti-CCR2  
15 immunoglobulin does not inhibit binding of ligand to CCR2.

The first binding moiety can be directly or indirectly bonded to the second binding moiety through a variety of suitable linkages. For example, when the first binding moiety and the second binding moiety are both proteins or peptides, the moieties can be part of a contiguous polypeptide (i.e., a fusion protein). Where the  
20 targeting molecule is a fusion protein, the first and second binding moieties can be arranged on the polypeptide in any suitable configuration. The first and second binding moieties can be indirectly bonded through a (i.e., one or more) peptide linker, or bonded directly to each other through a peptide bond.

Where the binding moieties are not part of a contiguous polypeptide they can  
25 be directly bonded by a chemical bond formed by reaction of a functional group (or activated derivative thereof) on the first moiety with a second functional group (or activated derivative thereof) on the second moiety. For example, two thiols can react to form a disulfide bond and an amine can react with a carboxylic acid or acyl halide to form an amide. A variety of other suitable reactions which can be used are  
30 known in the art (see, for example, Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, CA (1996)). The binding moieties can be indirectly bonded through a suitable linker (e.g., a peptide linker). Generally, a linker contains

two reactive groups which can react to form bonds with the first binding moiety and/or the second binding moiety. Linkers which contain two different reactive groups (e.g., a heterobifunctional linker) can be used to selectively conjugate the first binding moiety to the second binding moiety. Many linkers which are suitable for forming conjugates between proteins, nucleic acids, peptides, vitamins, sugars, lipids, small organic molecules and other suitable agents are known (see, for example, U.S. Patent Nos. 5,856,571, 5,880,270; Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, CA (1996)).

Preferably, the independent activities of the binding moieties (e.g., binding activities, chemoattractant activity) of the targeting molecule are not significantly different from the activities of the binding moieties as separate molecular entities. For example, where the first binding moiety is a humanized immunoglobulin or antigen-binding fragment that binds CCR2, the targeting molecule can bind to CCR2 with an affinity which is within a factor of about 1000, preferably within a factor of 100, more preferably within a factor of 10 or substantially the same as the affinity of the free antibody or antigen-binding fragment. Target molecules with these preferred characteristics can be prepared using any suitable method. The resulting targeting molecule can then be assayed for binding (e.g., by ELISA) and for chemoattractant activity.

In one embodiment, the targeting molecule is a bispecific humanized antibody or bispecific antigen-binding fragment thereof (e.g., F(ab')<sub>2</sub>) which has specificity for mammalian CCR2 and a molecule expressed on a target cell (e.g., tumor antigen, viral antigen). Bispecific antibodies can be secreted by triomas and hybrid hybridomas. The supernatants of triomas and hybrid hybridomas can be assayed for bispecific antibody using a suitable assay (e.g., ELISA), and bispecific antibodies can be purified using conventional methods. These antibodies can then be humanized according to methods described herein. Thus, the invention provides a targeting molecule which is a humanized bispecific antibody having binding specificity for CCR2 and an antigen expressed on a target cell, or a bivalent antigen-binding fragment of the bispecific antibody. The invention also relates to a method of effectuating the interaction of a CCR2-bearing cell with a target cell in a patient, comprising administering to the patient an effective amount of a targeting molecule

which is a humanized bispecific antibody having binding specificity for CCR2 and an antigen expressed on a target cell, or a bivalent antigen-binding fragment of the bispecific antibody.

### Method of Producing Humanized Immunoglobulins Having Specificity for

#### 5 CCR2

Another aspect of the invention relates to a method of preparing a humanized immunoglobulin which has binding specificity for CCR2. The humanized immunoglobulin can be obtained, for example, by the expression of one or more recombinant nucleic acids encoding a humanized immunoglobulin having binding  
10 specificity for CCR2 in a suitable host cell, for example.

Constructs or expression vectors suitable for the expression of a humanized immunoglobulin having binding specificity for CCR2 are also provided. The constructs can be introduced into a suitable host cell, and cells which express a humanized immunoglobulin of the present invention can be produced and  
15 maintained in culture. Suitable host cells can be prokaryotic, including bacterial cells such as *E. coli*, *B. subtilis* and or other suitable bacteria, or eucaryotic, such as fungal or yeast cells (e.g., *Pichia pastoris*, *Aspergillus species*, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Neurospora crassa*), or other lower eucaryotic cells, and cells of higher eucaryotes such as those from insects (e.g., Sf9  
20 insect cells (WO 94/26087, O'Connor, published November 24, 1994)) or mammals (e.g., COS cells, such as COS-1 (ATCC Accession No. CRL-1650) and COS-7 (ATCC Accession No. CRL-1651), CHO (e.g., ATCC Accession No. CRL-9096), 293 (ATCC Accession No. CRL-1573), HeLa (ATCC Accession No. CCL-2), CV1 (ATCC Accession No. CCL-70), WOP (Dailey *et al.*, *J. Virol.* 54:739-749 (1985)),  
25 3T3, 293T (Pear *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 90:8392-8396 (1993)), NSO cells, SP2/0, HuT 78 cells, and the like (see, e.g., Ausubel, F.M. *et al.*, eds. *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons Inc., (1993)).

Host cells which produce a humanized immunoglobulin having binding  
30 specificity for CCR2 can be produced as follows. For example, a nucleic acid encoding all or part of the coding sequence for the desired humanized

immunoglobulin can be inserted into a nucleic acid vector, e.g., a DNA vector, such as a plasmid, virus or other suitable replicon for expression. A variety of vectors are available, including vectors which are maintained in single copy or multiple copy, or which become integrated into the host cell chromosome.

5        Suitable expression vectors can contain a number of components, including, but not limited to one or more of the following: an origin of replication; a selectable marker gene; one or more expression control elements, such as a transcriptional control element (e.g., a promoter, an enhancer, terminator), and/or one or more translation signals; a signal sequence or leader sequence for membrane targeting or  
10        secretion. In a construct, a signal sequence can be provided by the vector or other source. For example, the transcriptional and/or translational signals of an immunoglobulin can be used to direct expression.

         A promoter can be provided for expression in a suitable host cell. Promoters can be constitutive or inducible. For example, a promoter can be operably linked to  
15        a nucleic acid encoding a humanized immunoglobulin or immunoglobulin chain, such that it directs expression of the encoded polypeptide. A variety of suitable promoters for procaryotic (e.g., lac, tac, T3, T7 promoters for *E. coli*) and eucaryotic (e.g., yeast alcohol dehydrogenase (ADH1), SV40, CMV) hosts are available.

         In addition, the expression vectors typically comprise a selectable marker for  
20        selection of host cells carrying the vector, and, in the case of replicable expression vector, an origin or replication. Genes encoding products which confer antibiotic or drug resistance are common selectable markers and may be used in procaryotic (e.g.,  $\beta$ -lactamase gene (ampicillin resistance), *Tet* gene for tetracycline resistance) and eucaryotic cells (e.g., neomycin (G418 or geneticin), gpt (mycophenolic acid),  
25        ampicillin, or hygromycin resistance genes). Dihydrofolate reductase marker genes permit selection with methotrexate in a variety of hosts. Genes encoding the gene product of auxotrophic markers of the host (e.g., *LEU2*, *URA3*, *HIS3*) are often used as selectable markers in yeast. Use of viral (e.g., baculovirus) or phage vectors, and vectors which are capable of integrating into the genome of the host cell, such as  
30        retroviral vectors, are also contemplated. In one embodiment, the vector is pLK TOK38. The present invention also relates to cells carrying these expression vectors.



An expression vector comprising a fused gene encoding a humanized immunoglobulin light chain, said gene comprising a nucleotide sequence encoding a CDR derived from a light chain of a nonhuman antibody having binding specificity for CCR2 and a framework region derived from a light chain of human origin.

5        Thus, the invention includes an expression vector comprising a gene encoding a humanized immunoglobulin light chain, said gene comprising a nucleotide sequence encoding a CDR derived from a light chain of a nonhuman antibody having binding specificity for CCR2 and a framework region derived from a light chain of human origin. The invention also relates to an expression vector  
10   comprising a gene encoding a humanized immunoglobulin heavy chain, said gene comprising a nucleotide sequence encoding a CDR derived from a heavy chain of a nonhuman antibody having binding specificity for CCR2 and a framework region derived from a heavy chain of human origin. In one embodiment, the nonhuman antibody is murine antibody 1D9. The invention also includes host cells comprising  
15   the expression vectors of the invention. The invention also relates to an isolated or recombinant gene encoding a humanized immunoglobulin light or heavy chain comprising a first nucleic acid sequence encoding an antigen binding region derived from murine monoclonal antibody 1D9; and a second nucleic acid sequence encoding at least a portion of a constant region of an immunoglobulin of human  
20   origin.

The invention also relates to a host cell (e.g., which expresses a humanized immunoglobulin or an antigen binding fragment thereof having specificity for CCR2) comprising a first recombinant nucleic acid molecule encoding a humanized immunoglobulin light chain or fragment thereof and a second recombinant nucleic  
25   acid molecule encoding a humanized immunoglobulin heavy chain or fragment thereof, wherein said first nucleic acid molecule comprises a nucleotide sequence encoding a CDR derived from the light chain of murine antibody 1D9 and a framework region derived from a light chain of human origin, and wherein said second nucleic acid molecule comprises a nucleotide sequence encoding a CDR  
30   derived from the heavy chain of murine antibody 1D9 and a framework region derived from a heavy chain of human origin. The invention also includes a method of preparing a humanized immunoglobulin or antigen-binding fragment thereof

comprising maintaining a host cell of the invention under conditions appropriate for expression of a humanized immunoglobulin, whereby humanized immunoglobulin chains are expressed and a humanized immunoglobulin or antigen-binding fragment thereof having specificity for CCR2 is produced. The method can further comprise  
5 the step of isolating the humanized immunoglobulin or fragment thereof.

For example, a nucleic acid molecule (i.e., one or more nucleic acid molecules) encoding the heavy and light chains of a humanized immunoglobulin having binding specificity for CCR2, or a construct (i.e., one or more constructs) comprising such nucleic acid molecule(s), can be introduced into a suitable host cell  
10 by a method appropriate to the host cell selected (e.g., transformation, transfection, electroporation, infection), such that the nucleic acid molecule(s) are operably linked to one or more expression control elements (e.g., in a vector, in a construct created by processes in the cell, integrated into the host cell genome). Host cells can be maintained under conditions suitable for expression (e.g., in the presence of inducer,  
15 suitable media supplemented with appropriate salts, growth factors, antibiotic, nutritional supplements, etc.), whereby the encoded polypeptide(s) are produced. If desired, the encoded protein (e.g., humanized 1D9 antibody) can be isolated from, e.g., the host cells, medium, milk. This process encompasses expression in a host cell of a transgenic animal (see e.g., WO 92/03918, GenPharm International,  
20 published March 19, 1992).

Fusion proteins can be produced in which a humanized immunoglobulin or immunoglobulin chain is linked to a non-immunoglobulin moiety (i.e., a moiety which does not occur in immunoglobulins as found in nature) in an N-terminal location, C-terminal location or internal to the fusion protein. For example, some  
25 embodiments can be produced by the insertion of a nucleic acid encoding immunoglobulin sequences into a suitable expression vector, such as a pET vector (e.g., pET-15b, Novagen), a phage vector (e.g., pCANTAB 5 E, Pharmacia), or other vector (e.g., pRIT2T Protein A fusion vector, Pharmacia). The resulting construct can be introduced into a suitable host cell for expression. Upon expression, some  
30 fusion proteins can be isolated or purified from a cell lysate by means of a suitable affinity matrix (see e.g., *Current Protocols in Molecular Biology* (Ausubel, F.M. et al., eds., Vol. 2, Suppl. 26, pp. 16.4.1-16.7.8 (1991))).

### Therapeutic Methods and Compositions

The present invention provides humanized immunoglobulins which (1) can bind CCR2 *in vitro* and/or *in vivo*; and/or (2) can modulate an activity or function of CCR2, such as (a) binding function (e.g., the ability of CCR2 to bind to a ligand) and/or (b) leukocyte trafficking, including recruitment and/or accumulation of leukocytes in tissues. Preferably the humanized immunoglobulins are capable of selectively binding CCR2 *in vitro* and/or *in vivo*, and inhibiting CCR2-mediated interactions. In one embodiment, a humanized immunoglobulin can bind CCR2, and can inhibit binding of CCR2 to one or more of its ligands (e.g., HIV, MCP-1, MCP-2, MCP-3, MCP-4). The humanized immunoglobulins of the present invention are useful in a variety of processes with applications in research, diagnosis and therapy. For instance, they can be used to detect, isolate, and/or purify CCR2 or variants thereof (e.g., by affinity purification or other suitable methods), and to study CCR2 structure (e.g., conformation) and function. The humanized immunoglobulins of the present invention can also be used in diagnostic applications (e.g., *in vitro*, *ex vivo*) or to modulate CCR2 function in therapeutic (including prophylactic) applications.

For example, the humanized immunoglobulins of the present invention can be used to detect and/or measure the level of CCR2 in a sample (e.g., tissues or body fluids, such as an inflammatory exudate, blood, serum, bowel fluid, on cells bearing CCR2). For example, a sample (e.g., tissue and/or body fluid) can be obtained from an individual and a suitable immunological method can be used to detect and/or measure CCR2 expression, including methods such as enzyme-linked immunosorbent assays (ELISA), including chemiluminescence assays, radioimmunoassay, and immunohistology. In one embodiment, a method of detecting a selected CCR2 in a sample is provided, comprising contacting a sample with a humanized immunoglobulin of the present invention under conditions suitable for specific binding of the humanized immunoglobulin to CCR2 and detecting antibody-CCR2 complexes which are formed. In an application of the method, humanized immunoglobulins can be used to analyze normal versus inflamed tissues (e.g., from a human) for CCR2 reactivity and/or expression (e.g., immunohistologically), to detect associations between particular conditions and

increased expression of CCR2 (e.g., in affected tissues). The humanized immunoglobulins of the present invention permit immunological methods of assessment of the presence of CCR2 in normal versus inflamed tissues, through which the presence of disease, disease progress and/or the efficacy of anti-CCR2  
5 integrin therapy in inflammatory disease can be assessed.

The humanized immunoglobulins of the present invention can also be used to modulate (e.g., inhibit (reduce or prevent)) binding function and/or leukocyte (e.g., lymphocyte, monocyte) trafficking modulated by CCR2. For example, humanized immunoglobulins which inhibit the binding of CCR2 to a ligand (i.e.,  
10 one or more ligands) can be administered according to the method in the treatment of diseases associated with leukocyte (e.g., lymphocyte, monocyte) infiltration of tissues. Additionally, humanized immunoglobulins which inhibit the binding of CCR2 to a ligand (i.e., one or more ligands) can be administered according to the method in the treatment of HIV. An effective amount of a humanized  
15 immunoglobulin of the present invention (i.e., one or more) is administered to an individual (e.g., a mammal, such as a human or other primate) in order to treat such a disease.

The humanized immunoglobulin is administered in an effective amount which inhibits binding of CCR2 to a ligand thereof. For therapy, an effective  
20 amount will be sufficient to achieve the desired therapeutic (including prophylactic) effect (such as an amount sufficient to reduce or prevent CCR2-mediated binding and/or signalling). The humanized immunoglobulin can be administered in a single dose or multiple doses. The dosage can be determined by methods known in the art and can be dependent, for example, upon the individual's age, sensitivity, tolerance  
25 and overall well-being. Suitable dosages for antibodies can be from about 0.1 mg/kg body weight to about 10.0 mg/kg body weight per treatment.

According to the method, the humanized immunoglobulin can be administered to an individual (e.g., a human) alone or in conjunction with another agent. A humanized immunoglobulin can be administered before, along with or  
30 subsequent to administration of the additional agent. Thus, the invention includes pharmaceutical compositions comprising a humanized immunoglobulin or antigen-binding fragment thereof of the invention and a suitable carrier. In one embodiment,

more than one humanized immunoglobulin which inhibits the binding of CCR2 to its ligands is administered. In another embodiment an additional monoclonal antibody is administered in addition to a humanized immunoglobulin of the present invention. In yet another embodiment, an additional pharmacologically active  
5 ingredient (e.g., an antiinflammatory compound, such as sulfasalazine, another non-steroidal antiinflammatory compound, or a steroidal antiinflammatory compound) can be administered in conjunction with a humanized immunoglobulin of the present invention.

A variety of routes of administration are possible, including, but not  
10 necessarily limited to, parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous injection), oral (e.g., dietary), topical, inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops), or rectal, depending on the disease or condition to be treated. Parenteral administration is a preferred mode of administration.

15 Formulation will vary according to the route of administration selected (e.g., solution, emulsion). An appropriate composition comprising the humanized antibody to be administered can be prepared in a physiologically acceptable vehicle or carrier. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline  
20 and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers (See, generally, *Remington's Pharmaceutical Sciences*, 17th Edition, Mack Publishing Co., PA, 1985). For inhalation, the compound can be  
25 solubilized and loaded into a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser).

Thus, the invention includes a method of inhibiting HIV infection of a cell, comprising contacting a cell with an effective amount of a composition comprising a humanized immunoglobulin or antigen-binding fragment thereof of the invention.  
30 The invention also relates to a method of treating HIV or inhibiting HIV infection in a patient comprising administering to the patient a composition comprising an

effective amount of a humanized immunoglobulin of or antigen-binding fragment thereof of the invention.

The invention also relates to a method of inhibiting a function associated with binding of a chemokine to mammalian CCR2 or a functional portion of CCR2,  
5 comprising contacting a composition comprising CCR2 or portion thereof with an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of the invention, wherein said humanized immunoglobulin inhibits binding of the chemokine to mammalian CCR2 and inhibits one or more functions associated with binding of the chemokine to CCR2. For example, the chemokine  
10 can be selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations thereof.

The invention also relates to a method of inhibiting leukocyte trafficking in a patient, comprising administering to the patient a composition comprising an effective amount of a humanized immunoglobulin or antigen-binding fragment  
15 thereof of the invention which binds to mammalian CCR2 and inhibits binding of a ligand to the receptor. For example, the ligand can be a chemokine (e.g., MCP-1, MCP-2, MCP-3, MCP-4) or HIV.

The invention also relates to a method of inhibiting the interaction of a first cell expressing CCR2 with a ligand (e.g., on a second cell expressing a ligand of  
20 CCR2), comprising contacting the first cell with an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of the invention, particularly wherein said immunoglobulin or fragment inhibits the binding of ligand to CCR2. For example, the cell can be selected from the group consisting of lymphocytes, monocytes, granulocytes, T cells, basophils, and cells comprising a recombinant  
25 nucleic acid encoding CCR2 or a portion thereof. In one embodiment, the ligand is a chemokine (e.g., MCP-1, MCP-2, MCP-3, MCP-4). In another embodiment, the ligand is HIV.

The invention also includes a method of treating a CCR2-mediated disorder in a patient, comprising administering to the patient an effective amount of a  
30 humanized immunoglobulin or antigen-binding fragment thereof of the invention which binds to mammalian CCR2. The disorder can include, but is not limited to, allergy, atherogenesis, anaphylaxis, malignancy, chronic and acute inflammatory

disorders, histamine and IgE-mediated allergic reactions, shock, and rheumatoid arthritis, atherosclerosis, multiple sclerosis, stenosis, restenosis, allograft rejection, fibrotic disease, asthma, and inflammatory glomerulopathies.

In a particular embodiment, the invention relates to a method of inhibiting  
5 restenosis in a patient, comprising administering to the patient an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of the invention which binds to mammalian CCR2. The invention also includes a humanized immunoglobulin or antigen-binding fragment thereof of the invention for use in therapy or diagnosis or for use in treating a CCR2-mediated disease or  
10 disorder. The invention also includes the use of a humanized immunoglobulin or antigen-binding fragment thereof of the invention for the manufacture of a medicament for treating a CCR2-mediated disease.

Anti-idiotypic antibodies are also provided. Anti-idiotypic antibodies recognize antigenic determinants associated with the antigen-binding site of another  
15 antibody. Anti-idiotypic antibodies can be prepared against second antibody by immunizing an animal of the same species, and preferably of the same strain, as the animal used to produce the second antibody. See e.g., U.S. Patent No. 4,699,880.

The present invention also pertains to the hybridoma cell lines deposited under ATCC Accession Nos. HB-12549 and HB-12550, as well as to the  
20 monoclonal antibodies produced by the hybridoma cell lines deposited under ATCC Accession Nos. HB-12549 and HB-12550. The cell lines of the present invention have uses other than for the production of the monoclonal antibodies. For example, the cell lines of the present invention can be fused with other cells (such as suitably drug-marked human myeloma, mouse myeloma, human-mouse heteromyeloma or  
25 human lymphoblastoid cells) to produce additional hybridomas, and thus provide for the transfer of the genes encoding the monoclonal antibodies. In addition, the cell lines can be used as a source of nucleic acids encoding the anti-CCR2 immunoglobulin chains, which can be isolated and expressed (e.g., upon transfer to other cells using any suitable technique (see e.g., Cabilly *et al.*, U.S. Patent No.  
30 4,816,567; Winter, U.S. Patent No. 5,225,539)). For instance, clones comprising a rearranged anti-CCR2 light or heavy chain can be isolated (e.g., by PCR) or cDNA libraries can be prepared from mRNA isolated from the cell lines, and cDNA clones

encoding an anti-CCR2 immunoglobulin chain can be isolated. Thus, nucleic acids encoding the heavy and/or light chains of the antibodies or portions thereof can be obtained and used in accordance with recombinant DNA techniques for the production of the specific immunoglobulin, immunoglobulin chain, or variants thereof (e.g., humanized immunoglobulins) in a variety of host cells or in an *in vitro* translation system. For example, the nucleic acids, including cDNAs, or derivatives thereof encoding variants such as a humanized immunoglobulin or immunoglobulin chain, can be placed into suitable prokaryotic or eukaryotic vectors (e.g., expression vectors) and introduced into a suitable host cell by an appropriate method (e.g., transformation, transfection, electroporation, infection), such that the nucleic acid is operably linked to one or more expression control elements (e.g., in the vector or integrated into the host cell genome). For production, host cells can be maintained under conditions suitable for expression (e.g., in the presence of inducer, suitable media supplemented with appropriate salts, growth factors, antibiotic, nutritional supplements, etc.), whereby the encoded polypeptide is produced. If desired, the encoded protein can be recovered and/or isolated (e.g., from the host cells, medium, milk). It will be appreciated that the method of production encompasses expression in a host cell of a transgenic animal (see e.g., WO 92/03918, GenPharm International, published March 19, 1992).

As described herein, antibodies and functional fragments thereof of the present invention can block (inhibit) binding of a ligand to CCR2 and/or inhibit function associated with binding of the ligand to the CCR2. As discussed below various methods can be used to assess inhibition of binding of a ligand to CCR2 and/or function associated with binding of the ligand to the receptor.

## 25 Binding Assays

As used herein "mammalian CCR2 protein" refers to naturally occurring or endogenous mammalian CCR2 proteins and to proteins having an amino acid sequence which is the same as that of a naturally occurring or endogenous corresponding mammalian CCR2 protein (e.g., recombinant proteins). Accordingly, as defined herein, the term includes mature receptor protein, polymorphic or allelic variants, and other isoforms of a mammalian CCR2 (e.g., produced by alternative



- splicing or other cellular processes), and modified or unmodified forms of the foregoing (e.g., glycosylated, unglycosylated). Mammalian CCR2 proteins can be isolated and/or recombinant proteins (including synthetically produced proteins). Naturally occurring or endogenous mammalian CCR2 proteins include wild type
- 5 proteins such as mature CCR2, polymorphic or allelic variants and other isoforms which occur naturally in mammals (e.g., humans, non-human primates), such as the CCR2a and CCR2b forms of the receptor protein which are produced by alternative splicing of the carboxy-terminus of the protein. Such proteins can be recovered or isolated from a source which naturally produces mammalian CCR2, for example.
- 10 These proteins and mammalian CCR2 proteins having the same amino acid sequence as a naturally occurring or endogenous corresponding mammalian CCR2, are referred to by the name of the corresponding mammal. For example, where the corresponding mammal is a human, the protein is designated as a human CCR2 protein (e.g., a recombinant human CCR2 produced in a suitable host cell).
- 15 "Functional variants" of mammalian CCR2 proteins include functional fragments, functional mutant proteins, and/or functional fusion proteins (e.g., produced via mutagenesis and/or recombinant techniques). Generally, fragments or portions of mammalian CCR2 proteins include those having a deletion (i.e., one or more deletions) of an amino acid (i.e., one or more amino acids) relative to the
- 20 mature mammalian CCR2 protein (such as N-terminal, C-terminal or internal deletions). Fragments or portions in which only contiguous amino acids have been deleted or in which non-contiguous amino acids have been deleted relative to mature mammalian CCR2 protein are also envisioned.
- Generally, mutants of mammalian CCR2 proteins include natural or artificial
- 25 variants of a mammalian CCR2 protein differing by the addition, deletion and/or substitution of one or more contiguous or non-contiguous amino acid residues (e.g., receptor chimeras). Such mutations can be in a conserved region or nonconserved region (compared to other CXC and/or CC chemokine receptors), extracellular, cytoplasmic, or transmembrane region, for example.
- 30 Generally, fusion proteins encompass polypeptides comprising a mammalian CCR2 (e.g., human CCR2) as a first moiety, linked via a peptide bond to a second moiety not occurring in the mammalian CCR2 as found in nature. Thus, the second

moiety can be an amino acid, oligopeptide or polypeptide. The first moiety can be in an N-terminal location, C-terminal location or internal to the fusion protein. In one embodiment, the fusion protein comprises an affinity ligand (e.g., an enzyme, an antigen, epitope tag) as the first moiety, and a second moiety comprising a linker  
5 sequence and human CCR2 or a portion thereof.

A "functional fragment or portion", "functional mutant" and/or "functional fusion protein" of a mammalian CCR2 protein refers to an isolated and/or recombinant protein or polypeptide which has at least one function characteristic of a mammalian CCR2 protein as described herein, such as a binding activity, a  
10 signaling activity and/or ability to stimulate a cellular response. Preferred functional variants can bind a ligand (i.e., one or more ligands such as MCP-1, MCP-2, MCP-3 and/or MCP-4), and are referred to herein as "ligand binding variants".

In one embodiment, a functional variant of mammalian CCR2 shares at least about 85% sequence identity with said mammalian CCR2, preferably at least about  
15 90% sequence identity, and more preferably at least about 95% sequence identity with said mammalian CCR2. The nucleic acid and amino acid sequences of human CCR2a and CCR2b are described in U.S. Patent No. 5,707,815. Sequence identity can be determined using a suitable program, such as the Blastx program (Version 1.4), using appropriate parameters, such as default parameters. In one embodiment,  
20 parameters for Blastx search are scoring matrix BLOSUM62, W=3. In another embodiment, a functional variant comprises a nucleic acid sequence which is different from the naturally-occurring nucleic acid molecule but which, due to the degeneracy of the genetic code, encodes mammalian CCR2 or a portion thereof.

A composition comprising an isolated and/or recombinant mammalian  
25 CCR2 or functional variant thereof can be maintained under conditions suitable for binding, the mammalian CCR2 or variant is contacted with an antibody or fragment to be tested, and binding is detected or measured directly or indirectly. In one embodiment, cells which naturally express CCR2 or cells comprising a recombinant nucleic acid sequence which encodes a mammalian CCR2 or variant thereof are  
30 used. The cells are maintained under conditions appropriate for expression of receptor. The cells are contacted with an antibody or fragment under conditions suitable for binding (e.g., in a suitable binding buffer), and binding is detected by

standard techniques. To determine binding, the extent of binding can be determined relative to a suitable control (e.g., compared with background determined in the absence of antibody, compared with binding of a second antibody (i.e., a standard), compared with binding of antibody to untransfected cells). A cellular fraction, such as a membrane fraction, containing receptor or liposomes comprising receptor can be used in lieu of whole cells.

In one embodiment, the antibody is labeled with a suitable label (e.g., fluorescent label, isotope label, antigen or epitope label, enzyme label), and binding is determined by detection of the label. In another embodiment, bound antibody can be detected by labeled second antibody. Specificity of binding can be assessed by competition or displacement, for example, using unlabeled antibody or a ligand as competitor.

Binding inhibition assays can also be used to identify antibodies or fragments thereof which bind CCR2 and inhibit binding of another compound such as a ligand (e.g., MCP-1, MCP-2, MCP-3 and/or MCP-4) to CCR2 or a functional variant. For example, a binding assay can be conducted in which a reduction in the binding of a ligand of CCR2 (in the presence of an antibody), as compared to binding of the ligand in the absence of the antibody, is detected or measured. A composition comprising an isolated and/or recombinant mammalian CCR2 or functional variant thereof can be contacted with the ligand and antibody simultaneously, or one after the other, in either order. A reduction in the extent of binding of the ligand in the presence of the antibody, is indicative of inhibition of binding by the antibody. For example, binding of the ligand could be decreased or abolished.

In one embodiment, direct inhibition of the binding of a ligand (e.g., a chemokine such as MCP-1) to a mammalian CCR2 or variant thereof by an antibody or fragment is monitored. For example, the ability of an antibody to inhibit the binding of  $^{125}\text{I}$ -labeled MCP-1,  $^{125}\text{I}$ -labeled MCP-2,  $^{125}\text{I}$ -labeled MCP-3 or  $^{125}\text{I}$ -labeled MCP-4 to mammalian CCR2 can be monitored. Such an assay can be conducted using suitable cells bearing CCR2 or a functional variant thereof, such as isolated blood cells (e.g., T cells, PBMC) or a suitable cell line naturally expressing

CCR2, or a cell line containing nucleic acid encoding a mammalian CCR2, or a membrane fraction from said cells, for instance.

Other methods of identifying the presence of an antibody which binds CCR2 are available, such as other suitable binding assays, or methods which monitor  
5 events which are triggered by receptor binding, including signaling function and/or stimulation of a cellular response (e.g., leukocyte trafficking).

It will be understood that the inhibitory effect of antibodies of the present invention can be assessed in a binding inhibition assay. Competition between antibodies for receptor binding can also be assessed in the method. Antibodies  
10 which are identified in this manner can be further assessed to determine whether, subsequent to binding, they act to inhibit other functions of CCR2 and/or to assess their therapeutic utility.

### Signaling Assays

The binding of a ligand or promoter, such as an agonist, to CCR2 can result  
15 in signaling by this G protein-coupled receptor, and the activity of G proteins as well as other intracellular signaling molecules is stimulated. The induction of signaling function by a compound (e.g., an antibody or fragment thereof) can be monitored using any suitable method. Such an assay can be used to identify antibody agonists of CCR2. The inhibitory activity of an antibody or functional fragment thereof can  
20 be determined using a ligand or promoter in the assay, and assessing the ability of the antibody to inhibit the activity induced by ligand or promoter.

G protein activity, such as hydrolysis of GTP to GDP, or later signaling events triggered by receptor binding, such as induction of rapid and transient increase in the concentration of intracellular (cytosolic) free calcium  $[Ca^{2+}]_i$ , can be  
25 assayed by methods known in the art or other suitable methods (see e.g., Neote, K. *et al.*, *Cell*, 72: 415-425 1993); Van Riper *et al.*, *J. Exp. Med.*, 177: 851-856 (1993); Dahinden, C.A. *et al.*, *J. Exp. Med.*, 179: 751-756 (1994)).

For example, the functional assay of Sledziewski *et al.* using hybrid G protein coupled receptors can be used to monitor the ability a ligand or promoter to  
30 bind receptor and activate a G protein (Sledziewski *et al.*, U.S. Patent No. 5,284,746, the teachings of which are incorporated herein by reference).

Such assays can be performed in the presence of the antibody or fragment thereof to be assessed, and the ability of the antibody or fragment to inhibit the activity induced by the ligand or promoter is determined using known methods and/or methods described herein.

## 5 Chemotaxis and Assays of Cellular Stimulation

Chemotaxis assays can also be used to assess the ability of an antibody or functional fragment thereof to block binding of a ligand to mammalian CCR2 or functional variant thereof and/or inhibit function associated with binding of the ligand to the receptor. These assays are based on the functional migration of cells *in vitro* or *in vivo* induced by a compound. Chemotaxis can be assessed as described in the Examples, e.g., in an assay utilizing a 96-well chemotaxis plate, or using other art-recognized methods for assessing chemotaxis. For example, the use of an *in vitro* transendothelial chemotaxis assay is described by Springer *et al.* (Springer *et al.*, WO 94/20142, published September 15, 1994, the teachings of which are incorporated herein by reference; see also Berman *et al.*, *Immunol. Invest.* 17: 625-677 (1988)). Migration across endothelium into collagen gels has also been described (Kavanaugh *et al.*, *J. Immunol.*, 146: 4149-4156 (1991)). Stable transfectants of mouse L1-2 pre-B cells or of other suitable host cells capable of chemotaxis can be used in chemotaxis assays, for example.

Generally, chemotaxis assays monitor the directional movement or migration of a suitable cell (such as a leukocyte (e.g., lymphocyte, eosinophil, basophil)) into or through a barrier (e.g., endothelium, a filter), toward increased levels of a compound, from a first surface of the barrier toward an opposite second surface. Membranes or filters provide convenient barriers, such that the directional movement or migration of a suitable cell into or through a filter, toward increased levels of a compound, from a first surface of the filter toward an opposite second surface of the filter, is monitored. In some assays, the membrane is coated with a substance to facilitate adhesion, such as ICAM-1, fibronectin or collagen. Such assays provide an *in vitro* approximation of leukocyte "homing".

For example, one can detect or measure inhibition of the migration of cells in a suitable container (a containing means), from a first chamber into or through a

microporous membrane into a second chamber which contains an antibody to be tested, and which is divided from the first chamber by the membrane. A suitable membrane, having a suitable pore size for monitoring specific migration in response to compound, including, for example, nitrocellulose, polycarbonate, is selected. For  
5 example, pore sizes of about 3-8 microns, and preferably about 5-8 microns can be used. Pore size can be uniform on a filter or within a range of suitable pore sizes.

To assess migration and inhibition of migration, the distance of migration into the filter, the number of cells crossing the filter that remain adherent to the second surface of the filter, and/or the number of cells that accumulate in the second  
10 chamber can be determined using standard techniques (e.g., microscopy). In one embodiment, the cells are labeled with a detectable label (e.g., radioisotope, fluorescent label, antigen or epitope label), and migration can be assessed in the presence and absence of the antibody or fragment by determining the presence of the label adherent to the membrane and/or present in the second chamber using an  
15 appropriate method (e.g., by detecting radioactivity, fluorescence, immunoassay). The extent of migration induced by an antibody agonist can be determined relative to a suitable control (e.g., compared to background migration determined in the absence of the antibody, compared to the extent of migration induced by a second compound (i.e., a standard), compared with migration of untransfected cells induced  
20 by the antibody).

In one embodiment, particularly for T cells, monocytes or cells expressing a mammalian CCR2, transendothelial migration can be monitored. In this embodiment, transmigration through an endothelial cell layer is assessed. To prepare the cell layer, endothelial cells can be cultured on a microporous filter or  
25 membrane, optionally coated with a substance such as collagen, fibronectin, or other extracellular matrix proteins, to facilitate the attachment of endothelial cells. Preferably, endothelial cells are cultured until a confluent monolayer is formed. A variety of mammalian endothelial cells can be available for monolayer formation, including for example, vein, artery or microvascular endothelium, such as human  
30 umbilical vein endothelial cells (Clonetics Corp, San Diego, CA). To assay chemotaxis in response to a particular mammalian receptor, endothelial cells of the

same mammal are preferred; however endothelial cells from a heterologous mammalian species or genus can also be used.

Generally, the assay is performed by detecting the directional migration of cells into or through a membrane or filter, in a direction toward increased levels of a compound, from a first surface of the filter toward an opposite second surface of the filter, wherein the filter contains an endothelial cell layer on a first surface. Directional migration occurs from the area adjacent to the first surface, into or through the membrane, towards a compound situated on the opposite side of the filter. The concentration of compound present in the area adjacent to the second surface, is greater than that in the area adjacent to the first surface.

In one embodiment used to test for an antibody inhibitor, a composition comprising cells capable of migration and expressing a mammalian CCR2 receptor can be placed in the first chamber. A composition comprising one or more ligands or promoters capable of inducing chemotaxis of the cells in the first chamber (having chemoattractant function) is placed in the second chamber. Preferably shortly before the cells are placed in the first chamber, or simultaneously with the cells, a composition comprising the antibody to be tested is placed, preferably, in the first chamber. Antibodies or functional fragments thereof which can bind receptor and inhibit the induction of chemotaxis, by a ligand or promoter, of the cells expressing a mammalian CCR2 in this assay are inhibitors of receptor function (e.g., inhibitors of stimulatory function). A reduction in the extent of migration induced by the ligand or promoter in the presence of the antibody or fragment is indicative of inhibitory activity. Separate binding studies (see above) could be performed to determine whether inhibition is a result of binding of the antibody to receptor or occurs via a different mechanism.

*In vivo* assays which monitor leukocyte infiltration of a tissue, in response to injection of a compound (e.g., chemokine or antibody) in the tissue, are described below (see Models of Inflammation). These models of *in vivo* homing measure the ability of cells to respond to a ligand or promoter by emigration and chemotaxis to a site of inflammation and to assess the ability of an antibody or fragment thereof to block this emigration.

In addition to the methods described, the effects of an antibody or fragment on the stimulatory function of CCR2 can be assessed by monitoring cellular responses induced by active receptor, using suitable host cells containing receptor.

### **Identification of Additional Ligands, Inhibitors and/or Promoters of**

#### **5 Mammalian CCR2 Function**

The assays described above, which can be used to assess binding and function of the antibodies and fragments of the present invention, can be adapted to identify additional ligands or other substances which bind a mammalian CCR2 or functional variant thereof, as well as inhibitors and/or promoters of mammalian  
10 CCR2 function. For example, agents having the same or a similar binding specificity as that of an antibody of the present invention or functional portion thereof can be identified by a competition assay with said antibody or portion thereof. Thus, the present invention also encompasses methods of identifying ligands of the receptor or other substances which bind a mammalian CCR2 protein,  
15 as well as inhibitors (e.g., antagonists) or promoters (e.g., agonists) of receptor function. In one embodiment, cells bearing a mammalian CCR2 protein or functional variant thereof (e.g., leukocytes, cell lines or suitable host cells which have been engineered to express a mammalian CCR2 protein or functional variant encoded by a nucleic acid introduced into said cells) are used in an assay to identify  
20 and assess the efficacy of ligands or other substances which bind receptor, including inhibitors or promoters of receptor function. Such cells are also useful in assessing the function of the expressed receptor protein or polypeptide.

According to the present invention, ligands and other substances which bind receptor, inhibitors and promoters of receptor function can be identified in a suitable  
25 assay, and further assessed for therapeutic effect. Inhibitors of receptor function can be used to inhibit (reduce or prevent) receptor activity, and ligands and/or promoters can be used to induce (trigger or enhance) normal receptor function where indicated. Thus, the present invention provides a method of treating inflammatory diseases, including autoimmune disease and graft rejection, comprising administering an  
30 inhibitor of receptor function to an individual (e.g., a mammal). The present invention further provides a method of stimulating receptor function by



administering a novel ligand or promoter of receptor function to an individual, providing a new approach to selective stimulation of leukocyte function, which is useful, for example, in the treatment of infectious diseases and cancer.

As used herein, a "ligand" of a mammalian CCR2 protein refers to a particular class of substances which bind to a mammalian CCR2 protein, including natural ligands and synthetic and/or recombinant forms of natural ligands. Infectious agents having a tropism for mammalian CCR2-positive cells (e.g., viruses such as HIV) can also bind to a mammalian CCR2 protein. A natural ligand of a selected mammalian receptor is of a mammalian origin which is the same as that of the mammalian CCR2 protein (e.g., a chemokine such as MCP-1, MCP-2, MCP-3 and/or MCP-4). In a preferred embodiment, ligand binding of a mammalian CCR2 protein occurs with high affinity.

As used herein, an "inhibitor" is a substance which inhibits (decreases or prevents) at least one function characteristic of a mammalian CCR2 protein (e.g., a human CCR2), such as a binding activity (e.g., ligand binding, promoter binding, antibody binding), a signaling activity (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium  $[Ca^{2+}]_i$ ), and/or cellular response function (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes). An inhibitor is also a substance which inhibits HIV entry into a cell. The term inhibitor refers to substances including antagonists which bind receptor (e.g., an antibody, a mutant of a natural ligand, small molecular weight organic molecules, other competitive inhibitors of ligand binding), and substances which inhibit receptor function without binding thereto (e.g., an anti-idiotypic antibody).

As used herein, a "promoter" is a substance which promotes (induces, causes, enhances or increases) at least one function characteristic of a mammalian CCR2 protein (e.g., a human CCR2), such as a binding activity (e.g., ligand, inhibitor and/or promoter binding), a signaling activity (e.g., activation of a mammalian G protein, induction of rapid and transient increase in the concentration of cytosolic free calcium  $[Ca^{2+}]_i$ ), and/or a cellular response function (e.g., stimulation of chemotaxis, exocytosis or inflammatory mediator release by leukocytes). The term promoter refers to substances including agonists which bind receptor (e.g., an

antibody, a homolog of a natural ligand from another species), and substances which promote receptor function without binding thereto (e.g., by activating an associated protein). In a preferred embodiment, the agonist is other than a homolog of a natural ligand.

5        Thus, the invention also relates to a method of detecting or identifying an agent which binds a mammalian CC-chemokine receptor 2 or ligand binding variant thereof, including ligands, inhibitors, promoters, and other substances which bind a mammalian CCR2 receptor or functional variant. According to the method, an agent to be tested, an antibody or antigen-binding fragment of the present invention (e.g.,  
10    8G2, 1D9, an antibody having an epitopic specificity which is the same as or similar to that of 8G2 or 1D9, and antigen-binding fragments thereof) and a composition comprising a mammalian CC-chemokine receptor 2 or a ligand binding variant thereof can be combined. The foregoing components are combined under conditions suitable for binding of the antibody or antigen-binding fragment to mammalian CC-  
15    chemokine receptor 2 or a ligand binding variant thereof, and binding of the antibody or fragment to the mammalian CC-chemokine receptor 2 or ligand binding variant is detected or measured, either directly or indirectly, according to methods described herein or other suitable methods. A decrease in the amount of complex formed relative to a suitable control (e.g., in the absence of the agent to be tested) is  
20    indicative that the agent binds said receptor or variant. The composition comprising a mammalian CC-chemokine receptor 2 or a ligand binding variant thereof can be a membrane fraction of a cell bearing recombinant chemokine receptor 2 protein or ligand binding variant thereof. The antibody or fragment thereof can be labeled with a label such as a radioisotope, spin label, antigen or epitope label, enzyme label,  
25    fluorescent group and chemiluminescent group.

      In one embodiment, the invention relates to a method of detecting or identifying an agent which binds a mammalian CC-chemokine receptor 2 or a ligand binding variant thereof, comprising combining an agent to be tested, an antibody or antigen-binding fragment of the present invention (e.g., 1D9, 8G2, an antibody  
30    having an epitopic specificity which is the same as or similar to that of 1D9 or 8G2, or antigen-binding fragments thereof) and a cell bearing a mammalian CC-chemokine receptor 2 or a ligand binding variant thereof. The foregoing

components are combined under conditions suitable for binding of the antibody or antigen-binding fragment to the CCR2 protein or ligand binding variant thereof, and binding of the antibody or fragment to the mammalian CC-chemokine receptor 2 or variant is detected or measured, either directly or indirectly, by methods described  
5 herein and or other suitable methods. A decrease in the amount of complex formed relative to a suitable control is indicative that the agent binds the receptor or variant. The antibody or fragment thereof can be labeled with a label selected from the group consisting of a radioisotope, spin label, antigen or epitope label, enzyme label, fluorescent group and chemiluminescent group. These and similar assays can be  
10 used to detect agents, including ligands (e.g., chemokines or strains of HIV which interact with CCR2) or other substances, including inhibitors or promoters of receptor function, which can bind CCR2 and compete with the antibodies described herein for binding to the receptor.

The assays described above can be used, alone or in combination with each  
15 other or other suitable methods, to identify ligands or other substances which bind a mammalian CCR2 protein, and inhibitors or promoters of a mammalian CCR2 protein or variant. The *in vitro* methods of the present invention can be adapted for high-throughput screening in which large numbers of samples are processed (e.g., a 96-well format). Cells expressing mammalian CCR2 (e.g., human CCR2) at levels  
20 suitable for high-throughput screening can be used, and thus, are particularly valuable in the identification and/or isolation of ligands or other substances which bind receptor, and inhibitors or promoters of mammalian CCR2 proteins. Expression of receptor can be monitored in a variety of ways. For instance, expression can be monitored using antibodies of the present invention which bind  
25 receptor or a portion thereof. Also, commercially available antibodies can be used to detect expression of an antigen- or epitope-tagged fusion protein comprising a receptor protein or polypeptide (e.g., FLAG tagged receptors), and cells expressing the desired level can be selected.

Nucleic acid encoding a mammalian CCR2 protein or functional variant  
30 thereof can be incorporated into an expression system to produce a receptor protein or polypeptide. An isolated and/or recombinant mammalian CCR2 protein or variant, such as a receptor expressed in cells stably or transiently transfected with a

construct comprising a recombinant nucleic acid encoding a mammalian CCR2 protein or variant, or in a cell fraction containing receptor (e.g., a membrane fraction from transfected cells, liposomes incorporating receptor), can be used in tests for receptor function. The receptor can be further purified if desired. Testing of  
5 receptor function can be carried out *in vitro* or *in vivo*.

An isolated and/or recombinant mammalian CCR2 protein or functional variant thereof, such as a human CCR2, can be used in the present method, in which the effect of a compound is assessed by monitoring receptor function as described herein or using other suitable techniques. For example, stable or transient  
10 transfectants (e.g., baculovirus infected Sf9 cells, stable transfectants of mouse L1/2 pre-B cells), can be used in binding assays. Stable transfectants of Jurkat cells or of other suitable cells capable of chemotaxis can be used (e.g., mouse L1/2 pre-B cells) in chemotaxis assays, for example.

According to the method of the present invention, compounds can be  
15 individually screened or one or more compounds can be tested simultaneously according to the methods herein. Where a mixture of compounds is tested, the compounds selected by the processes described can be separated (as appropriate) and identified by suitable methods (e.g., PCR, sequencing, chromatography, mass spectroscopy). The presence of one or more compounds (e.g., a ligand, inhibitor,  
20 promoter) in a test sample can also be determined according to these methods.

Large combinatorial libraries of compounds (e.g., organic compounds, recombinant or synthetic peptides, "peptoids", nucleic acids) produced by combinatorial chemical synthesis or other methods can be tested (see e.g., Zuckerman, R.N. *et al.*, *J. Med. Chem.*, 37: 2678-2685 (1994) and references cited  
25 therein; see also, Ohlmeyer, M.H.J. *et al.*, *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993) and DeWitt, S.H. *et al.*, *Proc. Natl. Acad. Sci. USA* 90:6909-6913 (1993), relating to tagged compounds; Rutter, W.J. *et al.* U.S. Patent No. 5,010,175; Huebner, V.D. *et al.*, U.S. Patent No. 5,182,366; and Geysen, H.M., U.S. Patent No. 4,833,092). Where compounds selected from a combinatorial library by the present  
30 method carry unique tags, identification of individual compounds by chromatographic methods is possible.

In one embodiment, phage display methodology is used. For example, a mammalian CCR2 protein or functional variant, an antibody or functional portion thereof of the present invention, and a phage (e.g., a phage or collection of phage such as a library) displaying a polypeptide, can be combined under conditions appropriate for binding of the antibody or portion thereof to the mammalian CCR2 protein or variant (e.g., in a suitable binding buffer). Phage which can compete with the antibody or portion thereof and bind to the mammalian CCR2 protein or variant can be detected or selected using standard techniques or other suitable methods. Bound phage can be separated from receptor using a suitable elution buffer. For example, a change in the ionic strength or pH can lead to a release of phage. Alternatively, the elution buffer can comprise a release component or components designed to disrupt binding of compounds (e.g., one or more compounds which can disrupt binding of the displayed peptide to the receptor, such as a ligand, inhibitor, and/or promoter which competitively inhibits binding). Optionally, the selection process can be repeated or another selection step can be used to further enrich for phage which bind receptor. The displayed polypeptide can be characterized (e.g., by sequencing phage DNA). The polypeptides identified can be produced and further tested for binding, and for inhibitor or promoter function. Analogs of such peptides can be produced which will have increased stability or other desirable properties.

In one embodiment, phage expressing and displaying fusion proteins comprising a coat protein with an N-terminal peptide encoded by random sequence nucleic acids can be produced. Suitable host cells expressing a mammalian CCR2 protein or variant and an anti-CCR2 antibody or functional portion thereof, are combined with the phage, bound phage are selected, recovered and characterized. (See e.g., Doorbar, J. and G. Winter, *J. Mol. Biol.*, 244: 361 (1994) discussing a phage display procedure used with a G protein-coupled receptor).

Other sources of potential ligands or other substances which bind to, or inhibitors and/or promoters of, mammalian CCR2 proteins include, but are not limited to, variants of CCR2 ligands, including naturally occurring, synthetic or recombinant variants of MCP-1, MCP-2, MCP-3 and/or MCP-4, substances such as other chemoattractants or chemokines, variants thereof, low molecular weight organic molecules, other inhibitors and/or promoters (e.g., anti-CCR2 antibodies,

antagonists, agonists), other G protein-coupled receptor ligands, inhibitors and/or promoters (e.g., antagonists or agonists), and soluble portions of a mammalian CCR2 receptor, such as a suitable receptor peptide or analog which can inhibit receptor function (see e.g., Murphy, R.B., WO 94/05695).

## 5. Models of Inflammation

*In vivo* models of inflammation are available which can be used to assess the effects of antibodies and fragments of the invention *in vivo* as therapeutic agents. For example, leukocyte infiltration upon intradermal injection of a chemokine and an antibody or fragment thereof reactive with mammalian CCR2 into a suitable  
10 animal, such as rabbit, mouse, rat, guinea pig or rhesus macaque can be monitored (see e.g., Van Damme, J. *et al.*, *J. Exp. Med.*, 176: 59-65 (1992); Zachariae, C.O.C. *et al.*, *J. Exp. Med.* 171: 2177-2182 (1990); Jose, P.J. *et al.*, *J. Exp. Med.* 179: 881-887 (1994)). In one embodiment, skin biopsies are assessed histologically for infiltration of leukocytes (e.g., eosinophils, granulocytes). In another embodiment,  
15 labeled cells (e.g., stably transfected cells expressing a mammalian CCR2, labeled with <sup>111</sup>In for example) capable of chemotaxis and extravasation are administered to the animal. For example, an antibody or fragment to be assessed can be administered, either before, simultaneously with or after ligand or agonist is administered to the test animal. A decrease of the extent of infiltration in the  
20 presence of antibody as compared with the extent of infiltration in the absence of inhibitor is indicative of inhibition.

## Diagnostic and Therapeutic Applications

The antibodies and fragments of the present invention are useful in a variety of applications, including research, diagnostic and therapeutic applications. In one  
25 embodiment, the antibodies are labeled with a suitable label (e.g., fluorescent label, chemiluminescent label, isotope label, antigen or epitope label or enzyme label). For instance, they can be used to isolate and/or purify receptor or portions thereof, and to study receptor structure (e.g., conformation) and function.

In addition, the various antibodies of the present invention can be used to  
30 detect CCR2 or to measure the expression of receptor, for example, on T cells (e.g.,

-66-

CD8+ cells, CD45RO+ cells), monocytes and/or on cells transfected with a receptor gene. Thus, they also have utility in applications such as cell sorting (e.g., flow cytometry, fluorescence activated cell sorting), for diagnostic or research purposes.

The anti-CCR2 antibodies of the present invention have value in diagnostic  
5 applications. An anti-CCR2 antibody or fragment thereof can be used to monitor expression of this receptor in HIV infected individuals, similar to the way anti-CD4 has been used as a diagnostic indicator of disease stage.

Typically, diagnostic assays entail detecting the formation of a complex resulting from the binding of an antibody or fragment thereof to CCR2. For  
10 diagnostic purposes, the antibodies or antigen-binding fragments can be labeled or unlabeled. The antibodies or fragments can be directly labeled. A variety of labels can be employed, including, but not limited to, radionuclides, fluorescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors and ligands (e.g., biotin, haptens). Numerous appropriate immunoassays are known to the skilled artisan  
15 (see, for example, U.S. Patent Nos. 3,817,827; 3,850,752; 3,901,654 and 4,098,876). When unlabeled, the antibodies or fragments can be detected using suitable means, as in agglutination assays, for example. Unlabeled antibodies or fragments can also be used in combination with another (i.e., one or more) suitable reagent which can be used to detect antibody, such as a labeled antibody (e.g., a second antibody)  
20 reactive with the first antibody (e.g., anti-idiotypic antibodies or other antibodies that are specific for the unlabeled immunoglobulin) or other suitable reagent (e.g., labeled protein A).

In one embodiment, the antibodies or fragments of the present invention can be utilized in enzyme immunoassays, wherein the subject antibody or fragment, or  
25 second antibodies, are conjugated to an enzyme. When a biological sample comprising a mammalian CCR2 protein is combined with the subject antibodies, binding occurs between the antibodies and CCR2 protein. In one embodiment, a sample containing cells expressing a mammalian CCR2 protein, such as human blood, is combined with the subject antibodies, and binding occurs between the  
30 antibodies and cells bearing a human CCR2 protein comprising an epitope recognized by the antibody. These bound cells can be separated from unbound reagents and the presence of the antibody-enzyme conjugate specifically bound to

the cells can be determined, for example, by contacting the sample with a substrate of the enzyme which produces a color or other detectable change when acted on by the enzyme. In another embodiment, the subject antibodies can be unlabeled, and a second, labeled antibody can be added which recognizes the subject antibody.

- 5           Kits for use in detecting the presence of a mammalian CCR2 protein in a biological sample can also be prepared. Such kits will include an antibody or functional fragment thereof which binds to a mammalian CC-chemokine receptor 2 or portion of said receptor, as well as one or more ancillary reagents suitable for detecting the presence of a complex between the antibody or fragment and CCR2 or
- 10           portion thereof. The antibody compositions of the present invention can be provided in lyophilized form, either alone or in combination with additional antibodies specific for other epitopes. The antibodies, which can be labeled or unlabeled, can be included in the kits with adjunct ingredients (e.g., buffers, such as Tris, phosphate and carbonate, stabilizers, excipients, biocides and/or inert proteins, e.g., bovine
- 15           serum albumin). For example, the antibodies can be provided as a lyophilized mixture with the adjunct ingredients, or the adjunct ingredients can be separately provided for combination by the user. Generally these adjunct materials will be present in less than about 5% weight based on the amount of active antibody, and usually will be present in a total amount of at least about 0.001% weight based on
- 20           antibody concentration. Where a second antibody capable of binding to the monoclonal antibody is employed, such antibody can be provided in the kit, for instance in a separate vial or container. The second antibody, if present, is typically labeled, and can be formulated in an analogous manner with the antibody formulations described above.
- 25           Similarly, the present invention also relates to a method of detecting and/or quantitating expression of a mammalian CCR2 or a portion of the receptor by a cell, in which a composition comprising a cell or fraction thereof (e.g., membrane fraction) is contacted with an antibody or functional fragment thereof (e.g., 1D9 and/or 8G2) which binds to a mammalian CCR2 or portion of the receptor under
- 30           conditions appropriate for binding of the antibody or fragment thereto, and binding is monitored. Detection of the antibody, indicative of the formation of a complex between antibody and CCR2 or a portion thereof, indicates the presence of the



receptor. Binding of antibody to the cell can be determined as described above under the heading "Binding Assays", for example. The method can be used to detect expression of CCR2 on cells from an individual (e.g., in a sample, such as a body fluid, such as blood, saliva or other suitable sample). The level of expression of CCR2 on the surface of T cells or monocytes can also be determined, for instance, by flow cytometry, and the level of expression (e.g., staining intensity) can be correlated with disease susceptibility, progression or risk.

Chemokine receptors function in the migration of leukocytes throughout the body, particularly to inflammatory sites. Inflammatory cell emigration from the vasculature is regulated by a three-step process involving interactions of leukocyte and endothelial cell adhesion proteins and cell specific chemoattractants and activating factors (Springer, T.A., *Cell*, 76:301-314 (1994); Butcher, E.C., *Cell*, 67:1033-1036 (1991); Butcher, E.C. and Picker, L.J., *Science (Wash. DC)*, 272:60-66 (1996)). These are: (a) a low affinity interaction between leukocyte selectins and endothelial cell carbohydrates; (b) a high-affinity interaction between leukocyte chemoattractant receptors and chemoattractant/activating factors; and (c) a tight-binding between leukocyte integrins and endothelial cell adhesion proteins of the immunoglobulin superfamily. Different leukocyte subsets express different repertoires of selectins, chemoattractant receptors and integrins. Additionally, inflammation alters the expression of endothelial adhesion proteins and the expression of chemoattractant and leukocyte activating factors. As a consequence, there is a great deal of diversity for regulating the selectivity of leukocyte recruitment to extravascular sites. The second step is crucial in that the activation of the leukocyte chemoattractant receptors is thought to cause the transition from the selectin-mediated cell rolling to the integrin-mediated tight binding. This results in the leukocyte being ready to transmigrate to perivascular sites. The chemoattractant/chemoattractant receptor interaction is also crucial for transendothelial migration and localization within a tissue (Campbell, J.J., *et al.*, *J. Cell Biol.*, 134:255-266 (1996); Carr, M.W., *et al.*, *Immunity*, 4:179-187 (1996)). This migration is directed by a concentration gradient of chemoattractant leading towards the inflammatory focus.

CCR2 has an important role in leukocyte trafficking. It is likely that CCR2 is a key chemokine receptor for T cell or T cell subset or monocyte migration to certain inflammatory sites, and so anti-CCR2 mAbs can be used to inhibit (reduce or prevent) T cell or monocyte migration, particularly that associated with T cell dysfunction, such as autoimmune disease, or allergic reactions or with monocyte-mediated disorders such as atherosclerosis. Accordingly, the antibodies and fragments thereof of the present invention can also be used to modulate receptor function in research and therapeutic applications. For instance, the antibodies and functional fragments described herein can act as inhibitors to inhibit (reduce or prevent) (a) binding (e.g., of a ligand, an inhibitor or a promoter) to the receptor, (b) a receptor signaling function, and/or (c) a stimulatory function. Antibodies which act as inhibitors of receptor function can block ligand or promoter binding directly or indirectly (e.g., by causing a conformational change). For example, antibodies can inhibit receptor function by inhibiting binding of a ligand, or by desensitization (with or without inhibition of binding of a ligand). Antibodies which bind receptor can also act as agonists of receptor function, triggering or stimulating a receptor function, such as a signaling and/or a stimulatory function of a receptor (e.g., leukocyte trafficking) upon binding to receptor.

Thus, the present invention provides a method of inhibiting leukocyte trafficking in a mammal (e.g., a human patient), comprising administering to the mammal an effective amount of an antibody or functional fragment of the present invention. Administration of an antibody or fragment of the present invention can result in amelioration or elimination of the disease state.

The antibody of the present invention, or a functional fragment thereof, can also be used to treat disorders in which activation of the CCR2 receptor by binding of chemokines is implicated. For example, the antibodies or functional fragments thereof (e.g., 1D9 and/or 8G2 or functional fragments thereof) can be used to treat allergy, atherogenesis, anaphylaxis, malignancy, chronic and acute inflammation, histamine and IgE-mediated allergic reactions, shock, and rheumatoid arthritis, atherosclerosis, multiple sclerosis, stenosis, restenosis, allograft rejection, fibrotic disease, asthma, and inflammatory glomerulopathies.

-70-

Diseases or conditions of humans or other species which can be treated with inhibitors of CCR2 receptor function (including antibodies or suitable fragments thereof), include, but are not limited to:

- inflammatory or allergic diseases and conditions, including respiratory  
5 allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); chronic obstructive pulmonary disease;  
10 anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies; inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and  
15 hypersensitivity vasculitis);
  - autoimmune diseases, such as arthritis (e.g., rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis), multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes, nephritides such as glomerulonephritis, autoimmune thyroiditis, Behcet's disease;
- 20 ● graft rejection (e.g., in transplantation), including allograft rejection or graft-versus-host disease, and organ transplant-associated arteriosclerosis;
  - atherosclerosis;
  - cancers with leukocyte infiltration of the skin or organs;
  - stenosis or restenosis of the vasculature, particularly of the arteries, e.g.,  
25 the coronary artery, such as stenosis or restenosis which results from vascular intervention (e.g., surgical, therapeutic or mechanical intervention), as well as neointimal hyperplasia. For example, restenosis, which typically produces a narrowing of the luminal opening of the vessel, can result from vascular injury including, but not limited to, that produced by vascular graft procedures,  
30 angioplasty, including angioplasty performed by balloon, atherectomy, laser or other suitable method (e.g., percutaneous transluminal coronary angioplasty (PTCA)), stent placement (e.g., mechanical or biological endovascular stent placement),

vascular bypass procedures or combinations thereof, as well as other procedures used to treat stenotic or occluded blood vessels;

- other diseases or conditions (including CCR2-mediated diseases or conditions), in which undesirable inflammatory responses are to be inhibited can be treated, including, but not limited to, reperfusion injury, certain hematologic malignancies, cytokine-induced toxicity (e.g., septic shock, endotoxic shock), polymyositis, dermatomyositis, and granulomatous diseases including sarcoidosis.

Diseases or conditions of humans or other species which can be treated with promoters of CCR2 receptor function (including antibodies or fragments thereof), include, but are not limited to:

- immunosuppression, such as that in individuals with immunodeficiency syndromes such as AIDS, individuals undergoing radiation therapy, chemotherapy, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy), which causes immunosuppression; and immunosuppression due congenital deficiency in receptor function or other causes.

Anti-CCR2 antibodies of the present invention can block the binding of one or more chemokines, thereby blocking the downstream cascade of one or more events leading to the above disorders.

Antibodies and functional fragments thereof which are antagonists of CCR2 can be used as therapeutics for AIDS, as well as certain inflammatory diseases. HIV-1 and HIV-2 are the etiologic agents of acquired immunodeficiency syndrome (AIDS) in humans. AIDS results in part from the depletion of CD4+ T lymphocytes in HIV infected individuals. HIV-1 infects primarily T lymphocytes, monocytes/macrophages, dendritic cells and, in the central nervous system, microglia. All of these cells express the CD4 glycoprotein, which serves as a receptor for HIV-1 and HIV-2. Efficient entry of HIV into target cells is dependent upon binding of the viral exterior envelope glycoprotein, gp120, to the amino-terminal CD4 domain. After virus binding, the HIV-1 envelope glycoproteins mediate the fusion of viral and host cell membranes to complete the entry process. Membrane fusion directed by HIV-1 envelope glycoproteins expressed on the infected cell surface leads to cell-cell fusion, resulting in syncytia.

Recently, host cell factors in addition to CD4 have been suggested to determine the efficiency of HIV-1 envelope glycoprotein-mediated membrane fusion. The 7 transmembrane receptor (7TMR) termed HUMSTSR, LESTR, or "fusin" has been shown to allow a range of CD4-expressing cells to support infection and cell fusion mediated by laboratory-adapted HIV-1 envelope glycoproteins (Feng, Y., *et al.*, *Science (Wash. DC)*, 272:872-877 (1996)). Antibodies to HUMSTSR blocked cell fusion and infection by laboratory-adapted HIV-1 isolates but not by macrophage-tropic primary viruses *in vitro* (Feng, Y., *et al.*, *Science (Wash. DC)*, 272:872-877 (1996)).

10       The ability of chemokine receptors and related molecules to facilitate the infection of primary clinical HIV-1 isolates has been reported recently by several groups (see e.g., Bates, P., *Cell*, 86:1-3 (1996); Choe, H., *et al.*, *Cell*, 85:1135-1148 (1996); Doranz *et al.*, *Cell* 85:1149-1158 (1996)). These studies indicated that involvement of various members of the chemokine receptor family in the early stages of HIV-1 infection helps to explain viral tropism and  $\beta$ -chemokine inhibition of primary HIV-1 isolates.

15       The present invention also provides a method of inhibiting HIV infection of a cell (e.g., new infection and/or syncytium formation) which expresses a mammalian CCR2 or portion thereof, comprising contacting the cell with a composition comprising an effective amount of an antibody or functional fragment thereof which binds to a mammalian CCR2 or portion of said receptor. The composition can also comprise one or more additional agents effective against HIV, including, but not limited to, anti-CCR3 antibodies, anti-CCR5 antibodies, and anti-fusin antibodies.

25       Various methods can be used to assess binding of HIV to a cell and/or infection of a cell by HIV in the presence of the antibodies of the present invention. For example, assays which assess binding of gp120 or a portion thereof to the receptor, HIV infection and syncytium formation can be used (see, for example, Choe, H., *et al.*, *Cell*, 85:1135-1148 (1996)). The ability of the antibody of the present invention to inhibit these processes can be assessed using these or other suitable methods.

30

In addition, the present invention provides a method of treating HIV in a patient, comprising administering to the patient a composition comprising an effective amount of an antibody or functional fragment thereof which binds to a mammalian CCR2 or portion of said receptor. Again, the composition can also  
5 comprise one or more additional agents effective against HIV, including, but not limited to, anti-CCR3 antibodies, anti-CCR5 antibodies, and anti-fusin antibodies. Therapeutic use of antibody to treat HIV includes prophylactic use (e.g., for treatment of a patient who may be or who may have been exposed to HIV). For example, health care providers who may be exposed or who have been exposed to  
10 HIV (e.g., by needle-stick) can be treated according to the method. Another example is the treatment of a patient exposed to virus after unprotected sexual contact or failure of protection.

In AIDS, multiple drug treatment appears the most promising. An anti-chemokine receptor antagonist that inhibits HIV infection can be added to the drug  
15 treatment regimen, in particular by blocking virus infection of new cells. Thus, administration of an antibody or fragment of the present invention in combination with one or more other therapeutic agents such as nucleoside analogues (e.g., AZT, 3TC, ddI) and/or protease inhibitors is envisioned, and provides an important addition to an HIV treatment regimen. In one embodiment, a humanized anti-CCR2  
20 mAb is used in combination with a (i.e., one or more) therapeutic agent to reduce viral load from patients, by preventing fusion and/or infection of new cells. Such an antibody can also be useful in preventing perinatal infection.

Another aspect of the invention relates to a method of preventing HIV infection in an individual, comprising administering to the individual an effective  
25 amount of an antibody or functional fragment thereof which binds to CCR2. According to the method, preventing HIV infection includes treatment in order to prevent (reduce or eliminate) infection of new cells in an infected individual or in order to prevent infection in an individual who may be, may have been, or has been, exposed to HIV. For example, individuals such as an HIV infected individual, a  
30 fetus of an HIV infected female, or a health care worker may be treated according to the method of the present invention.

### Modes of Administration

One or more antibodies or fragments of the present invention can be administered to an individual by an appropriate route, either alone or in combination with (before, simultaneous with, or after) another drug or agent, or before, simultaneous with or after surgical, mechanical or therapeutic intervention. For example, the antibodies of the present invention can also be used in combination with other monoclonal or polyclonal antibodies (e.g., in combination with antibodies which bind other chemokine receptors, including, but not limited to, CCR3 and CCR5) or with existing blood plasma products, such as commercially available gamma globulin and immune globulin products used in prophylactic or therapeutic treatments. The antibodies or fragments of the present invention can be used as separately administered compositions given in conjunction with antibiotics and/or antimicrobial agents.

An effective amount of an antibody or fragment (i.e., one or more antibodies or fragments) is administered. An effective amount is an amount sufficient to achieve the desired therapeutic (including prophylactic) effect, under the conditions of administration, such as an amount sufficient for inhibition of a CCR2 function, and thereby, inhibition of an inflammatory response or HIV infection, or an amount sufficient for promotion of a CCR2 function, as indicated. The antibody or fragment can be administered in a single dose or multiple doses. The dosage can be determined by methods known in the art and is dependent, for example, upon the antibody or fragment chosen, the subject's age, sensitivity and tolerance to drugs, and overall well-being. Antibodies and antigen-binding fragments thereof, such as human, humanized and chimeric antibodies and antigen-binding fragments can often be administered with less frequency than other types of therapeutics. For example, an effective amount of an antibody can range from about 0.01 mg/kg to about 5 or 10 mg/kg administered daily, weekly, biweekly or monthly.

A variety of routes of administration are possible including, but not necessarily limited to, oral, dietary, topical, parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous injection or infusion), inhalation (e.g., intrabronchial, intraocular, intranasal or oral inhalation, intranasal drops), depending on the disease or condition to be treated. Other suitable methods of administration

can also include rechargeable or biodegradable devices and slow release polymeric devices. The pharmaceutical compositions of this invention can also be administered as part of a combinatorial therapy with other agents.

Formulation of an antibody or fragment to be administered will vary  
5 according to the route of administration and formulation (e.g., solution, emulsion, capsule) selected. An appropriate pharmaceutical composition comprising an antibody or functional fragment thereof to be administered can be prepared in a physiologically acceptable vehicle or carrier. A mixture of antibodies and/or fragments can also be used. For solutions or emulsions, suitable carriers include, for  
10 example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. A variety of appropriate aqueous carriers are known to the skilled artisan, including water, buffered water, buffered saline, polyols (e.g., glycerol,  
15 propylene glycol, liquid polyethylene glycol), dextrose solution and glycine. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers (See, generally, *Remington's Pharmaceutical Science*, 16th Edition, Mack, Ed. 1980). The compositions can optionally contain pharmaceutically acceptable auxiliary substances as required to approximate  
20 physiological conditions such as pH adjusting and buffering agents and toxicity adjusting agents, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride and sodium lactate. The antibodies and fragments of this invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use according to art-known lyophilization and reconstitution techniques. The optimum  
25 concentration of the active ingredient(s) in the chosen medium can be determined empirically, according to procedures well known to the skilled artisan, and will depend on the ultimate pharmaceutical formulation desired. For inhalation, the antibody or fragment can be solubilized and loaded into a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser).

30 The present invention will now be illustrated by the following Examples, which are not intended to be limiting in any way. The teachings of all references cited herein are incorporated herein by reference.



-76-

## EXAMPLES

## Example 1

## Materials:

The following materials were obtained from the indicated sources:

- 5 PE-conjugated anti-CD16, PE-conjugated streptavidin, and biotinylated anti-human IgE were from Pharmingen (San Diego, CA). FITC-conjugated goat anti-mouse IgG was from Jackson ImmunoResearch Laboratories (West Grove, PA). FACS Lysing Buffer was from Becton Dickinson (Mountain View, CA) and [<sup>125</sup>I]-MCP-1 was from NEN (Boston, MA).

## 10 Cells, Cell Lines, and Tissue Culture

- The murine pre-B lymphoma cell line L1/2 was maintained in RPMI-1640 supplemented with 10% Fetal Clone I (Gibco BRL, Gaithersburg, MD) 50 Units/mL penicillin (Gibco BRL), 50 µg/mL streptomycin (Gibco BRL), 2 mM L-Glutamine (Gibco BRL), and 55 µM β-mercaptoethanol (Gibco BRL). Other cell lines
- 15 included transfectants of L1/2 cells expressing either CCR1 (Campbell, J. *et al.* (1996) *J. Cell Bio.*, 134:255-266), CCR5 (Wu *et al.*, *Nature* 384:179-183 (1996)) grown in the above culture medium supplemented with 800 µg/ml active G418. THP-1 cells (ATCC No. TIB202) were grown in accordance with ATCC instructions. PBMC were purified from heparinized blood as described in Ponath *et al.*, *J. Clin. Invest.*, 97:604-612 (1996).
- 20

## Preparation of CCR2b Expression Construct and Stable Transfectants

- The coding region for the human CCR2b (Charo *et al.* (1994) *Proc. Natl. Acad. Sci. USA*, 91:2752) was obtained by RT-PCR amplification as described (Qin, S. *et al.* (1996) *Eur. J. Immunol.*, 26:640-647). cDNA was made using oligo(dT)-
- 25 priming, and amplification of the CCR2b coding region was achieved by nested PCR with the following sets of primers which correspond to the positions of the CCR2b sequence (GenBank Accession No. U03905; Charo *et al.*, *Proc. Natl. Acad. Sci. USA* 91:2752-2756 (1994)) as indicated:

- 1) 5' primer: 5'-TGAGACAAGCCACAAGCTGAAC-3' (nucleotides 11 to 32; SEQ ID NO: 1);  
3' Primer: 5'-TCTGTATTAGTACACACAGCCC-3' (nucleotides 1301 to 1280; SEQ ID NO: 2);
- 5 2) 5' Primer: 5'-ATGCTGTCCACATCTCGTTCTCGG-3' (nucleotides 81 to 104; SEQ ID NO: 3);  
3' Primer: 5'-TTATAAACCAGCCGAGACTTCCTGCTC-3' (nucleotides 1164 to 1137; SEQ ID NO: 4).

The CCR2B cDNA coding region was modified to contain the CD5 signal peptide leader sequence (Aruffo *et al.*, *Cell* 61:1303-1313 (1990)). The predicted amino acid sequence of this peptide is:

NH<sub>2</sub>-Met-Pro-Met-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Thr-Leu-Tyr-Leu-Leu-Gly-Met-Leu-Val-Ala-Ser-Val-Leu-Ala... (SEQ ID NO: 5)

Using PCR with the CCR2b cDNA as template and two overlapping 5' primers that contain a BamHI restriction site, encode the CD5 signal peptide sequence and the amino terminal sequence of CCR2b, and a 3' primer located internally in the CCR2b coding region.

5' CD5 Seq1 primer

20 5'- GGGGATCCAGAAACCATGCCCATGGGGTCTCTGCAACCGC  
TGGCCACCTTGTACCTGCTG-3' (SEQ ID NO: 6)

5' CD5 Seq2 primer

5'- GCCACCTTGTACCTGCTGGGGATGCTGGTCGCTTCCGTGCT  
AGCGATGCTGTCCACATCTCGTTC-3' (SEQ ID NO: 7)

25 3' CCR2AB2 primer - 5' - GACGACCAGCATGTTGCC-3' (SEQ ID  
NO: 8; U03905 nucleotides 272 to 255)

The 278 base pair amplified fragment was digested with BamHI and Apal and the resulting 209 base pair fragment was inserted at the Apal site at position 206 of the CCR2b cDNA (GenBank Accession No. U03905) to replace the endogenous 5' base pair fragment of CCR2. The resulting sequence that encodes a CCR2b with the CD5 signal peptide leader sequence immediately preceding the receptor initiator methionine was inserted into the BamHI and XhoI sites of pcDNA3 (Invitrogen, San Diego, CA) to create the mammalian expression plasmid pCD5MCPRB. The CD5-CCR2b fragment was subcloned into the BamH I-Not I site of pCDEF3 (Goldman *et al.*, (1996) *Biotechniques* 21:1013-1015), and this construct was designated CCR2bDEF3. In this expression vector, the expression of the inserted gene is driven by the EF-1 $\alpha$  promoter.

Fifty milliliters of L1/2 cells were seeded at  $4 \times 10^5$  cells/mL the day before the electroporation. On the day of the electroporation, the cells, which had grown up to a density of  $1 \times 10^6$ /mL, were centrifuged out of their medium and resuspended in 800  $\mu$ l room temperature electroporation buffer (Zajac *et al.*, *DNA* 7:509-513). 120 mM L-Glutamic Acid (Sigma), 7 mM Mg Acetate (EM Science), 4.3 mM Glucose (Sigma), 17 mM K Pipes, pH 6.9 (Sigma), 1 mM EGTA (Sigma), 5 mM ATP, pH 7.0 (Sigma). Twenty-five micrograms Sca I linearized, phenol/chloroform/isoamyl alcohol extracted and isopropanol precipitated CCR2bDEF3 plasmid DNA was placed in an 0.4 cm gap electroporation curvette. The resuspended cells were added to the curvette, and a single pulse applied at 450 volts, 960  $\mu$ Fd. The cells were then transferred from the curvette to a T-75 flask containing 15 mL L1/2 growth medium (described above, and grown for three days, at which time the cells were centrifuged out of their medium and resuspended in L1/2 growth medium additionally supplemented with 1 mM sodium pyruvate (Gibco BRL) and 0.8 mg/mL active G418 (Gibco BRL).

#### Selection of Cells Expressing CCR2b by Chemotaxis

The transfected cells were allowed to grow for eleven days, at which point they were split 1:20 into fresh growth medium. On the sixteenth day, the cells were selected by chemotaxis. 600  $\mu$ L 1 nM MCP-1 in RPMI 1640 supplemented with 0.5% BSA (RPMI/BSA) was placed in the lower chamber and  $1 \times 10^6$  CCR2bDEF3

cells in 100  $\mu$ l of RPMI/BSA were placed in the upper chamber of a 3.0 micron pore 24-well chemotaxis plate (Becton Dickinson). The cells were allowed to chemotax for four hours and twenty minutes in a 37° C, 5% CO<sub>2</sub>, humidified incubator, at which time the upper chamber was removed. This incubation time was chosen at the time of the experiment because it was sufficiently long for cells responding to the MCP-1 to chemotax, but short enough to keep the background low.

#### Secondary Selection of CCR2b Expressing-Cells by FACS Sorting

The cells which had chemotaxed through the membrane and into the lower chamber were grown up, and further purified by sterile FACS sorting. Ten million CCR2bDEF3 cells were centrifuged out of their medium, resuspended in 2.5 mL PBS(+Ca, Mg) supplemented with 1% heat-inactivated Fetal Calf Serum ("HI FCS") (Gibco BRL) and 2.5 mL sterile filtered anti-CCR2b amino-terminal peptide antibody supernatant 5A11. The cells and the antibody were mixed and allowed to incubate on ice for thirty minutes. The cells were then washed twice with PBS (+) (Gibco BRL), and resuspended in 5 mL of a sterile filtered, 1:250 dilution of FITC-conjugated, affinity-purified F(ab')<sub>2</sub> goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) in PBS (+) supplemented with 1% HI FCS. The cells were incubated for thirty minutes on ice in the dark, and then washed twice with PBS(+) (GIBCO BRL). The cells were sorted on the FACSCalibur® and the brightest 4% of cells were collected. (FL1  $\geq 3 \times 10^3$ ).

The sorted cells were allowed to grow up, and they were resorted using the same protocol as above. The brightest 1% of cells were collected. (FL1  $\geq 3 \times 10^3$ ).

#### Monoclonal Antibody Production

To produce mAbs to CCR2b, transfectants were continually monitored to ensure that levels of expression did not drift downward. FACS staining was performed periodically to ascertain receptor expression on the transfectants using the anti CCR2b antibody supernatant 5A11 with goat anti-mouse IgG FITC as the secondary antibody.

Twenty million CCR2bDEF3.L1/2 cells were washed in RPMI 1640 (Gibco BRL) and incubated in RPMI 1640 plus 0.2 mg/mL Mitomycin C for 30 minutes at

37°C. The cells were then washed twice with PBS (+) and  $2 \times 10^7$  cells in 0.5 mL PBS (+) were injected intraperitoneally into a C57 BL/6 female mouse. This was repeated two more times at two week intervals. The fourth time,  $2 \times 10^7$  cells were resuspended in 0.25 mL and injected intravenously. Three days after the  
5 intravenous injection, the mouse was sacrificed and the spleen removed and the cells fused with the SP2/0 cell line as described (*Current Protocols in Immunology*, John Wiley and Sons, New York, 1992).

This set of mice had previously been immunized many times with 2 different cell lines as well as a synthetic peptide, but no antibodies that stained CCR2 positive  
10 cells were generated from several fusions. The above four immunizations with the CCR2bDEF3.L1/2 cell line expressing high levels of CCR2b were critical to obtain the described antibody.

#### Selecting Single Cell Clone of CCR2 Transfectants by Limiting Dilution

After the mouse received the last injection, the twice sorted cells were  
15 allowed to grow up again, and then they were further purified by limiting dilution. The cells were plated at 1 and 0.5 cell per well in 96 well plates. Subcloned cells from the 0.5 cell per well dilution were grown up and tested for CCR2b expression by indirect immunofluorescent FACS analysis using the anti-CCR2b antibody supernatant 5A11 with goat anti-mouse IgG FITC as the secondary antibody. The  
20 procedure was the same as described above, except that the staining volume was 100  $\mu$ l. Four positives were selected and frozen down.

#### Identification of Positive Monoclonal Antibodies

Immunofluorescent staining analysis using a FACScan® (Becton Dickinson & Co., Mountain View, CA) was used to identify the monoclonal antibodies which  
25 were reactive with the CCR2b receptor. Hybridoma culture supernatants were assayed in a 96-well format using goat anti-mouse IgG FITC as the secondary antibody. CCR2bDEF3.L1/2 cells were used to identify monoclonal antibodies reactive with CCR2b, and untransfected L1/2 cells were used to eliminate monoclonal antibodies reactive with other cell surface proteins.

### FACS Staining - Cultured Cells

For the staining of cultured transfectant cell lines  $0.5 \times 10^6$  cells in  $50 \mu\text{l}$  were resuspended in PBS + 1% FCS in a 96 well polystyrene V-bottom plate.  $50 \mu\text{l}$  of primary antibody supernatants or HT medium (negative control) were added, and the samples were incubated at  $4^\circ\text{C}$  for 30 min.  $100 \mu\text{l}$  of PBS were added and the cells were pelleted by centrifugation and washed once with PBS. The pellet was resuspended in  $100 \mu\text{l}$  PBS + 1% FCS containing FITC-conjugated goat anti-mouse IgG antibody (a 1:250 dilution) and incubated for thirty minutes at  $4^\circ\text{C}$  in the dark. The cells were washed twice with PBS, resuspended in PBS, and analyzed by flow cytometry with a FacScan cytometer using the CellQuest software (Becton-Dickenson). Cells were fixed with PBS/1% formaldehyde if they were not to be analyzed the same day. Monoclonal antibodies 1D9 and 8G2 stain CCR2 transfectants but not CCR1 or CCR5 transfectants (Figure 1).

### FACS Staining - Whole Blood

$100 \mu\text{l}$  whole blood was mixed with  $100 \mu\text{L}$  of 1D9 antibody hybridoma supernatants or HT medium (negative control) and incubated at  $4^\circ\text{C}$  for 30 min. After one wash with PBS,  $100 \mu\text{L}$  FITC-conjugated goat anti-mouse IgG antibody (a 1:250 dilution) was added to each sample and incubated for 30 min. at  $4^\circ\text{C}$  in the dark. Samples were then washed once with PBS if a second color staining is to be done, otherwise washed twice more in PBS. For two color staining  $5 \mu\text{l}$  of mouse serum was added to the cell pellets after the single wash, mixed, and incubated for five minutes at  $4^\circ\text{C}$  in the dark. Second primary antibodies (or PBS as a negative control) were added ( $10 \mu\text{l}$  anti-CD16,  $100 \mu\text{l}$  1:200 dilution of anti-IgE) and incubated for thirty minutes at  $4^\circ\text{C}$  in the dark. Samples were then washed one time with PBS and resuspended in  $100 \mu\text{L}$  streptavidin PE (1:200 PBS + 1% BSA) and incubated for fifteen minutes at  $4^\circ\text{C}$  in the dark. Erythrocytes were lysed by adding 2 ml of FACS Lysing Buffer to each sample and incubating at room temperature in the dark for fifteen minutes or until samples were clear. The cells were pelleted by centrifugation and all but  $200 \mu\text{l}$  of the supernatant was aspirated. The samples were analyzed by flow cytometry on a FacScan cytometer using the CellQuest software (Becton-Dickenson). CCR2b is expressed on most monocytes, a

subpopulation of lymphocytes and a subset of granulocytes (Figure 2). CCR2b is expressed on an IgE-positive population in peripheral blood (basophils)(Figure 3).

#### MCP-1 Binding Assays

MCP-1 binding was performed in a final volume of 0.1 ml of 50 mM Hepes  
5 pH 7.4, 1 mM  $\text{CaCl}_2$ , 5 mM  $\text{MgCl}_2$ , 0.02% sodium azide, 0.5% BSA (HBB),  
containing either 2.5  $\mu\text{g}$  THP-1 membrane protein or 500,000 PBMC and 0.1 nM of  
[ $^{125}\text{I}$ ]-MCP-1. Competition binding experiments were performed by including  
variable concentrations of unlabeled MCP-1, 1D9 antibody, or a negative control  
IgG2a. Nonspecific binding was determined following the addition of a 2500-fold  
10 excess of unlabeled MCP-1. Samples were incubated for 60 minutes at room  
temperature, and bound and free tracer were separated by filtration through 96-well  
GF/B filterplates presoaked in 0.3% polyethyleneimine. The filters were washed in  
HBB further supplemented with 0.5 M NaCl, dried, and the amount of bound  
radioactivity determined by liquid scintillation counting. mAb 1D9 inhibits  
15 [ $^{125}\text{I}$ ]MCP-1 binding to THP-1 cell membranes with an  $\text{IC}_{50}$  of about 0.004  $\mu\text{g}/\text{ml}$   
(approximately 0.02 nM; Figure 4) and to fresh PBMC with an  $\text{IC}_{50}$  of 0.04  $\mu\text{g}/\text{ml}$   
(approximately 0.2 nM; Figure 5).

#### Chemotaxis of PBMC

Chemotaxis was assayed using a 3  $\mu\text{m}$  pore size 96-well chemotaxis plate  
20 (Neuroprobe, Cabin John, MD). PBMC isolated by standard methods using Ficoll-  
Hypaque density gradient centrifugation were washed with PBS/0.5%BSA and then  
resuspended in chemotaxis assay media (HBSS/10mM HEPES/0.5% Fatty acid free  
BSA) to a final concentration of  $10 \times 10^6$  cells/ml. Cells were preincubated in  
chemotaxis assay media at room temperature for 20 min. with various  
25 concentrations of the anti-CCR2 antibody, 1D9, or nonspecific murine IgG2a. The  
same dilutions of antibody were mixed with chemokine and 30  $\mu\text{l}$  of the mixture  
was added to each of the bottom wells of the chemotaxis plate. The bottom wells  
are covered with the membrane, and 25  $\mu\text{l}$  of the cell and antibody mixture are  
added to the top of the filter. The plates are incubated at 37°C in 5%  $\text{CO}_2$  incubator  
30 for approximately 80 min. At the completion of the migration, the membrane is

removed and the plate with the bottom wells is incubated -80C for 30 minutes to freeze the contents. The plates are thawed at 37°C for 10 minutes. 6 µl of a 1:400 dilution of CyQuant reagent (Molecular Probes, Eugene, OR) in a lysis buffer provided by the supplier is added to each well, and the cell migration is quantified as indicated by fluorescence intensity determined using a CytoFlour fluorescence plate reader at 485ex/535em. mAb 1D9 inhibits MCP-1-induced chemotaxis, but not RANTES-induced chemotaxis, of fresh PBMC (Figures 6A and 6B). Inhibition of MCP-1-induced chemotaxis of fresh PBMC has been demonstrated with 10 µg/ml (≈40 nM).

## 10 Example 2

### Humanisation of monoclonal antibody 1D9

The 1D9 monoclonal antibody is likely to be immunogenic in humans, potentially eliciting a human anti-mouse antibody (HAMA) response. This HAMA response usually results in rapid clearance of the mouse monoclonal antibody from the body, thus limiting any therapeutic effect the 1D9 monoclonal antibody might have. Therefore, in an effort to reduce the immunogenicity of this antibody in humans and to maximize its therapeutic potential, the humanisation of the 1D9 mouse monoclonal antibody was undertaken. The following examples provide a detailed analysis of the 1D9 amino acid sequence data, the building of a molecular model of the murine 1D9 F<sub>v</sub> domain, and the design strategy for the successful humanization of the mouse antibody. This design strategy resulted in the design of a number of humanized versions of both the kappa light chain variable (V<sub>K</sub>) region and the heavy chain variable (V<sub>H</sub>) region. In total, the humanized V<sub>H</sub> region included up to 16 amino acid changes in the FRs of the selected human V<sub>H</sub> region. These changes were subdivided between four versions of the humanized V<sub>H</sub> region. In addition, twelve amino acid changes in the FRs of the selected human V<sub>K</sub> region were included in the four versions of the humanized VK region which were also designed.



#### Sequence analysis of the mouse 1D9 kappa light chain variable region

The amino acid sequence of the 1D9 V<sub>K</sub> region (Figure 7) was compared with other mouse kappa light chain variable regions and also the consensus sequences of the subgroups that the variable regions were subdivided in to in the Kabat database (Kabat *et al.*, *Sequences of proteins of immunological interest*, Fifth edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991)). From this analysis the 1D9 V<sub>K</sub> region was found to most closely match the mouse consensus sequence of mouse kappa subgroup II (Identity = 79.46%, Similarity = 82.14%). When only the FRs of the 1D9 kappa light chain variable region were compared in the mouse subgroup II, percentage identity increased to 87.5%, while percentage similarity increased to 88.75%. In addition, the mouse 1D9 V<sub>K</sub> region showed good homology to a translation of the 70/3 murine V<sub>K</sub> germline gene (Figure 13). Taken together, the above evidence clearly proved that the 1D9 sequence was typical of a mouse V<sub>K</sub> region.

#### Sequence analysis of the mouse 1D9 heavy chain variable region

A similar analysis of the 1D9 V<sub>H</sub> region (Figure 8) found that it matched closest to the consensus sequence of the mouse heavy chain subgroup IIIc in the Kabat database (Kabat *et al.*, *Sequences of proteins of immunological interest*, Fifth edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991)). Identity between the mouse heavy chain variable region amino acid sequence of 1D9 and the consensus sequence of mouse subgroup IIIc was measured at 70.94%, while the similarity was calculated to be 76.07%. When only the FRs of the 1D9 V<sub>H</sub> region was compared to mouse subgroup IIIc, percentage identity increased to 75.86%, while the similarity increased to 80.46%. The mouse 1D9 V<sub>H</sub> region also showed good homology to a translation of the MLR-RF24BG murine V<sub>H</sub> germline gene, among others (Figure 14). Thus, the above evidence confirmed that the 1D9 sequence was typical of a mouse V<sub>H</sub> region.

#### Molecular modelling of the 1D9 domain.

To assist in the design of the humanized variable regions of the 1D9 antibody, a series of molecular models were constructed of the murine 1D9 F<sub>v</sub>

region and the eight CDR grafted variants. This was done using the AbM molecular modeling package supplied and utilized by Oxford Molecular Limited (OML).

Antibody x-ray crystallographic structures available from the Brookhaven database were formatted to allow them to be used for modeling with AbM.

5       The FRs of the 1D9 variable regions were modeled on FRs from similar, structurally-solved immunoglobulin variable regions. While identical amino acid side chains were kept in their original orientation, mismatched side chains were substituted as in the original 1D9 F<sub>v</sub>. The backbone atoms of the FRs of the Fab Bv04-01 V<sub>K</sub> region were used for the model of the Fv framework region of 1D9 for  
10 both the V<sub>K</sub> and V<sub>H</sub> chains (Brookhaven PDB code 1nbv, solved to 2.0 Å). The sequence of Fab Bv04-01 was a good match for the variable region sequences of murine 1D9 and their humanized variants. The identities between Fab Bv04-01 and the murine 1D9 and humanized sequences ranged from 76% to 78% for V<sub>K</sub> sequences and from 74% to 84% for V<sub>H</sub> sequences. Testing of AbM with known  
15 structures has shown that FR backbone homology is an important factor in the quality of any model, since the use of FR structures that poorly match a sequence being modeled can significantly and adversely affect the position and orientation of the CDR loops.

For the backbone structures of CDRs L1, L2, L3, H1 and H2, conformations  
20 for all of the models were taken from canonical classes used by AbM without modification, using the classes shown in Figures 9 and 10.

For the backbone structure of the L1 loop, the loop conformations of the murine 1D9 V<sub>K</sub> region was taken from canonical Class 4 from AbM. This canonical class is based on those described by Chothia and his colleagues (Chothia  
25 and Lesk, *J. Mol. Biol.* 197:901 (1987); Chothia *et al.*, *Nature* 34:877 (1989); Tramontano *et al.*, *J. Mol. Biol.* 215:175 (1990); and Chothia *et al.*, *J. Mol. Biol.* 227:799 (1992)), but they have been modified to take into consideration structures that have become available since the original articles were published. Testing of the performance of AbM predictions for known loop structures has shown that CDR  
30 loops which are created in this way are usually modeled very accurately, i.e. to within 1-1.5 Å RMS deviation.

The H3 loop in the 1D9 V<sub>H</sub> region is comparatively short at six residues long. It was modeled using a search for backbone conformations from X-ray structures in the Brookhaven databank. For short loops like this, there are sufficient loop conformations from known X-ray structures to saturate the conformational space available to the loop. Testing of the predictions made by AbM with the structures of new antibodies, where the structure is not included in the databases used by the program, shows that for CDR H3 loops of this size, the accuracy is likely to be at least 2.0Å.

After adjusting the whole of the model for obvious steric clashes it was subjected to energy minimisation, as implemented in MACROMODEL, both to relieve unfavorable atomic contacts and to optimize van der Waals and electrostatic interactions.

#### Design of the humanised 1D9 V<sub>K</sub> antibody variants.

The first step in the design of the humanised variable regions of the 1D9 antibody was the selection of the human kappa light chain variable region that would serve as the basis for the humanized 1D9 V<sub>K</sub> region. As an aid to this process the 1D9 V<sub>K</sub> region was initially compared to the consensus sequence of the four human kappa light chain variable region subgroups as defined by Kabat (Kabat *et al.*, *Sequences of proteins of immunological interest*, Fifth edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991)). The mouse 1D9 light chain variable region was most similar to the consensus sequence of human kappa light chain subgroup II, with which it displayed a 76.2% identity over the whole variable region and a 82.5% identity within the FRs alone. When measured with respect to similarity, these values increased to 79.7% overall and 85.0% within the FRs alone. Consequently it generally appeared to match well to human kappa light chain variable region sequences from kappa subgroup II.

The mouse 1D9 V<sub>K</sub> was then compared to all the recorded examples of individual sequences of human variable regions publicly available. Figure 15 shows the best seventeen matches to the mouse 1D9 V<sub>K</sub> region which were identified through this analysis. Overall, the search algorithm selected the human V<sub>K</sub> region antibody 036521 (Rheinnecker *et al.*, *Journal of Immunology*. 157(7):2989-97

(1996)) as the best match to the mouse 1D9 V<sub>K</sub> region (Figure 16). However, a review of the source paper for this antibody revealed that murine oligonucleotide primers had been used to rescue the genes from the hybridoma. This meant that this antibody was in fact a murine antibody and not human, as suggested by the Kabat database. Thus, the next best match to the murine 1D9 V<sub>K</sub> region that was selected by the database search was the human V<sub>K</sub> region from antibody HF-21/28 (Kabat database ID number 005056; Chastagner *et al.*, *Gene*. 101(2):305-6 (1991)). The human sequence had an overall identity to the 1D9 V<sub>K</sub> region of 79.3% and 85.0% within the FRs alone. When measured with respect to similarity, these values increase to 83.99% overall and 87.5% within the FRs alone. In addition, key FR amino acids were more conservatively preserved in HF-21/28 V<sub>K</sub> region than in the other candidate human kappa light chain variable regions. Consequently, the HF-21/28 kappa light chain variable region FR was selected as the human acceptor sequence for the humanization of the 1D9 antibody kappa light chain variable region.

Unfortunately, the very last residue in FR4 (at position 107, according to the Kabat numbering system) of the human HF-21/28 V<sub>K</sub> region was not defined by the Kabat database or the authors who originally isolated this variable region sequence. Therefore, it was decided to insert the most commonly found amino acid at this position in the variable region sequences described by Kabat human kappa light chain subgroup  $\kappa$ -II (Kabat *et al.*, *Sequences of proteins of immunological interest*, Fifth edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991)). Accordingly, lysine was added at position 107 in FR4 based upon an analysis of the Kabat database which found that 85.7% of the sequences in Kabat human kappa light chain subgroup  $\kappa$ -II had a lysine at this position. This then became the basis of the first humanized version of the 1D9 kappa light chain (1D9RK<sub>A</sub>), which essentially comprised the CDR's of the 1D9 V<sub>K</sub> region and the FRs of HF-21/28 V<sub>K</sub> region. Figures 19A-19C define the amino acid sequence of this first CDR-grafted version of the humanised 1D9 V<sub>K</sub> region.

The next step in the design process was to study the amino acid sequences of the human acceptor HF-21/28 V<sub>K</sub> region FRs to determine if any of these amino acid residues were likely to adversely influence binding to antigen. This could be caused

directly through interactions with antigen, or indirectly by altering the confirmation or orientation of the CDR loops. This was a difficult process which was only made possible through the availability of a model of the 1D9 variable regions, i.e., both the  $V_K$  and the  $V_H$  regions. Nevertheless, any amino acids in the mouse 1D9 FRs that did appear to affect antigen binding were then considered for conversion in the humanized 1D9 antibody. In deciding which murine residues to conserve the following points were addressed:

- It was of great importance that the canonical structures of the hypervariable loops (Chothia and Lesk, *J. Mol. Biol.* 197:901 (1987); Chothia *et al.*, *Nature* 34:877 (1989); Tramontano *et al.*, *J. Mol. Biol.* 215:175 (1990); and Chothia *et al.*, *J. Mol. Biol.* 227:799 (1992)) were conserved. Consequently, it was crucial to conserve in the humanized 1D9 variable regions all the mouse FR residues that were part of these canonical structures (Figures 9 and 10).
- The sequences of the 1D9 antibody variable regions were compared to similar sequences from other mouse antibodies to identify unusual or rare residues which may have indicated an important role in antigen binding. This was then investigated using the mouse model of the 1D9 variable region genes.
- A direct analysis of the model was also made to try and predict whether any of the other mouse FR residues not present in the humanized FRs could influence antigen binding in some way.
- Comparisons of the individual human acceptor sequences for the kappa light chain and heavy chain variable regions to the consensus sequence of human variable regions subgroups to which the acceptor sequences belonged were also made. The identification of any idiosyncratic amino acids in the human donor sequences was important, as these could have adversely affected antigen binding.

- Since the human light and heavy chain variable regions selected would be derived from two different human antibodies, a careful analysis of the interdomain packing residues of both the donor and the acceptor kappa light chain variable regions should be carried out (Chothia *et al.*, *J. Mol. Biol.* 186:651 (1985)). This was because any mispacking in this region could have had a dramatic affect upon antigen binding, irrespective of the conformation of the CDR loop structures of the humanized 1D9 antibody.

Although there were 12 amino acid differences between the FRs of the donor mouse 1D9 V<sub>K</sub> region and the acceptor human HF-21/28 V<sub>K</sub> region, only two mouse residues were considered sufficiently important for binding affinity to preserve them in the humanised FRs. The first of the FR changes that were introduced into 1D9RK<sub>B</sub> was located at position 36. This residue is a Vernier residue (Foote and Winter, *J. Mol. Biol.* 224:487 (1992)) and is predicted to be a key structure determining residue for L1 loop structure as defined by Chothia and his coworkers (Chothia and Lesk, *J. Mol. Biol.* 197:901 (1987); Chothia *et al.*, *Nature* 34:877 (1989); Tramontano *et al.*, *J. Mol. Biol.* 215:175 (1990); and Chothia *et al.*, *J. Mol. Biol.* 227:799 (1992)). Although both residues are hydrophobic, the human Phe is bulkier at this position, and X-ray structures with Leu and Phe at this position show that if Phe is present steric hindrance causes the side chain at 34Asn to point in the opposite direction. Thus, it was considered critical for the successful humanization of the 1D9 kappa light chain.

The second change incorporated into the 1D9RK<sub>B</sub> humanized version was at residue 37, i.e., Gln37Leu. Although this was a conservative change it occurred in a highly conserved region at the base of CDRL. It was thought that by preserving this murine Leu residue in this version, alongside the murine Leu residue at position 36, the affinity of the humanised antibody could be preserved.

Two other versions of the humanised V<sub>K</sub> region were also considered for construction to explore the structural and binding affinity consequences of manipulating the FRs of the humanised 1D9 antibody. 1D9RK<sub>C</sub> was essentially identical to 1D9RK<sub>B</sub>, except for the mutation Gln100Gly. There is a dramatic difference in molecule bulk between these two residues, and thus this version was

made to explore the consequences of this change to the FRs of the reshaped human kappa light chain on antibody structure and overall antibody affinity. 1D9RK<sub>D</sub> contained the modifications described in 1D9RK<sub>C</sub> and, in addition, contained the FR change Gln17His. Although Gln and His are similar in size and both are weakly polar, the mouse residue (His) at this position is extremely rare amongst all mouse V<sub>K</sub> sequences (0.07% overall, but has not been seen in mouse Kabat subgroup II sequences) and has never been seen in any human V<sub>K</sub> sequences. Conversely, the Gln residue is more commonly seen at this position in both mouse (16.16% overall and 6.12% in mouse Kabat subgroup II sequences) and human (5.00% overall and 39.7% in human Kabat subgroup II sequences) sequences. Thus, the simple rarity of the His at this position suggests that it may be important for binding, although there is no clear evidence to support this from the molecular modeling data. A description of the amino acid sequences of all the humanised 1D9 antibody V<sub>K</sub> region variants proposed above are given in Figure 11.

#### 15 Design of humanised 1D9 V<sub>H</sub> antibody variants

Once again, the first step in the design of the humanised V<sub>H</sub> region of the mouse 1D9 antibody was the selection of the acceptor human heavy chain variable region that would serve as the basis of the humanised 1D9 V<sub>H</sub> region. When the 1D9 V<sub>H</sub> region was initially compared to the consensus sequences of the three human heavy chain variable region subgroups it was found to be most similar to the consensus sequence for the human heavy chain subgroup III, with a 69.231% identity overall and a 78.161% identity between the FRs alone. When measured with respect to similarity, these values increased to 74.359% overall and to 82.759% within the FRs alone.

25 The mouse 1D9 V<sub>H</sub> region was then compared to all the recorded examples of individual sequences of human variable regions publicly available. Figures 17A-B show the best 24 matches to the mouse 1D9 V<sub>H</sub> region which were identified through this analysis. Overall the search algorithm selected the human V<sub>H</sub> region from antibody 4B4'CL (Kabat data base ID number 000490; Sanz *et al.*, *Journal of Immunology*. 142:883 (1989)) as the best match to the mouse 1D9 V<sub>H</sub> region. The V<sub>H</sub> region of this clone had an overall identity to the 1D9 V<sub>H</sub> region of 67.2%, a

value which increased to 80.95% when the FRs alone were compared (Figures 18A-B). When measured with respect to similarity, these values increased to 69.66% overall and to 84.52% within the FRs alone. Thus, although once again not the most homologous of the potential human acceptor  $V_H$  sequences, this human FR became  
5 the basis of the humanised version of the 1D9 heavy chain.

The next step in the design process was to study the amino acid sequences of the human acceptor 4B4'CL  $V_H$  region FRs to determine if any of these amino acid residues were likely to adversely affect binding to antigen. Once again the molecular models built by OML were important in this design process, from which a  
10 number of amino acids in the murine 1D9  $V_H$  region FRs were identified for conversion in the first (1D9RH<sub>A</sub>) and subsequent versions of the humanised 1D9 antibody (Figure 12 and Figures 20A-C). There were 16 amino acid differences between the FRs of the donor mouse 1D9 and the acceptor human 4B4'CL  $V_H$  regions, and up to 5 murine residues were considered for conservation in the  
15 humanised FRs (Figure 12).

1D9RH<sub>A</sub> consisted of the CDRs of the murine 1D9 antibody  $V_H$  region genetically inserted into the FRs of the human 4B4'CL antibody  $V_H$  region. 1D9RH<sub>B</sub> was identical to version 1D9RH<sub>A</sub> apart from two FR1 mutations, Thr28Ser and Asn30Ser. These changes were made because they represented Vernier amino acids  
20 as defined by Foote and Winter (*J. Mol. Biol.* 224:487 (1992)), which were thought to be critical for H1 loop conformation. Residues 27-30 are considered part of the H1 loop itself and so are even more critical to the correct conformation and orientation of this loop, justifying their conservation even more strongly. Thus, these two residues represented the sum of the changes made to the FRs of the human  
25 4B4'CL  $V_H$  sequence in 1D9RH<sub>B</sub>. 1D9RH<sub>C</sub> was identical to version 1D9RH<sub>B</sub> except that it contained two further changes at positions Gly49Ala and Phe67Tyr. The Gly49Ala was a conservative change. However, residue position 49 has been identified as a Vernier residue (Foote and Winter, *J. Mol. Biol.* 224:487 (1992)), important for H2 hypervariable loop structure, so it was decided to conserve the  
30 murine Ala residue in this version. Residue position 67 was also a Vernier residue position, identifying it as important for maintaining CDR loop conformation. Tyr is very rarely seen in human  $V_H$  sequences (0.08% overall) and has not previously been



-92-

found in murine  $V_H$  regions at this position. Consequently, it must have arisen through somatic mutation. Thus, given its location close to CDR2 according to the molecular model and its Vernier residue status, it was decided to conserve the murine Tyr residue at this position. 1D9RH<sub>D</sub> was identical to 1D9RH<sub>C</sub> except for a  
5 Thr93Val mutation. This residue had been identified as important as both a  $V_H/V_K$  packing residue (Chothia *et al.*, *J. Mol. Biol.* 186:651 (1985)). Moreover, its buried position between CDR loops H1 and H3, according to the molecular model, supported the decision to conserve the murine Val residue at this position. A description of the amino acid sequences of all the humanised  $V_H$  region variants  
10 described above are given in Figure 12.

#### Inhibition of MCP-1 Binding by Humanized Version of 1D9

Figure 25 illustrates the ability of murine mAb 1D9 and a humanized version of mAb 1D9 comprising the 1D9RH<sub>A</sub> $V_H$  heavy chain (Figure 12) and the 1D9RK<sub>A</sub> $V_K$  light chain (Figure 11) to inhibit the binding of [<sup>125</sup>I]-MCP-1 to whole  
15 THP-1 cells. 0.5 X 10<sup>6</sup> THP-1 cells were incubated in 50 mM HEPES, 1 mM CaCl<sub>2</sub>, 5 mM MgCl<sub>2</sub>, 0.1% BSA, 0.05% sodium azide (binding buffer) with different dilutions of antibody samples for 10 minutes at 37°C. An equal volume of [<sup>125</sup>I]-MCP-1 in binding buffer was added to a final concentration of 0.1 nM and incubated for a further 30 minutes at 37°C. Cells were diluted and vortexed with an equal  
20 volume of binding buffer with 0.5 M NaCl (wash buffer) and pelleted by centrifugation (benchtop centrifuge, 7000 rpm, 2 minutes). After removal of the supernatant, the pellet was vortexed in 200 µL of wash buffer, spun as before, and the supernatant removed. The cells were resuspended in 100 µL wash buffer and counted on a gamma counter (Cobra, Packard Instruments). Data analysis was  
25 performed using Graphpad software.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Applicant's or agent's file reference	1855.1052005	International application No.
--	--------------	-------------------------------

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on pages <u>22 and 50</u> , lines <u>7-16; and 19-21, respectively</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <b>American Type Culture Collection</b>	
Address of depositary institution (including postal code and country) <b>10801 University Boulevard Manassas, Virginia 20110-2209</b>	
Date of deposit <b>17 July 1998</b>	Accession Number <b>HB-12549 and HB-12550*</b>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
In respect of those designations for which a European patent is sought, the Applicant(s) hereby informs the International Bureau that the Applicant wishes that, until the publication of the mention of the grant of a European patent or for 20 years from the date of filing if the application is refused or withdrawn or deemed to be withdrawn, the biological material deposited with the American Type Culture Collection under Accession No. <u>see above*</u>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application Authorized officer <b>THOMAS S. BROOKS SR</b> <b>INTERNATIONAL DIVISION</b> <b>703-905-5163</b> <b>MJB</b>	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer

Form PCT/RO/134 (July 1998)

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM**  
**(Additional Sheet)**

**C. ADDITIONAL INDICATIONS (Continued)**

shall be made available as provided in Rule 28(3) EPC only by the issue of a sample to an expert nominated by the requester (Rule 28(4) EPC).

In respect of the designation of Australia in the subject PCT application, and in accordance with Regulation 3.25(3) of the Australian Patents Regulations, the Applicant hereby gives notice that the furnishing of a sample of the biological material deposited with the American Type Culture Collection under Accession No. see PG 1\* shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention and who is nominated in a request for the furnishing of a sample.

In respect of the designation of Canada in the subject PCT application, the Applicant hereby informs the International Bureau that the Applicant wishes that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the biological material deposited with the American Type Culture Collection under Accession No. see PG 1\* and referred to in the application to an independent expert nominated by the Commissioner.

-93-

## CLAIMS

What is claimed is:

1. A humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2, said immunoglobulin or fragment comprising  
5 an antigen binding region of nonhuman origin and at least a portion of an immunoglobulin of human origin.
2. The humanized immunoglobulin or antigen-binding fragment of Claim 1, wherein the portion of an immunoglobulin of human origin is derived from a human constant region.
- 10 3. The humanized immunoglobulin or antigen-binding fragment of Claim 2 wherein the human constant region is of the gamma type.
4. The humanized immunoglobulin or antigen-binding fragment of Claim 2 wherein the antigen binding region is of rodent origin.
5. The humanized immunoglobulin or antigen-binding fragment of Claim 2  
15 wherein the antigen binding region is derived from monoclonal antibody 1D9.
6. The humanized immunoglobulin or antigen-binding fragment of Claim 1 wherein the antigen binding region comprises at least one complementarity determining region of rodent origin, and the portion of an immunoglobulin of  
20 human origin is derived from a human framework region.
7. The humanized immunoglobulin or antigen-binding fragment of Claim 6, wherein the complementarity determining region is derived from monoclonal antibody 1D9.

-94-

8. The humanized immunoglobulin or antigen-binding fragment of Claim 6, wherein the complementarity determining region is selected from the group consisting of:
- a) amino acids 24-39 of SEQ ID NO: 9;
  - 5 b) amino acids 55-61 of SEQ ID NO: 9;
  - c) amino acids 94-102 of SEQ ID NO: 9;
  - d) amino acids 31-35 of SEQ ID NO: 10;
  - e) amino acids 50-68 of SEQ ID NO: 10; and
  - f) amino acids 101-106 of SEQ ID NO: 10.
- 10 9. A humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain and a light chain, wherein said light chain comprises at least one complementarity determining region derived from an antibody of nonhuman origin which binds CCR2 and
- 15 said heavy chain comprises at least one complementarity determining region derived from an antibody of nonhuman origin which binds CCR2 and a framework region derived from a heavy chain of human origin.
10. The humanized immunoglobulin or antigen-binding fragment thereof of Claim 9 wherein said immunoglobulin can compete with murine antibody
- 20 1D9 for binding to CCR2.
11. The humanized immunoglobulin or antigen-binding fragment thereof of Claim 9 wherein the light chain comprises three complementarity determining regions derived from the light chain of the 1D9 antibody, and the heavy chain comprises three complementarity determining regions
- 25 derived from the heavy chain of the 1D9 antibody.
12. The humanized immunoglobulin or antigen-binding fragment of Claim 11, wherein the complementarity determining regions derived from the light

-95-

chain of 1D9 are amino acids 24-39 of SEQ ID NO: 9, amino acids 55-61 of  
SEQ ID NO: 9 and amino acids 94-102 of SEQ ID NO: 9, and wherein the  
complementarity determining regions derived from the heavy chain of 1D9  
are amino acids 31-35 of SEQ ID NO: 10, amino acids 50-68 of SEQ ID NO:  
5 10 and amino acids 101-106 of SEQ ID NO: 10.

13. The humanized immunoglobulin or antigen-binding fragment thereof of  
Claim 9 wherein the light chain of human origin is the light chain of the HF-  
21/28 antibody.

14. The humanized immunoglobulin of Claim 9 wherein the heavy chain of  
10 human origin is the human 4B4'CL antibody.

15. A humanized immunoglobulin light chain or antigen-binding fragment  
thereof comprising CDR1, CDR2 and CDR3 of the light chain of murine  
1D9 antibody and a human light chain framework region.

16. The humanized immunoglobulin light chain or antigen-binding fragment  
15 thereof of Claim 15 wherein the human framework region is derived from  
the light chain of the HF-21/28 antibody.

17. The humanized immunoglobulin light chain or antigen-binding fragment  
thereof of Claim 16 comprising the variable region of SEQ ID NO: 9.

18. An isolated nucleic acid molecule encoding the humanized immunoglobulin  
20 light chain or antigen-binding fragment thereof of Claim 17.

19. The isolated nucleic acid molecule of Claim 18 comprising the variable  
region coding sequence of SEQ ID NO: 95.

-96-

20. A humanized immunoglobulin heavy chain or antigen-binding fragment thereof comprising CDR1, CDR2 and CDR3 of the heavy chain of the 1D9 antibody and a human heavy chain framework region.
- 5 21. The humanized immunoglobulin heavy chain or antigen-binding fragment thereof of Claim 20 wherein the human framework region is derived from the heavy chain of the human 4B4'CL antibody.
22. The humanized immunoglobulin heavy chain or antigen-binding fragment thereof of Claim 21 comprising the variable region of SEQ ID NO: 10.
- 10 23. An isolated nucleic acid molecule encoding the humanized immunoglobulin heavy chain or antigen-binding fragment thereof of Claim 22.
24. The isolated nucleic acid molecule of Claim 23 comprising the variable region coding sequence of SEQ ID NO: 96.
- 15 25. A humanized immunoglobulin light chain or antigen-binding fragment thereof, said light chain or antigen-binding fragment thereof having an amino acid sequence comprising at least a functional portion of the light chain variable region amino acid sequence of SEQ ID NO: 9.
26. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a humanized immunoglobulin light chain or antigen-binding fragment thereof of Claim 25.
- 20 27. The isolated nucleic acid molecule of Claim 26 comprising the variable region coding sequence of SEQ ID NO: 95.
28. A humanized immunoglobulin heavy chain or antigen-binding fragment thereof, said heavy chain or antigen-binding fragment thereof having an

-97-

amino acid sequence comprising at least a functional portion of the heavy chain variable region amino acid sequence shown in SEQ ID NO: 10.

29. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the humanized immunoglobulin heavy chain or antigen-binding fragment thereof of Claim 28.
30. The isolated nucleic acid molecule of Claim 29 comprising the variable region coding sequence of SEQ ID NO: 96.
31. An expression vector comprising a fused gene encoding a humanized immunoglobulin light chain, said gene comprising a nucleotide sequence encoding a CDR derived from a light chain of a nonhuman antibody having binding specificity for CCR2 and a framework region derived from a light chain of human origin.
32. The expression vector of Claim 31, wherein the nonhuman antibody is murine antibody 1D9.
33. A host cell comprising the expression vector of Claim 31.
34. An expression vector comprising a fused gene encoding a humanized immunoglobulin heavy chain, said gene comprising a nucleotide sequence encoding a CDR derived from a heavy chain of a nonhuman antibody having binding specificity for CCR2 and a framework region derived from a heavy chain of human origin.
35. The expression vector of Claim 34, wherein the nonhuman antibody is murine antibody 1D9.
36. A host cell comprising the expression vector of Claim 34.



-98-

37. A host cell comprising a first recombinant nucleic acid molecule encoding a humanized immunoglobulin light chain and a second recombinant nucleic acid molecule encoding a humanized immunoglobulin heavy chain, wherein said first nucleic acid molecule comprises a nucleotide sequence encoding a CDR derived from the light chain of murine antibody 1D9 and a framework region derived from a light chain of human origin, and wherein said second nucleic acid molecule comprises a nucleotide sequence encoding a CDR derived from the heavy chain of murine antibody 1D9 and a framework region derived from a heavy chain of human origin.
38. A method of preparing a humanized immunoglobulin comprising maintaining a host cell of Claim 37 under conditions appropriate for expression of a humanized immunoglobulin, whereby humanized immunoglobulin chains are expressed and a humanized immunoglobulin is produced.
39. The method of Claim 38 further comprising the step of isolating the humanized immunoglobulin.
40. A fused gene encoding a humanized immunoglobulin light or heavy chain comprising:
- a) a first nucleic acid sequence encoding an antigen binding region derived from murine monoclonal antibody 1D9; and
  - b) a second nucleic acid sequence encoding at least a portion of a constant region of an immunoglobulin of human origin.
41. A method of inhibiting the interaction of a cell expressing CCR2 with a ligand of CCR2, comprising contacting said cell with an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1.

-99-

42. A method according to Claim 41 wherein the cell is selected from the group consisting of lymphocytes, monocytes, granulocytes, T cells, basophils, and cells comprising a recombinant nucleic acid encoding CCR2 or a portion thereof.
- 5 43. A method according to Claim 41 wherein the ligand is a chemokine.
44. A method according to Claim 43 wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations thereof.
45. A method according to Claim 41 wherein the ligand is HIV.
- 10 46. A method of inhibiting HIV infection of a cell, comprising contacting a cell with an effective amount of a composition comprising a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1.
- 15 47. A method of treating HIV in a patient comprising administering to the patient a composition comprising an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1.
48. A method of inhibiting HIV infection in a patient, comprising administering to the patient a composition comprising an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1.
- 20 49. A method of inhibiting a function associated with binding of a chemokine to mammalian CCR2, comprising contacting CCR2 with an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1, wherein said humanized immunoglobulin inhibits binding of said chemokine to mammalian CCR2 and inhibits one or more functions associated with binding of the chemokine to CCR2.

-100-

50. A method according to Claim 49 wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations thereof.
51. A method of inhibiting leukocyte trafficking in a patient, comprising  
5 administering to the patient a composition comprising an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 which binds to mammalian CCR2 or portion of CCR2 and inhibits binding of a ligand to the receptor.
52. A method according to Claim 51 wherein the ligand is a chemokine.
- 10 53. A method according to Claim 52 wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations of the foregoing.
54. A method of treating a CCR2-mediated disorder in a patient, comprising  
15 administering to the patient an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 which binds to mammalian CCR2 or portion thereof.
55. A method according to Claim 54 wherein the disorder is an inflammatory disorder.
56. A method of inhibiting restenosis in a patient, comprising administering to  
20 the patient an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 which binds to mammalian CCR2 or portion thereof.
57. A humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 for use in therapy or diagnosis.

-101-

58. A humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 for use in treating a CCR2-mediated disease.
59. Use of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 for the manufacture of a medicament for treating a CCR2-mediated disease.
60. A pharmaceutical composition comprising a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 and a physiologically acceptable carrier.
61. A humanized immunoglobulin light chain or antigen-binding fragment thereof having binding specificity for CCR2 comprising an amino acid sequence selected from the group consisting of:
- a) SEQ ID NO: 12;
  - b) SEQ ID NO: 13;
  - c) SEQ ID NO: 14; and
  - d) SEQ ID NO: 15.
62. A humanized immunoglobulin heavy chain or antigen-binding fragment thereof having binding specificity for CCR2 comprising an amino acid sequence selected from the group consisting of:
- a) SEQ ID NO: 17;
  - b) SEQ ID NO: 18;
  - c) SEQ ID NO: 19; and
  - d) SEQ ID NO: 20.
63. A humanized immunoglobulin light chain or antigen-binding fragment thereof having binding specificity for CCR2 encoded by a nucleic acid molecule comprising SEQ ID NO: 98.

-102-

64. A humanized immunoglobulin heavy chain or antigen-binding fragment thereof having binding specificity for CCR2 encoded by a nucleic acid molecule comprising SEQ ID NO: 97.
- 5 65. A chimeric immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a light chain variable region of nonhuman origin and a human constant region.
66. A chimeric immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain variable region of nonhuman origin and a human constant region.
- 10 67. A chimeric immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a light chain variable chain region of nonhuman origin and a heavy chain variable region of nonhuman origin and further comprising a human constant region.
- 15 68. A method according to Claim 56, wherein said restenosis is associated with vascular intervention in said mammal.
69. A method according to Claim 68, wherein said vascular intervention comprises angioplasty.
70. A method according to Claim 68, wherein said vascular intervention comprises stent placement.
- 20 71. A method according to Claim 68, wherein said vascular intervention comprises angioplasty and stent placement.
72. A method of inhibiting narrowing of the lumen of a vessel in a mammal, comprising administering to said mammal an effective amount of a

-103-

humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 or Claim 9 which binds to mammalian CCR2 or portion thereof.

73. A method of inhibiting neointimal hyperplasia of a vessel in a mammal, comprising administering to said mammal an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of Claim 1 or Claim 9 which binds to mammalian CCR2 or portion thereof.
74. A method according to Claim 73, wherein said neointimal hyperplasia is associated with vascular intervention in said mammal.
75. A method according to Claim 74, wherein said vascular intervention comprises angioplasty.
76. A method according to Claim 74, wherein said vascular intervention comprises stent placement.
77. A method according to Claim 74, wherein said vascular intervention comprises angioplasty and stent placement.
78. A method according to Claim 54, wherein said CCR2-mediated disorder is an autoimmune disorder.
79. A method according to Claim 78, wherein the autoimmune disorder is selected from the group consisting of multiple sclerosis and rheumatoid arthritis.
80. A method according to Claim 79 wherein the autoimmune disorder is multiple sclerosis.

-104-

81. A method according to Claim 54, wherein the CCR2-mediated disorder is selected from the group consisting of atherogenesis and atherosclerosis.
82. A humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain and a light chain,  
5 wherein said light chain comprises at least one complementarity determining region derived from murine monoclonal antibody 1D9 and a framework region derived from the light chain of human antibody HF-21/28, and wherein said heavy chain comprises at least one complementarity determining region derived from murine monoclonal antibody 1D9 and a  
10 framework region derived from the heavy chain of human antibody 4B4'CL.
83. The humanized immunoglobulin or antigen-binding fragment thereof of Claim 82 wherein the light chain comprises three complementarity determining regions derived from the light chain of the 1D9 antibody, and the heavy chain comprises three complementarity determining regions  
15 derived from the heavy chain of the 1D9 antibody.
84. The humanized immunoglobulin or antigen-binding fragment of Claim 83, wherein the complementarity determining regions derived from the light chain of 1D9 are amino acids 24-39 of SEQ ID NO: 9, amino acids 55-61 of SEQ ID NO: 9 and amino acids 94-102 of SEQ ID NO: 9, and wherein the  
20 complementarity determining regions derived from the heavy chain of 1D9 are amino acids 31-35 of SEQ ID NO: 10, amino acids 50-68 of SEQ ID NO: 10 and amino acids 101-106 of SEQ ID NO: 10.
85. A humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a light chain and a complementary  
25 heavy chain, wherein said light chain comprises a variable region comprising SEQ ID NO: 12.

-105-

86. A humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain and a complementary light chain, wherein said heavy chain comprises a variable region comprising SEQ ID NO: 17.
- 5 87. A humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for CCR2 comprising a heavy chain and a light chain, wherein said light chain comprises a variable region comprising SEQ ID NO: 12, and wherein said heavy chain comprises a variable region comprising SEQ ID NO: 17.
- 10 88. The humanized immunoglobulin or antigen-binding fragment of Claim 87, wherein said immunoglobulin can compete with murine antibody 1D9 for binding to CCR2.
89. The humanized immunoglobulin or antigen-binding fragment of Claim 87, wherein said immunoglobulin inhibits binding of a ligand to CCR2.
- 15 90. The humanized immunoglobulin or antigen-binding fragment of Claim 89, wherein the ligand is a chemokine.
91. The humanized immunoglobulin or antigen-binding fragment of Claim 90, wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations of the foregoing.
- 20 92. A pharmaceutical composition comprising a humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87 and a physiologically acceptable carrier.



-106-

93. A method of inhibiting the interaction of a cell expressing CCR2 with a ligand of CCR2, comprising contacting said cell with an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87.
- 5 94. A method of inhibiting HIV infection in a patient, comprising administering to the patient a composition comprising an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87.
- 10 95. A method of inhibiting a function associated with binding of a chemokine to mammalian CCR2, comprising contacting CCR2 with an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87, wherein said humanized immunoglobulin inhibits binding of said chemokine to mammalian CCR2 and inhibits one or more functions associated with binding of the chemokine to CCR2.
- 15 96. A method of treating a CCR2-mediated disorder in a patient, comprising administering to the patient an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87 which binds to mammalian CCR2 or portion thereof.
- 20 97. A method of inhibiting restenosis in a patient, comprising administering to the patient an effective amount of a humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87 which binds to mammalian CCR2 or portion thereof.
98. A humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87 for use in therapy or diagnosis.

-107-

99. A humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87 for use in treating a CCR2-mediated disease.
100. Use of a humanized immunoglobulin or antigen-binding fragment thereof of any one of Claims 82-87 for the manufacture of a medicament for treating a CCR2-mediated disease.
- 5
101. A humanized immunoglobulin light chain or antigen-binding fragment thereof having binding specificity for CCR2 comprising the amino acid sequence of SEQ ID NO: 107.




FIG. 1




FIG. 2

3/31




FIG. 3




FIG. 4




FIG. 5

6/31




Fig. 6B




Fig. 6A



7/31

1 DVVMTQTPLT LSVTVGHPAS ISCKSSQSLL DSDGKTEFLNW LLQRPGQSPK  
51 RLIYLVSKLD SGVPDRFTGS GSGTDFTLKE SRVEREDLGV YYCWQGTWFP  
101 YTSGGGKLE IK

FIG. 7

8/31

1	EVQLVESGGG	LVQPKGSLKL	SCAASGFSEN	AYAMNWVRQA	PGKGLEWVAR
51	IRTKNNNYAT	YYADSVKDRY	TISRDDSESM	LFLQMNNLKT	EDTAMYYCVT
101	FYGNQVWGTC	TTVTVSS			

FIG. 8

9/31

**Chothia Canonical Classes**

- L1 (16 amino acids) = Class 4  
Key residues: 2(V), 25(SA), 29(L), 33(L), 71(F)
- L2 (7 amino acids) = Class 1  
Key residues: 48(TV), 51(AT), 52(ST), 64(G)
- L3 (9 amino acids) = Class 1  
Key residues: 90(QNH), 95(P)

**Martin Canonical Classes**

- L1 (16 amino acids) = Class 4/16A  
Key residues: 2(V), 4(ML), 23(C), 25(SSP), 26(SN),  
27(Q), 29(LI), 30A(HL), 30B(S),  
30C(NDS), 30D(G), 32(YS), 33(LF),  
34(HEN), 35(W), 51(V), 71(F), 88(C),  
90(Q), 92(TS), 93(H)
- L2 (7 amino acids) = Class 1/7A  
Key residues: 23(C)
- L3 (9 amino acids) = Class 1/9A  
Key residues: 2(IVL), 3(VQLE), 4(ML),  
28(SNDTE), 30(DYLVISNFGHT),  
31(SNTKG), 32(FYNAHSR),  
33(MLVIF), 88(C), 89(QSGFL),  
90(QNH), 91(NFGSRDHTYV),  
92(NYWTSRQHAD),  
93(ENGHTSRAQHAD),  
94(DYTVLHNNIWPS), 95(P),  
96(PLYRIWF), 97(T), 98(F)

FIG. 9

10/31

**Chothia Canonical Classes**

- H1 (5 amino acids) = Class 1  
Key residues: 24(AVG), 26(G), 27(FY)
- H2 (19 amino acids) = Class 4  
Key residues: 54(S), 55(Y), 71(R)

**Martin Canonical Classes**

- H1 (5 amino acids) = Class 1/10A  
Key residues: 2(VIG), 4(LG), 20(LIMV), 22(C),  
24(TAGVS), 26(G), 29(IFLS),  
32(IHYFTNCED), 33(AWGTLV),  
34(TVMW), 35(HENQSYT), 36(W),  
48(IMLV), 51(LIVTSN),  
69(ILFMV), 78(ALVYF), 80(LM),  
90(YF), 92(C), 94(RKGSNH),  
102(YHVISDG).
- H2 (19 amino acids) = Class 7/12B  
Key residues: 47(W), 50(RQ), 51(I), 59(Y), 69(I),  
71(R), 78(LV)

FIG. 10

CITE	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	148
------	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-----

12/31

CJHs	-----a }---	-----a }2-----	-----a }3-----	
Kabat numbers	1 2 3 4 5 6 7 8 9 10 11 12			
119	EVQIVESGGSLVKPKGISIKLSAASGFSFNAYAMN--WVRQAPGKGLIEWVARIRTKNNHYATYYADSVKURYSIRNDSKHTLYIQMHISLKTETAVYYCTTFYGH-----GVWGQCTLTVTVSS			
404 <sup>a</sup> Cl. V <sub>H</sub>	.....K.G...R.....T.SNAW.S	.....G..KS.TDGGT.D..AP..G.F.....KIFT.Y...S.....V...T..DSLPPH	R...Q..L.....	
119R <sub>H</sub> V <sub>H</sub>	EVQIVESGGSLVKPKGISIKLSAASGFSFNAYAMN--WVRQAPGKGLIEWVARIRTKNNHYATYYADSVKURYSIRNDSKHTLYIQMHISLKTETAVYYCTTFYGH-----GVWGQCTLTVTVSS			
119R <sub>H</sub> V <sub>H</sub>	EVQIVESGGSLVKPKGISIKLSAASGFSFNAYAMN--WVRQAPGKGLIEWVARIRTKNNHYATYYADSVKURYSIRNDSKHTLYIQMHISLKTETAVYYCTTFYGH-----GVWGQCTLTVTVSS			
119R <sub>H</sub> V <sub>H</sub>	EVQIVESGGSLVKPKGISIKLSAASGFSFNAYAMN--WVRQAPGKGLIEWVARIRTKNNHYATYYADSVKURYSIRNDSKHTLYIQMHISLKTETAVYYCTTFYGH-----GVWGQCTLTVTVSS			
119R <sub>H</sub> V <sub>H</sub>	EVQIVESGGSLVKPKGISIKLSAASGFSFNAYAMN--WVRQAPGKGLIEWVARIRTKNNHYATYYADSVKURYSIRNDSKHTLYIQMHISLKTETAVYYCTTFYGH-----GVWGQCTLTVTVSS			

Key

- 119 V<sub>H</sub> : Mouse 119 V<sub>H</sub> region.
- 404<sup>a</sup> Cl. V<sub>H</sub> : Chosen human framework acceptor V<sub>H</sub> region sequence with mismatches to the 119 V<sub>H</sub> region highlighted.
- 119R<sub>H</sub> V<sub>H</sub> : CDR grafted 119 V<sub>H</sub> region, with no back mutations.
- 119R<sub>H</sub> V<sub>H</sub> : CDR grafted 119 V<sub>H</sub> region, with back mutations at T28S and N30S.
- 119R<sub>H</sub> V<sub>H</sub> : CDR grafted 119 V<sub>H</sub> region, with back mutations at T28S, N30S, C49A and F67Y.
- 119R<sub>H</sub> V<sub>H</sub> : CDR grafted 119 V<sub>H</sub> region, with back mutations at T28S, N30S, C49A, F67Y and T93V.

FIG. 12

[illegible]

FIG. 13

14/31

## Amino Acid Sequence

Sequence Identical  
Name Residues

109 V <sub>n</sub>	117	EVQLVESGGGLVQPGKSLKLSCAASGFSFNAYAMN--WVRQAPGKGLIEWVARIR'KNNNYATYYADSVKDRYTTISRDDSESMI.FIQMHHLKTEDTAMYYCVTF
MRL-RF24BG	86	.....S.SS.....F.....Q.Y.....I-
V(H)22.1	70	..K.E.....Q.L.SD.....H.E...G.F.....K.SVY.....NA.GJ...TG-
VH1/pBV19B4	66	..K.....G.R.....T.....T.SN.W.S
VH7183(Vh69.1)	66	..K.....G.R.....T.....T.TD.Y.S
VH10-19	65	..K.....K.G.....T.SS.T.S
VHE4-ps1	65	..L.....K.G.....T.SS.T.S
V(H)50.1	65	..K.....G.R.....T.SS.T.S
VJ	65	..K.....G.....T.....T.SD.Y.Y
V1/pBV132	64	..K.....CA.R.....S.....T.TD.Y.
VH283	64	..K.....G.....T.....T.SD.FY.E
V(H)37.1	63	..M.....K.G.....T.....T.SS.T.S
V13	61	..K.....K.G.....T.....T.SS.G.S
V-H 441/V441	59	..K.L.....G.....T.TD.Y.S
6H-5N	59	.....G.....D.SR.W.S
76-1HG/VH7183.9	58	.....K.G.....T.SS.G.S
61-1P	58	.....K.G.....T.SS.S
57-1M/VH7183.12	58	.....K.G.....T.SS.G.H
V(H)55	56	..K.L.....G.N.....T.SS.S
VH7183.13	55	.....K.G.....D.SR.W.S
		.....T.SS.T.S

FIG. 14



Name	ID	Amino Acid Sequence									
MD9 V <sub>k</sub>	100.0	DVVMTQTPLTSLVTVGIIPASISCKSSOSILDS-DGKTEFLNWLLOREGQSPKRIITYINVKLSIDSGVPINRFTSGSGSTUFTLK1SRKVENEDIGVYVCNQGTHTFP-----YTFGSGTPTKLEI-K									
		IQL..S..	T..Q..	Y..Y..	YQ..	R..K..	NR..	E..	N..	FFQ..	
	90.4	L..S..S..P..L..Q..	R..D..	VY..	Y..YQ..	R..K..	NR..	E..	V..M..	G..Q..V..	
	78.8	S..S..P..L..Q..	R..	VY..	N..Y..	FQ..	R..K..	NR..	S..M..	W..Q..V..	
	78.8	S..S..P..L..Q..	R..L..V..		N..Y..	F..	R..QL..	SLR..	S..M..	I..Q..R..	
	78.1	S..S..P..L..Q..	R..G..VY..		D..Y..	FQ..	R..K..	NR..	S..G..	M..W..	
	79.3	S..S..P..L..Q..	R..	VII..	N..Y..	FQ..	R..K..	NR..	S..M..	F..Q..R..	
	77.9	S..S..P..L..Q..	R..	I..	D..Y..	YQ..	R..K..	NR..	S..M..	A..W..	
	77.9	S..S..P..L..Q..	R..T..I..VF..		N..Y..	FQ..T..	R..R..	NR..	S..M..	W..	
	77.9	S..S..P..L..Q..	R..	VF..	N..Y..	FQ..	R..R..	K..NR..	S..M..	W..	
	75.7	S..S..P..L..Q..	R..	VII..	N..Y..	FQ..	R..R..	NR..	S..M..	W..	
	74.8	S..S..P..Q..		II..	Y..Y..Y..	K..P..QI..	E..IINE..	S..M..	SVQL..R	F..P..V..	
	74.8	S..S..P..Q..	R..	II..	Y..Y..Y..	K..P..QI..	E..IINE..	S..M..	SVQL..R	F..P..V..	
	76.1	S..S..P..L..Q..	R..	VY..	N..Y..	FQ..	R..K..	NR..	S..M..	W..	
	75.2	S..S..P..L..Q..	T..	VYI..	I..Y..	FQ..	R..K..	NR..	S..M..	W..	
	73.9	S..S..P..P..E..	R..		G..N..Y..	Y..KA..	QI..TL..YIR..	S..M..	RIEL..	Q..V..	
	74.6	S..S..P..L..Q..	R..RG..VII..		N..Y..	FQ..	R..K..	NR..	S..M..	W..	
	75.2	S..S..P..L..Q..	R..N..VY..		N..Y..	FQ..	R..K..	NR..	S..M..	W..	

FIG. 15

16/31

Name	ID	Surface	Core	Kabat CDR	FR	FR Surface	Core FR	FR Near CDR	V <sub>K</sub>	J Chain	Closest Human Germline Gene	L1 Len	L2 Len	L3 Len	L1 Class	L2 Class	L3 Class
ID9 V <sub>K</sub>	100.0	30	82	32	82	22	60	33	14	100	14	16	7	9	4	1	1
036521	90.4	27	76	28	75	19	56	31	13	90	13	Same	Same	Same	Same	Same	Same
II.66	78.8	25	67	22	69	18	52	30	13	80	12	Same	Same	Same	Same	Same	?
RPMI6410	78.8	25	67	22	69	18	52	30	13	79	12	Same	Same	Same	Same	Same	Same
2M1-1	78.8	25	66	21	68	18	52	30	13	79	12	Same	Same	Same	?	Same	Same
VL clone 54	78.1	25	66	21	68	18	52	30	13	79	12	Same	Same	Same	Same	Same	Same
IIF-21/28	79.3	24	66	21	68	18	52	30	13	78	12	Same	Same	Same	Same	Same	Same
SpA2-08	77.9	24	65	21	68	18	51	30	13	77	12	Same	Same	Same	?	Same	Same
II.30	77.9	24	65	21	68	18	51	30	12	77	12	Same	Same	Same	Same	Same	Same
IIUNVK	77.9	24	65	21	68	18	51	30	12	77	12	Same	Same	Same	Same	Same	Same
O-81	75.7	24	65	21	68	18	51	30	12	77	12	Same	Same	Same	Same	Same	Same
ToP309	74.8	24	64	20	68	18	51	29	12	76	12	Same	Same	10	Same	Same	?
ToP218	74.8	24	64	20	68	18	51	29	12	76	12	Same	Same	10	?	Same	?
SpA3-02	76.1	24	63	20	68	18	51	29	12	76	12	Same	Same	10	?	Same	?
II.37	75.2	24	63	20	68	18	51	29	12	76	12	Same	Same	Same	?	Same	Same
CIUM	73.9	24	63	20	68	18	50	29	12	75	12	Same	Same	Same	Same	Same	Same
VL clone 51	74.6	24	62	20	67	18	50	29	12	75	12	17	Same	Same	3	Same	Same
II.20	75.2	23	62	20	67	18	50	29	12	75	12	Same	Same	Same	?	Same	Same
												Same	Same	Same	?	Same	Same

FIG. 16

[illegible]

**FIG. 17A**

Amino Acid Sequence

Name ID

UB1-24	67.2	.....GR..R.....T.DD...II	.....SG.SW--.9G91G.....G.F.....NAKNS.Y....S.RA....I...A.II---	.....CCCCCCCC	.....CCCCCCCC
029764	64.5	Q..L.O.....G...R.....T.SS...S	..II.....A.SG--SGGS..L.....G.F.....N.KIT.Y....S.RA....V...ARGW.LRGEED	.....CCCCCCCC	.....CCCCCCCC
IW2-105	64.5	.....K.G...R.....T.BNAM.S	.....G..KS.TDGGT.D..AP..G.F.....KIT.Y....S.....V...T.PITFSGVIVIS	.....CCCCCCCC	.....CCCCCCCC
UB1-17	65.0	.....K.R...R.....T.SNAM.S	.....G..KS.TDGGT.D..AP..G.F.....KIT.Y....S.....V...T.PITFSGVIVIS	.....CCCCCCCC	.....CCCCCCCC
VII Clone 41	66.1	.....G...R.....T.SS...S	.....SA.SG--SGGS..L.....G.F.....N.KIT.Y....S.RA....V...ANDISMCDIEGL	.....CCCCCCCC	.....CCCCCCCC
4D4*CL	67.2	.....K.G...R.....T.SNAM.S	.....G..KS.TDGGT.D..AP..G.F.....KIT.Y....S.....V...T.USLPPHVV	.....CCCCCCCC	.....CCCCCCCC
M26	65.0	.....K.G...R.....T.SNAM.S	.....G..KS.TDGGT.D..AP..G.F.....KIT.Y....S.....V...T.USLPPHVV	.....CCCCCCCC	.....CCCCCCCC

FIG. 17B

19/31

Name	ID	All	Surface	Core	Kabat CDR	FR	FR Surface	Core FR	FR Near CDR	Vernier	Vu	J Chain	Closest Human Germ-line Gene	III Size	II2 Size	II3 Size	III Class	II2 Class
1D9 V <sub>H</sub>	100.0	117	29	84	30	87	21	65	30	16	100	17		5	19	6	1	4
030094	67.7	86	19	67	15	72	17	57	26	12	75	13	DP-29-122+	Same	Same	16	Same	Same
N51P8	68.3	86	18	66	15	72	16	57	25	12	75	13	DP-29-122+	Same	Same	15	?	Same
1W2-91	67.5	85	18	65	15	72	16	56	25	12	75	12	DP-29-122+	Same	Same	15	Same	Same
112-46	66.7	84	18	65	15	72	16	56	25	12	75	12	DP-29-122+	Same	Same	15	Same	Same
039158	72.2	83	17	64	15	71	15	56	25	12	74	12	DP-29-122+					
038064	65.6	82	17	64	14	71	15	56	25	11	74	12	V1126Rabbits+					
038062	64.6	82	17	63	14	71	15	56	25	11	73	12	V1126Rabbits+					
32.R9	64.6	82	17	63	14	71	15	56	25	11	72	12	V1126Rabbits+	Same	17	19	Same	3
038062	64.6	82	17	63	14	71	15	56	25	11	72	12	V1126Rabbits+					
034514	69.8	81	17	63	14	70	15	56	25	11	72	12	V1126Rabbits+					
038066	65.3	81	16	63	14	70	15	55	25	11	71	12	V1126Rabbits+					
035365	65.9	81	16	63	14	70	15	55	25	11	71	12	V1126Rabbits+					

FIG. 18A

20/31

Name	ID	All	Surface	Core	Kabat CDR	FR	Surface	Core	FR	Near CDR	Vernier	V <sub>H</sub>	J Chain	Closest Human Germ-line Gene	III Size	II2 Size	II3 Size	III Class	II2 Class
IIb-5	69.2	81	16	63	14	69	15	55	25	11	71	12	12	VII26Rabbitst+	Same	17	16	Same	3
4G12	64.8	81	16	63	14	69	15	55	25	11	71	12	12	VII26Rabbitst+	Same	17	16	Same	3
VII clone 39	66.7	80	16	63	14	69	14	55	25	11	71	12	12	VII26Rabbitst+	Same	17	11	Same	3
040094	62.5	80	16	63	14	69	14	55	25	11	71	12	12	LSG3.1	Same	17	11	Same	3
VII clone 18	63.0	80	16	63	13	69	14	55	25	11	71	12	12	VII26Rabbitst+	Same	17	18	Same	3
UB1-24	67.2	80	16	63	13	69	14	55	25	11	71	12	12	DP-31-V39P+	Same	17	10	Same	3
029764	64.5	80	16	63	13	69	14	55	25	11	71	12	12	VII26Rabbitst+	Same	17	15	Same	3
IV2-105	64.5	80	16	63	13	69	14	55	25	11	71	12	12	LSG3.1	Same	Same	13	Same	?
UB1-17	65.0	80	16	63	13	69	14	55	25	11	71	11	11	LSG3.1	Same	Same	12	Same	?
VII clone 41	66.1	80	16	62	13	69	14	55	25	11	71	11	11	VII26Rabbitst+	Same	17	12	Same	3
4B4*CL	67.2	80	16	62	13	68	14	55	25	11	71	11	11	LSG3.1	Same	Same	8	Same	?
M26	65.0	80	16	62	13	68	14	55	25	11	71	11	11	LSG3.1	Same	Same	12	Same	?

FIG. 18B

Kabat	#	FR or CDR	Mouse ID9 V <sub>K</sub>	Mouse κ-II	Human κ-II	Human Acceptor HF-21/23 (005056)	Surface or Core	ID9 RK <sub>1</sub>	ID9 RK <sub>3</sub>	Comment
1	1	FR1	D	D*	D		S	D	D	
2	2		V	V	I*		C	V	V	
3	3		V	V	V*		S	V	V	
4	4		M	M	M		C	M	M	
5	5		T	T*	T		C	T	T	
6	6		O	O*	O		C	O	O	
7	7		T	T	S	S	S	S	S	
8	8		P	P	P		c	P	P	
9	9		L	L	L		s	L	L	
10	10		T	S	S	S	C	S	S	
11	11		L	L	L*		c	L	L	
12	12		S	P	P	P	c	P	P	
13	13		V	V*	V*		c	V	V	
14	14		T	S	T		c	T	T	
15	15		V	L	P	L	s	L	L	
16	16		G	G	G		c	G	G	
17	17		H	D	E	O	c	O	O	
18	18		P	Q	P		s	P	P	
19	19		A	A	A		c	A	A	
20	20		S	S*	S		c	S	S	
21	21		I	I*	I		c	I	I	
22	22		S	S*	S*		C	S	S	
23	23	FR1	C	C	C		C	C	C	
24	24	CDR1	K	R	R	R	s	K	K	
25	25		S	S*	S*		c	S	S	
26	26		S	S*	S		s	S	S	
27	27		Q	Q	Q		s	Q	Q	
27A	28		S	S	S		s	S	S	
27B	29		L	L	L		c	L	L	
27C	30		L	V	L	V	s	L	L	
27D	31	-1	D	H	H	H	c	D	D	
27E	32		S	S	S		s	S	S	
27F			-		x			-	-	
28	33		D	N	D		s	D	D	
29	34		G	G*	G		c	G	G	
30	35		K	N	N	N	c	K	K	
31	36		T	T	N		c	T	T	
32	37		F	Y*	Y	Y	c	F	F	
33	38		L	L*	L		c	L	L	
34	39	CDR1	N	E	N		c	N	N	
35	40	FR2	W	W	W		C	W	W	
36	41		L	Y	Y	F	C	F	L	Δ1

Fig. 19A

22/31

Kabat	#	FR or CDR	Mouse ID9 V <sub>h</sub>	Mouse κ-II		Human κ-II	Human Acceptor HF-21/23 (005056)	Surface or Core		ID9 RK <sub>1</sub>	ID9 RK <sub>2</sub>	Comment
37	42		L	L		L	O	c		O	L	Δ2
38	43		O	O*		O		c		O	O	
39	44		R	K		K		c		R	R	
40	45		P	P*		P		s		P	P	
41	46		G	G*		G		s		G	G	
42	47		O	O		O		c		O	O	
43	48		S	S*		S		c		S	S	
44	49		P	P*		P		C		P	P	
45	50		K	K		O	R	c		R	R	
46	51		R	L		L		C		R	R	
47	52		L	L*		L		C		L	L	
48	53		I	I*		I		C		I	I	
49	54	FR2	Y	Y		Y		C		Y	Y	
50	55	CDR2	L	K		L		c		L	L	
51	56		V	V		V	K	c		V	V	
52	57		S	S		S		c		S	S	
53	58		K	N		N		c		K	K	
54	59		L	R		R	N	c		L	L	
55	60		D	F		A	R	c		D	D	
56	61	CDR2	S	S*		S		s		S	S	
57	62	FR3	G	G		G		S		G	G	
58	63		V	V		V		C		V	V	
59	64		P	P		P		C		P	P	
60	65		D	D*		D		S		D	D	
61	66		R	R		R		C		R	R	
62	67		F	F*		F		C		F	F	
63	68		T	S		S	S	C		S	S	
64	69		G	G*		G		C		G	G	
65	70		S	S*		S		C		S	S	
66	71		G	G*		G		C		G	G	
67	72		S	S*		S		s		S	S	
68	73		G	G*		G		C		G	G	
69	74		T	T*		T		C		T	T	
70	75		D	D*		D		C		D	D	
71	76		F	F*		F		C		F	F	
72	77		T	T*		T		c		T	T	
73	78		L	L		L		c		L	L	
74	79		K	K		K		c		K	K	
75	80		I	I		I		c		I	I	
76	81		S	S		S		c		S	S	
77	82		R	R*		R		s		R	R	
78	83		V	V		V		c		V	V	
79	84		E	E		E		s		E	E	
80	85		A	A*		A		c		A	A	
81	86		E	E*		E		s		E	E	
82	87		D	D*		D		c		D	D	
83	88		L	L		V	V	c		V	V	
84	89		G	G*		G		c		G	G	
85	90		V	V		V		c		V	V	
86	91		Y	Y*		Y		c		Y	Y	
87	92		Y	Y		Y		C		Y	Y	
88	93	FR3	C	C		C		C		C	C	

FIG. 19B



Kabat	#	FR or CDR	Mouse 1D9 V <sub>K</sub>	Mouse κ-II		Human κ-II	Human Acceptor HF-21/23 (005056)	Surface or Core		1D9 RK <sub>A</sub>	1D9 RK <sub>B</sub>	Comment
39	94	CDR3	W	F		M		c		W	W	
90	95		O	O*		Q	M	c		Q	Q	
91	96		G	G		A		c		G	G	
92	97		T	T		L		c		T	T	
93	98		H	H		Q		c		H	H	
94	99		F	V		x		s		F	F	
95	100		P	P*		P	W	c		P	P	
95A			-	P		R				-	-	
95B			-	-		-				-	-	
95C			-	-		-				-	-	
95D			-	-		-				-	-	
95E			-	-		-				-	-	
95F			-	-		-				-	-	
96	101		Y	Y		x	-	c		Y	Y	
97	102	CDR3	T	T*		T	F	c		T	T	
98	103	FR4	F	F*		F		C		F	F	
99	104		G	G		G		c		G	G	
100	105		G	G		O	O	c		O	G	
101	100		G	G		G		c		G	G	
102	106		T	T		T		c		T	T	
103	107		K	K*		K	R	s		R	R	
104	108		L	L		V		c		L	L	
105	109		E	E		E		s		E	E	
106	110		I	I		I		s		I	I	
106A			-	-		-				-	-	
107	111	FR4	K	K*		K	-	s		K	K	

FIG. 19C

Kabat	#	FR or CDR	Mouse ID9 V <sub>H</sub>	Mouse IIIc		Human III	Human Acceptor 4B4'CL (000490)	Surface Or Core		ID9 RH <sub>A</sub>	ID9 RH <sub>B</sub>	Comment
1	1	FR1	E	E*		E		s		E	E	
2	2		V	V		V		C		V	V	
3	3		Q	K*		Q		s		Q	Q	
4	4		L	L*		L*		C		L	L	
5	5		V	E		V		s		V	V	
6	6		E	E		E		c		E	E	
7	7		S	S		S*		c		S	S	
8	8		G	G		G*		c		G	G	
9	9		G	G		G*		c		G	G	
10	10		G	G*		G		c		G	G	
11	11		L	L		L		S		L	L	
12	12		V	V*		V		c		V	V	
13	13		Q	Q		Q	K	s		K	K	
14	14		P	P		P*		c		P	P	
15	15		K	G		G*	G	s		G	G	
16	16		G	G		G		s		G	G	
17	17		S	S		S*		c		S	S	
18	18		L	M*		L*		c		L	L	
19	19		K	K*		R	R	c		R	R	
20	20		L	L		L		c		L	L	
21	21		S	S		S*		c		S	S	
22	22		C	C		C*		C		C	C	
23	23		A	V		A		c		A	A	
24	24		A	A		A		C		A	A	
25	25		S	S		S*		c		S	S	
26	26		G	G		G		c		G	G	
27	27		F	F		F*		C		F	F	
28	28		S	T*		T	T	C		T	S	Δ1
29	29		F	F*		F		C		F	F	
30	30	FR1	N	S		S	S	S		S	N	Δ2
31	31	CDR1	A	N		S	N	c		A	A	
32	32		Y	Y		Y	A	S		Y	Y	
33	33		A	T		A	W	S		A	A	
34	34		M	M		M		c		M	M	
35	35		N	N		S	S	c		N	N	
35a			-	-		-		c		-	-	
35b		CDR1	-	-		-		c		-	-	

Fig. 20A

Kaba c	#	FR or CDR	Mouse ID9 V <sub>H</sub>	Mouse IIIc		Human III	Human Acceptor 4B4'CL (000490)	Surface Or Core		ID9 RH <sub>A</sub>	ID9 RH <sub>B</sub>	Comment
36	36	FR2	W	W		W*		C		W	W	
37	37		V	V		V*		C		V	V	
38	38		R	R		R*		C		R	R	
39	39		Q	Q		Q*		c		Q	Q	
40	40		A	S		A		c		A	A	
41	41		P	P		P		s		P	P	
42	42		G	E		G*		s		G	G	
43	43		K	K		K		s		K	K	
44	44		G	G		G		c		G	G	
45	45		L	L		L*		C		L	L	
46	46		E	E*		E		C		E	E	
47	47		W	W		W*		C		W	W	
48	48		V	V*		V*		C		V	V	
49	49	FR2	A	A		S	G	C		G	G	
50	50	CDR2	R	E		V		c		R	R	
51	51		I	I		I		c		I	I	
52	52		R	R		S	K	s		R	R	
52a	53		T	L		G	S	s		T	T	
52b	54		K	K		K*		s		K	K	
52c	55		N	S		T	T	c		N	N	
53	56		N	H		D	D			N	N	
54	57		N	N		G	G			N	N	
55	58		Y	Y		G	G			Y	Y	
56	59		A	A		S	T	s		A	A	
57	60		T	T		T		c		T	T	
58	61		Y	H		Y	D	c		Y	Y	
59	62		Y	Y		Y		c		Y	Y	
60	63		A	A		A		c		A	A	
61	64		D	E		D	A	s		D	D	
62	65		S	S		S	P	s		S	S	
63	66		V	V		V*		c		V	V	
64	67		K	K		K		s		K	K	
65	68	CDR2	D	G		G*	G	s		D	D	
66	69	FR3	R	R		R*		C		R	R	
67	70		Y	F		F*	F	C		F	F	
68	71		T	T		T		C		T	T	
69	72		I	I*		I*		C		I	I	
70	73		S	S		S*		S		S	S	
71	74		R	R		R*		C		R	R	
72	75		D	D		D		c		D	D	
73	76		D	D		N		C		D	D	
74	77		S	S		S		s		S	S	
75	78		E	K		K	K	s		K	K	
76	79		S	S		N	N	s		N	N	
77	80		M	S		T	T	c		T	T	
78	81		L	V		L		C		L	L	
79	82		F	Y		Y	Y	c		Y	Y	
80	83		L	L		L*		c		L	L	

FIG. 20B

26/31

Kabat	#	FR or CDR	Mouse ID9 V <sub>B</sub>	Mouse IIIc	Human III	Human Acceptor 4B-4'CL (000490)	Surface Or Core	ID9 RH <sub>A</sub>	ID9 RH <sub>B</sub>	Comment
31	84		O	O*	O		c	O	O	
32	85		M	M	M*		C	M	M	
32a	86		N	N	N		s	N	N	
32b	87		N	N	S	S	s	S	S	
32c	88		L	L	L*		c	L	L	
33	89		K	R	R		s	K	K	
34	90		T	A	A		c	T	T	
35	91		E	E	E		s	E	E	
36	92		D	D	D		C	D	D	
37	93		T	T	T		c	T	T	
38	94		A	G	A*		c	A	A	
39	95		M	I	V	V	c	V	V	
90	96		Y	Y	Y*		c	Y	Y	
91	97		Y	Y	Y*		C	Y	Y	
92	98		C	C*	C*		C	C	C	
93	99		V	T	A	T	C	T	T	
94	100	FR3	T	T	R		C	T	T	
95	101	CDR3	F	G	G	D	c	F	F	
96	102		Y	F	R	S	c	Y	Y	
97	103		G	-	x	L	s	G	G	
98	104		N	-	G	P	c	N	N	
99			-	-	x	P	c	-	-	
100			-	-	S	H	c	-	-	
100 a			-	-	L		C	-	-	
100 b			-	-	S		C	-	-	
100 c			-	-	G			-	-	
100 d			-	-	x			-	-	
100 e			-	-	Y			-	-	
100 f			-	-	Y			-	-	
100 g			-	-	Y			-	-	
100 h			-	-	Y			-	-	
100 i			-	-	H			-	-	
100 j			-	-	Y			-	-	
100 k			-	F	F		C	-	-	
101	105		G	A	D	R	C	G	G	
102	106	CDR3	V	Y	Y		C	V	V	
103	107	FR4	W	W	W*		C	W	W	
104	108		G	G	G*		C	G	G	
105	109		T	Q	O	Q	S	O	O	
106	110		G	G	G*		C	G	G	
107	111		T	T	T*		C	T	T	
108	112		T	L	L	L	C	L	L	
109	113		V	V	V*		C	V	V	
110	114		T	T	T*		C	T	T	
111	115		V	V*	V*			V	V	
112	116		S	S	S*			S	S	
113	117	FR4	S	S	S*			S	S	

FIG. 20C

ATGGACTTCGAGTTAAACATGGTTTTCTTCTTGTTTTATCAAGGTTGTCATTGTGAGGTGCAGCTTGTTGAGTCTGGACCAGGATTCGTCACGCTTA  
 100  
 TACCCTGAGCCCAATTCACCCAAAGAAACAAACAAAAAATAGTCCACACGTAACACTCCAGCTCGAACAACTCAGACCTCTCTTAACCACGTCGCAAT  
 leader ← variable  
 M D F G I. N L V F F V F V F Y Q G V H C E V Q L Y E S G C O L V O P  
 AAGGATCAATGAAACTCTCATGTGACGCTCTGGATTACGCTTCATGCTTCAATGCCATACCCCATGAACTGGTCCGCCAGGCTCCACGAAGGGTTTCGAATGGGT  
 200  
 TCCCACTAATCTTGAGAGTACACGTCGGAGACCTAAGTCCAAAGTTACGATGCGGTACTTGACCCAGGCGGTCCGAGGTCTCTTTCCCAACCTTACCCA  
 TCCAGTAACTTTGAGAGTACACGTCGGAGACCTAAGTCCAAAGTTACGATGCGGTACTTGACCCAGGCGGTCCGAGGTCTCTTTCCCAACCTTACCCA  
 K G S I K L S C A A S G F S F N A Y A M N W V R O A P G K G L E W V  
 TGCCTGGATAAGCAACATAAATAATTAATGCAACATATTATGCGGATTCAGTGAAGACAGATACACCATCTCCACAGATGATTCACAAAGTATGCTC  
 300  
 ACCAGCGTATCTTGATTTTATTATTAAATACGTTGTATAATACGGCTAAGTCACATTCCTGCTATGCTAGAGGTCTCTACTAAGTCTTTCATACGAC  
 A R I R T K N N N Y A T Y Y A O S V K D R Y T I S R D D S E S H L  
 TTTCTGCAATTCACAACTTGAANCTCAGBACACAGCCATGATTACTGCTCACCITTTACGGTAACGTTGTCGGCCACAGGGACCCAGGTCACCG  
 400  
 AAGACGTTTACTTGTTGAACTTTGACTCCTGCTGCTGGTACATATGACACACTGGAAATGCCATTGCCACAGACCCCGTGTCTCCCTGCTCCAGTCGG  
 F L O M N N L K T E D T A H Y Y C V T F Y G N G V W G T C T T V I  
 TCTCCTCAACCAAAACAGCCCATCCCTCTATCCCCCTGGT  
 443  
 ACAGAGTCGGTTTTGTTGTCGGGTAGCAGATAGCCACCA  
 variable ← constant  
 V R S A K T T A P S V Y P L V

FIG. 21

28/31

ATGAAGTTCCTGTTAGGCTGTTGGTCTGATTCGGGAGACATCGGGGATGTTGTGATGACCCAGACTCCACTCCTTTGTGGTACCGTTGGAC  
 TACTTCAGCGACAAATCCGACAAACCAGACCTAAGCCCTCTGTAGCCGCTACACACTACTGGGCTGAGTGAGTGAACACGCAATGGCAACCTG  
 M K L P V R L L V L W I R E T I G D V V M T O T P L T L S V T V C  
 ACCAGCTTCATCTTGAAGTCAAGTCARAGCCCTTAGATAGTGTGGAAGACATTTTGAATTGGTTGTACAGAGGCCAGGCCAGTCTCCAAA  
 TGGGTCGGAGTAGAGAACGTTTCAGTTCAGTTCGGAGAAATCTATCACTACCTTTCTGTAAAACTTAACCAACAATGCTCCGGTCCGGTCAGAGGTTT  
 H P A S I S C K S Q S L L D S D G K T F L N W L L O R P O O S P K  
 CCGCTAATCTATCTGGTGTAAACGGACTCTGAGTCCCTGACAGGTTCACTGGCAGTGGATCAGGACAGATTTACACTGAAATCAGCAGAGTG  
 CCGGATTAGATAGACCAACAGATTGACCTGAGACCTCAGGGAAGTCCCAAGTGAAGTCCCTGCTGCTAAGTGTGACTTTTAGTCTGCTCAG  
 R I I Y L V S K I, O S G V P D R F T G S G S G T D F T L K I S R V  
 GAGGCTGAGGATTTGGGAGTTTATTATTCCTGCAAGGTACACATTTTCCTGATACAGTTCGGAGGGGGACCAAGCTGGAATTAACGGGCTGATGCTG  
 CTCCGACTCCTAAACCCCTCAATAATAACGACCGTCCCATGTGTAAAGGCAIGTGAAGCCCTCCCCCTGGTTCGACCTTTATTGGCCGACTACGAC  
 E A E D L G V Y Y C W Q G T H F P Y T F G G G T K L F I K R A D A  
 CACCACTGTATCCATCTTCCCAACA  
 GTGGTTGACATAGGTAGAGGGTGGT 426  
 A P T V S I F P P

leader ← → variable  
 variable → constant

FIG. 22

29/31




FIG. 23

Snab I

CTACGTAGTGTGATGACCCAGTCTCCACTCTCCCTTGCCCGTTACCCCTGGACAGCCAGCCCTCCATCTCTTGCAGTCAAGTCAGAGCCCTCTTAGATAGTAT  
10  
CATGCAATCATACTGGGTGAGAGGTGAGAGGAAAGGCAATGGGAACCTGTGGGTGGAGGTAGAGAACGTTTCAGTTCAGTCTCGGAGAAATCTATCATA

[Y] V V N T Q S P L S L P V T L G Q P A S I S C K S S C S L L D S D  
GGAAAGACATTTTGGATTGGTTTCAGCAGAGGECAGGTCAGGCGGCTAATCTATCTGGTGTCTAAACIGGACTCTGGAGTCCCTGACAGGT  
20  
CCTTCTGTAAACTTAACCAAGTCGTCGCGGTCCGTCAGAGGTTCCGGBATTAGATAGACCCACAGATTGACCTGAGACCTCAGGGACIGTCCA

G K T F L N W F Q O R P G Q S P R R L I Y L V S K L D S G V P U R  
TCAGCGGCAGTGGATCAGGACAGATTTCACACTGAAATCAGCAGAGTGGAGGTGGAGTTTATTTATTTGCTGGCAAGGTACACATTTTCC  
30  
AGTGGCGTCACTAGTCCCTGCTAAAGTGTGACTTTTATGCTGCTCAGCTCCGACTCCCTACACCTCAATAATATACGAGCGTTCCATGTGTAAAGG

F S G S G S G T D F T L K I S R V E A E D V G V Y Y C W Q G T H F P

Rs:W1

GTACACGTTCCGACAGGGACCCGACTGGAAATAAACGTACGG  
344  
CATGTGCAAGCCTGTCCCTGGGCTGACCTTTATTTTGCATGCC


Y T F G Q G T R L E I K R T

FIG. 24



31/31

### Comparison of Humanized 1D9 vs. m1D9



	hum-1D9	mus-1D9
<b>Equation 1</b>		
<b>Best-fit values</b>		
BOTTOM	23.46	22.40
TOP (Constant)	100.0	100.0
LOGEC50	1.452	1.472
HILLSLOPE	-1.972	-1.627
EC50	28.32	29.68
<b>Std. Error</b>		
BOTTOM	2.656	3.945
LOGEC50	0.04151	0.06251
HILLSLOPE	0.2946	0.3143
<b>95% Confidence Intervals</b>		
BOTTOM	17.18 to 29.74	13.07 to 31.73
LOGEC50	1.354 to 1.550	1.325 to 1.620
HILLSLOPE	-2.668 to -1.275	-2.370 to -0.8835
EC50	22.59 to 35.51	21.12 to 41.71
<b>Goodness of Fit</b>		
Degrees of Freedom	7	7
R squared	0.9931	0.9858
Absolute Sum of Squares	48.60	88.53
Sy.x	2.635	3.556
<b>Data</b>		
Number of X values	10	10
# of Y replicates (mean analyzed)	3	3
Total number of values	10	10
Number of missing values	20	20

Figure 25

1/41

## SEQUENCE LISTING

<110> Millennium Pharmaceuticals, Inc.  
LaRosa, Gregory J.  
Horvath, Christopher  
Newman, Walter  
Jones, S. Tarran  
O'Brien, Siobhan H.  
O'Keefe, Theresa

<120> HUMANIZED ANTI-CCR2 ANTIBODIES AND  
METHODS OF USE THEREFOR

<130> 1855.1052005

<150> 09/497,625

<151> 2000-02-03

<150> 09/359,193

<151> 1999-07-22

<150> 09/121,781

<151> 1998-07-23

<160> 107

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer sequence

<400> 1

tgagacaagc cacaagctga ac

22

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer sequence

<400> 2

tctgtattag tacacacagc cc

22

<210> 3

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

2/41

&lt;223&gt; Primer sequence

&lt;400&gt; 3

atgctgtcca catctcggtc tcgg

24

&lt;210&gt; 4

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer sequence

&lt;400&gt; 4

ttataaacca gccgagactt cctgctc

27

&lt;210&gt; 5

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; CD5 signal peptide leader sequence

&lt;400&gt; 5

Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu Leu Gly

1

5

10

15

Met Leu Val Ala Ser Val Leu Ala

20

&lt;210&gt; 6

&lt;211&gt; 60

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 6

ggggatccag aaaccatgcc catgggggtct ctgcaaccgc tggccacctt gtacctgctg

60

&lt;210&gt; 7

&lt;211&gt; 65

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 7

gccaccttgt acctgctggg gatgctggtc gcttccgtgc tagcgatgct gtccacatct  
cggtc

60

65

&lt;210&gt; 8

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

3/41

&lt;220&gt;

&lt;223&gt; Primer

&lt;400&gt; 8

gacgaccagc atgttgcc

18

&lt;210&gt; 9

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 9

```

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Val Gly
 1           5           10           15
His Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser
      20           25           30
Asp Gly Lys Thr Phe Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
      35           40           45
Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
      50           55           60
Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly
      85           90           95
Thr His Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
      100           105           110

```

&lt;210&gt; 10

&lt;211&gt; 117

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 10

```

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Gly
 1           5           10           15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Asn Ala Tyr
      20           25           30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ala Arg Ile Arg Thr Lys Asn Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
      50           55           60
Ser Val Lys Asp Arg Tyr Thr Ile Ser Arg Asp Asp Ser Glu Ser Met
65           70           75           80
Leu Phe Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr
      85           90           95
Tyr Cys Val Thr Phe Tyr Gly Asn Gly Val Trp Gly Thr Gly Thr Thr
      100           105           110
Val Thr Val Ser Ser
      115

```

&lt;210&gt; 11

&lt;211&gt; 111

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

4/41

```

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
           20           25           30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
           35           40           45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
           50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser
           85           90           95
Thr His Trp Pro Phe Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
           100           105           110

```

```

<210> 12
<211> 112
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Humanized sequence

```

```

<400> 12
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser
           20           25           30
Asp Gly Lys Thr Phe Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
           35           40           45
Pro Arg Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
           50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly
           85           90           95
Thr His Phe Pro Tyr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
           100           105           110

```

```

<210> 13
<211> 112
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Humanized sequence

```

```

<400> 13
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser
           20           25           30
Asp Gly Lys Thr Phe Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
           35           40           45
Pro Arg Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
           50           55           60

```

5/41

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly  
 85 90 95  
 Thr His Phe Pro Tyr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys  
 100 105 110

<210> 14  
 <211> 112  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Humanized sequence

<400> 14  
 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser  
 20 25 30  
 Asp Gly Lys Thr Phe Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly  
 85 90 95  
 Thr His Phe Pro Tyr Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys  
 100 105 110

<210> 15  
 <211> 112  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Humanized sequence

<400> 15  
 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1 5 10 15  
 His Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser  
 20 25 30  
 Asp Gly Lys Thr Phe Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly  
 85 90 95  
 Thr His Phe Pro Tyr Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys  
 100 105 110

<210> 16  
 <211> 119

6/41

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

```

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1              5              10              15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala
      20              25              30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35              40              45
Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala
      50              55              60
Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
      65              70              75              80
Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
      85              90              95
Tyr Cys Thr Thr Asp Ser Leu Pro Pro His Arg Val Trp Gly Gln Gly
      100              105              110
Thr Leu Val Thr Val Ser Ser
      115

```

&lt;210&gt; 17

&lt;211&gt; 117

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized sequence

&lt;400&gt; 17

```

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1              5              10              15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Tyr
      20              25              30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35              40              45
Gly Arg Ile Arg Thr Lys Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
      50              55              60
Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
      65              70              75              80
Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
      85              90              95
Tyr Cys Thr Thr Phe Tyr Gly Asn Gly Val Trp Gly Gln Gly Thr Leu
      100              105              110
Val Thr Val Ser Ser
      115

```

&lt;210&gt; 18

&lt;211&gt; 117

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized sequence

&lt;400&gt; 18

7/41

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Asn Ala Tyr  
 20 25 30  
 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Arg Thr Lys Asn Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp  
 50 55 60  
 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr Phe Tyr Gly Asn Gly Val Trp Gly Gln Gly Thr Leu  
 100 105 110  
 Val Thr Val Ser Ser  
 115

&lt;210&gt; 19

&lt;211&gt; 117

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized sequence

&lt;400&gt; 19

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Asn Ala Tyr  
 20 25 30  
 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Arg Ile Arg Thr Lys Asn Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp  
 50 55 60  
 Ser Val Lys Asp Arg Tyr Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr Phe Tyr Gly Asn Gly Val Trp Gly Gln Gly Thr Leu  
 100 105 110  
 Val Thr Val Ser Ser  
 115

&lt;210&gt; 20

&lt;211&gt; 117

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized sequence

&lt;400&gt; 20

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Asn Ala Tyr  
 20 25 30



8/41

Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Arg Ile Arg Thr Lys Asn Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp  
 50 55 60  
 Ser Val Lys Asp Arg Tyr Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Val Thr Phe Tyr Gly Asn Gly Val Trp Gly Gln Gly Thr Leu  
 100 105 110  
 Val Thr Val Ser Ser  
 115

<210> 21  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 21  
 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Val Gly  
 1 5 10 15  
 His Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser  
 20 25 30  
 Asp Gly Lys Thr Phe Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly  
 85 90 95  
 Thr His Phe Pro  
 100

<210> 22  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 22  
 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser  
 20 25 30  
 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly  
 85 90 95  
 Thr His Phe Pro  
 100

<210> 23  
 <211> 100

9/41

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 23

```

Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
          20           25           30
Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
          35           40           45
Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
          50           55           60
Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Val Gln Gly
          85           90           95
Thr His Phe Pro
          100

```

&lt;210&gt; 24

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(100)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 24

```

Asp Val Val Met Thr Gln Xaa Leu His Ser Leu Ser Val Thr Ile Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
          20           25           30
Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Val Gln Pro
          35           40           45
Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Tyr Ser Gly Val Pro
          50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Xaa Pro Glu Asp Leu Gly Val Tyr Xaa Cys Met Gln Asp
          85           90           95
Thr His Phe Pro
          100

```

&lt;210&gt; 25

&lt;211&gt; 100

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 25

```

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
 1           5           10           15
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
          20           25           30
Asn Gly Asn Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          35           40           45

```

10/41

Pro Lys Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Phe Gln Gly  
 85 90 95  
 Thr His Val Pro  
 100

<210> 26  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 26  
 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly  
 1 5 10 15  
 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser  
 20 25 30  
 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
 35 40 45  
 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Leu Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly  
 85 90 95  
 Ser His Val Pro  
 100

<210> 27  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 27  
 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly  
 1 5 10 15  
 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser  
 20 25 30  
 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
 35 40 45  
 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser  
 85 90 95  
 Thr His Val Pro  
 100

<210> 28  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 28

11/41

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly  
 1 5 10 15  
 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser  
 20 25 30  
 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
 35 40 45  
 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly  
 85 90 95  
 Ser His Val Pro  
 100

<210> 29  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 29  
 Asp Ala Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly  
 1 5 10 15  
 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Glu Asn Ser  
 20 25 30  
 Asn Gly Asn Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
 35 40 45  
 Pro Gln Leu Leu Ile Tyr Arg Val Ser Asn Arg Phe Ser Gly Val Leu  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Leu Gln Val  
 85 90 95  
 Thr His Val Pro  
 100

<210> 30  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 30  
 Asp Val Leu Leu Thr Gln Thr Pro Leu Phe Leu Pro Val Ser Leu Gly  
 1 5 10 15  
 Asp Gln Ala Ser Ile Ser Cys Ser Ser Gln Ser Leu Val His Ser  
 20 25 30  
 Asn Gly Asn Tyr Tyr Leu Glu Trp His Leu Gln Lys Ser Gly Gln Ser  
 35 40 45  
 Leu Gln Leu Leu Ile Tyr Glu Val Ser Lys Arg His Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Pro Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly  
 85 90 95  
 Thr His Leu Pro  
 100

12/41

<210> 31  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 31  
 Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly  
 1 5 10 15  
 Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser  
 20 25 30  
 Ser Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Lys Pro Gly Gln Ser  
 35 40 45  
 Pro Gln Leu Leu Ile Tyr Tyr Ile Ser Asn Leu Ala Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly  
 85 90 95  
 Leu Glu Tyr Pro  
 100

<210> 32  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 32  
 Asp Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly  
 1 5 10 15  
 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys  
 20 25 30  
 Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile  
 65 70 75 80  
 Ser Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu  
 85 90 95  
 Val Glu Tyr Pro  
 100

<210> 33  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 33  
 Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly  
 1 5 10 15  
 Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser  
 20 25 30  
 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
 35 40 45  
 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro  
 50 55 60

13/41

Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn  
 85 90 95  
 Leu Glu Leu Pro  
 100

<210> 34  
 <211> 101  
 <212> PRT  
 <213> Mus musculus

<400> 34  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Gly  
 1 5 10 15  
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Asn Ala Tyr  
 20 25 30  
 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Arg Ile Arg Thr Lys Asn Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp  
 50 55 60  
 Ser Val Lys Asp Arg Tyr Thr Ile Ser Arg Asp Asp Ser Glu Ser Met  
 65 70 75 80  
 Leu Phe Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr  
 85 90 95  
 Tyr Cys Val Thr Phe  
 100

<210> 35  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 35  
 Glu Val Gln Leu Val Glu Val Trp Trp Arg Met Val Gln Pro Lys Gly  
 1 5 10 15  
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr  
 20 25 30  
 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Arg Ile Arg Ser Lys Ser Ser Asn Tyr Ala Thr Tyr Tyr Ala Asp  
 50 55 60  
 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr  
 85 90 95  
 Tyr Cys Val Ile  
 100

<210> 36  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 36  
 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15

14/41

Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr  
                   20                  25                  30  
 Trp Met Ser Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val  
                   35                  40                  45  
 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu  
                   50                  55                  60  
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser  
 65                  70                  75                  80  
 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr  
                   85                  90                  95  
 Tyr Cys Thr Gly  
                   100

<210> 37  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 37  
 Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1                  5                  10                  15  
 Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Thr Asp Tyr  
                   20                  25                  30  
 Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu  
                   35                  40                  45  
 Gly Phe Ile Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu Tyr Ser Ala  
                   50                  55                  60  
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Ser Ile  
 65                  70                  75                  80  
 Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Ser Ala Thr Tyr  
                   85                  90                  95  
 Tyr Cys Ala Arg  
                   100

<210> 38  
 <211> 98  
 <212> PRT  
 <213> Mus musculus

<400> 38  
 Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1                  5                  10                  15  
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
                   20                  25                  30  
 Thr Met Ser Trp Val Arg Gln Ser Pro Glu Lys Arg Leu Glu Trp Val  
                   35                  40                  45  
 Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val  
                   50                  55                  60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr  
 65                  70                  75                  80  
 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys  
                   85                  90                  95  
 Thr Arg

<210> 39  
 <211> 98

15/41

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 39

```

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1           5           10           15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20           25           30
Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
 35           40           45
Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val
 50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65           70           75           80
Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys
 85           90           95
Thr Arg

```

&lt;210&gt; 40

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(98)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 40

```

Glu Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1           5           10           15
Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20           25           30
Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
 35           40           45
Ala Ala Ile Ser Thr Asp Gly Ser Phe Ile Tyr Xaa Pro Asp Thr Val
 50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe
 65           70           75           80
Leu Gln Met Ser Ser Leu Arg Tyr Glu Asp Thr Ala Met Tyr Tyr Cys
 85           90           95
Leu Arg

```

&lt;210&gt; 41

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 41

```

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1           5           10           15
Ser Leu Lys Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Tyr
 20           25           30
Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
 35           40           45

```



16/41

Ala Tyr Ile Ser Asn Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Ser Arg Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 42  
 <211> 101  
 <212> PRT  
 <213> Mus musculus

<400> 42  
 Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ser Ser Gly Phe Thr Phe Thr Asp Tyr  
 20 25 30  
 Tyr Met Asn Trp Val His Arg Pro Pro Gly Lys Pro Leu Glu Trp Leu  
 35 40 45  
 Ala Leu Ile Arg Asn Lys Ala Asn Gly Tyr Ile Thr Glu Tyr Ser Ala  
 50 55 60  
 Ser Met Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Ser Ile  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Thr Leu Ser Thr Glu Asp Ser Ala Thr Tyr  
 85 90 95  
 Tyr Cys Ala Arg Asp  
 100

<210> 43  
 <211> 100  
 <212> PRT  
 <213> Mus musculus

<400> 43  
 Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Phe  
 20 25 30  
 Tyr Met Glu Trp Val Arg Gln Pro Pro Gly Lys Arg Leu Glu Trp Ile  
 35 40 45  
 Ala Ala Ser Arg Asn Lys Ala Asn Asp Tyr Thr Thr Glu Tyr Ser Ala  
 50 55 60  
 Ser Val Lys Gly Arg Phe Ile Val Ser Arg Asp Thr Ser Gln Ser Ile  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ala Leu Arg Ala Glu Asp Thr Ala Ile Tyr  
 85 90 95  
 Tyr Cys Ala Arg  
 100

<210> 44  
 <211> 98  
 <212> PRT  
 <213> Mus musculus

<400> 44

17/41

Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val  
 35 40 45  
 Ala Thr Ile Ser Ser Gly Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr  
 65 70 75 80  
 Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 45  
 <211> 98  
 <212> PRT  
 <213> Mus musculus

<400> 45  
 Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Lys Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Gly Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val  
 35 40 45  
 Ala Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr  
 65 70 75 80  
 Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 46  
 <211> 101  
 <212> PRT  
 <213> Mus musculus

<400> 46  
 Glu Val Lys Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Thr Asp Tyr  
 20 25 30  
 Tyr Met Ser Trp Val Arg Gln Leu Pro Arg Lys Ser Pro Glu Trp Leu  
 35 40 45  
 Ala Leu Ile Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu Tyr Ser Ala  
 50 55 60  
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Asn Ile  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala Glu Ala Ser Ala Thr Tyr  
 85 90 95  
 Tyr Cys Ala Lys Asp  
 100

18/41

<210> 47  
 <211> 98  
 <212> PRT  
 <213> Mus musculus

<400> 47  
 Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile  
 35 40 45  
 Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu  
 50 55 60  
 Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys  
 85 90 95  
 Ala Arg

<210> 48  
 <211> 89  
 <212> PRT  
 <213> Mus musculus

<400> 48  
 Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser  
 1 5 10 15  
 Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Thr Pro  
 20 25 30  
 Asp Lys Arg Leu Glu Leu Val Ala Thr Ile Asn Ser Asn Gly Gly Ser  
 35 40 45  
 Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp  
 50 55 60  
 Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu  
 65 70 75 80  
 Asp Thr Ala Met Tyr Tyr Cys Ala Arg  
 85

<210> 49  
 <211> 89  
 <212> PRT  
 <213> Mus musculus

<400> 49  
 Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser  
 1 5 10 15  
 Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro  
 20 25 30  
 Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr  
 35 40 45  
 Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp  
 50 55 60  
 Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu  
 65 70 75 80

19/41

Asp Thr Ala Met Tyr Tyr Cys Ala Arg  
85

&lt;210&gt; 50

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 50

Gly Leu Val Gln Pro Gly Gly Ser Arg Lys Leu Ser Cys Ala Ala Ser  
1 5 10 15  
Gly Phe Thr Phe Ser Ser Phe Gly Met His Trp Val Arg Gln Ala Pro  
20 25 30  
Glu Lys Gly Leu Glu Trp Val Ala Tyr Ile Ser Ser Gly Ser Ser Thr  
35 40 45  
Ile Tyr Tyr Ala Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp  
50 55 60  
Asn Pro Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu  
65 70 75 80  
Asp Thr Ala Met Tyr Tyr Cys Ala Arg  
85

&lt;210&gt; 51

&lt;211&gt; 88

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 51

Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser  
1 5 10 15  
Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Thr Pro  
20 25 30  
Glu Lys Arg Leu Glu Trp Val Ala Ser Ile Ser Ser Gly Gly Ser Thr  
35 40 45  
Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn  
50 55 60  
Ala Arg Asn Ile Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp  
65 70 75 80  
Thr Ala Met Tyr Tyr Cys Ala Arg  
85

&lt;210&gt; 52

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 52

Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15  
Ser Leu Asn Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr  
20 25 30  
Trp Met Ser Trp Ala Arg Gln Ala Pro Gly Lys Gly Gln Glu Trp Ile  
35 40 45  
Gly Glu Ile Asn Pro Gly Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu  
50 55 60  
Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr  
65 70 75 80

20/41

Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys  
                   85                  90                  95  
 Ala Arg

<210> 53  
 <211> 87  
 <212> PRT  
 <213> Mus musculus

<400> 53  
 Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe  
 1                  5                  10                  15  
 Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys  
                   20                  25                  30  
 Arg Leu Glu Trp Val Ala Tyr Ile Ser Asn Gly Gly Gly Ser Thr Tyr  
                   35                  40                  45  
 Tyr Pro Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala  
                   50                  55                  60  
 Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr  
 65                  70                  75                  80  
 Ala Met Tyr Tyr Cys Ala Arg  
                   85

<210> 54  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 54  
 Asp Ile Gln Leu Thr Gln Ser Pro Leu Thr Leu Ser Val Thr Ile Gly  
 1                  5                  10                  15  
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser  
                   20                  25                  30  
 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser  
                   35                  40                  45  
 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
                   50                  55                  60  
 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65                  70                  75                  80  
 Ser Arg Val Glu Ala Asp Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly  
                   85                  90                  95  
 Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
                   100                  105                  110

<210> 55  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 55  
 Asp Val Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1                  5                  10                  15  
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Asp Gln Ser Leu Val Tyr Ser  
                   20                  25                  30  
 Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln Ser  
                   35                  40                  45

21/41

Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly  
 85 90 95  
 Thr His Trp Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105 110

<210> 56  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 56  
 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser  
 20 25 30  
 Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly  
 85 90 95  
 Thr His Trp Ser Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
 100 105 110

<210> 57  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 57  
 Asp Val Val Val Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Leu Ser Leu Val Asp Ser  
 20 25 30  
 Asp Gly Asn Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Gln Leu Ser Ser Arg Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly  
 85 90 95  
 Thr His Trp Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys  
 100 105 110

<210> 58  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 58

22/41

```

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Gly Leu Val Tyr Ser
          20           25           30
Asp Gly Asp Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
          35           40           45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
          50           55           60
Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
          85           90           95
Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
          100          105          110

```

<210> 59  
 <211> 111  
 <212> PRT  
 <213> Homo sapiens

```

<400> 59
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
          20           25           30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
          35           40           45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
          50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
          85           90           95
Thr His Trp Pro Phe Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
          100          105          110

```

<210> 60  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

```

<400> 60
Ala Glu Glu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Leu Ser
          20           25           30
Asp Gly Asp Thr Tyr Leu Asn Trp Tyr Gln Gln Arg Pro Gly Gln Ser
          35           40           45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
          50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
          85           90           95
Ala His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
          100          105          110

```

23/41

<210> 61  
 <211> 112  
 <212> PRT.  
 <213> Homo sapiens

<400> 61  
 Asp Val Val Leu Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Leu Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Thr Gln Ile Leu Val Phe Ser  
 20 25 30  
 Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Thr Pro Gly His Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Arg Val Ser Asn Arg Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly  
 85 90 95  
 Thr His Trp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys  
 100 105 110

<210> 62  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 62  
 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Phe Ser  
 20 25 30  
 Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Gly  
 85 90 95  
 Ala His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Thr  
 100 105 110

<210> 63  
 <211> 113  
 <212> PRT  
 <213> Homo sapiens

<400> 63  
 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser  
 20 25 30  
 Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Arg Val Ser Asn Arg Asp Ser Gly Val Pro  
 50 55 60



24/41

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Leu Tyr Tyr Cys Met Gln His  
 85 90 95  
 Thr His Trp Ser Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile  
 100 105 110  
 Lys

<210> 64  
 <211> 113  
 <212> PRT  
 <213> Homo sapiens

<400> 64  
 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser  
 20 25 30  
 Asp Gly Lys Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Pro  
 35 40 45  
 Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser  
 85 90 95  
 Val Gln Leu Pro Arg Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile  
 100 105 110  
 Lys

<210> 65  
 <211> 113  
 <212> PRT  
 <213> Homo sapiens

<400> 65  
 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu His Ser  
 20 25 30  
 Asp Gly Lys Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Pro  
 35 40 45  
 Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser  
 85 90 95  
 Ile Gln Leu Pro Arg Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile  
 100 105 110  
 Lys

<210> 66  
 <211> 112

25/41

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 66

```

Ala Glu Glu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1           5           10           15
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser
      20           25           30
Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
      35           40           45
Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro
      50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
      65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
      85           90           95
Thr His Trp Pro Lys Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
      100          105          110

```

&lt;210&gt; 67

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 67

```

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1           5           10           15
Gln Ser Ala Ser Ile Ser Cys Thr Ser Ser Gln Ser Leu Val Tyr Thr
      20           25           30
Asp Gly Lys Ile Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser
      35           40           45
Pro Arg Arg Leu Ile Phe Lys Val Ser Asn Arg Asp Ser Gly Val Pro
      50           55           60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
      65           70           75           80
Ser Arg Val Glu Ala Glu Asp Val Ala Ile Tyr Tyr Cys Met Gln Gly
      85           90           95
Thr His Trp Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
      100          105          110

```

&lt;210&gt; 68

&lt;211&gt; 113

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 68

```

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly
 1           5           10           15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser
      20           25           30
Gly Asp Gly Asn Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Ala Gly Gln
      35           40           45
Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val
      50           55           60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys
      65           70           75           80

```

26/41

Ile Ser Arg Val Gln Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln  
                   85                  90                  95  
 Arg Leu Glu Ile Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile  
                   100                  105                  110  
 Arg

<210> 69  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 69  
 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Leu Gly  
   1                  5                  10                  15  
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Arg Gly Leu Val His Ser  
                   20                  25                  30  
 Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser  
                   35                  40                  45  
 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro  
                   50                  55                  60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Lys Ile  
 65                  70                  75                  80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ser  
                   85                  90                  95  
 Ile His Trp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys  
                   100                  105                  110

<210> 70  
 <211> 112  
 <212> PRT  
 <213> Homo sapiens

<400> 70  
 Asp Ile Val Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
   1                  5                  10                  15  
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Leu Val Tyr Ser  
                   20                  25                  30  
 Asp Gly Asn Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser  
                   35                  40                  45  
 Pro Arg Arg Leu Ile Tyr Lys Val Ser Asn Arg Asp Ser Gly Val Pro  
                   50                  55                  60  
 Asp Ser Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile  
 65                  70                  75                  80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln Gly  
                   85                  90                  95  
 Thr Arg Trp Pro Tyr Thr Phe Gly Glu Gly Thr Lys Leu Glu Ile Lys  
                   100                  105                  110

<210> 71  
 <211> 127  
 <212> PRT  
 <213> Homo sapiens

<400> 71  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
   1                  5                  10                  15

27/41

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Ser  
 20 25 30  
 Thr Met His Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Arg Asn Lys Asp Asn Ser Tyr Ala Thr Ala Tyr Ala Ala  
 50 55 60  
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Glu Asn Thr  
 65 70 75 80  
 Ala Tyr Leu Gln Met Asn Ser Leu Lys Ile Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Arg Gly Ser Ser Met Val Arg Gly Val Asn Gly Tyr Tyr  
 100 105 110  
 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
 115 120 125

<210> 72  
 <211> 126  
 <212> PRT  
 <213> Homo sapiens

<400> 72  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Asp Tyr  
 20 25 30  
 Tyr Met Asp Trp Val Arg Gln Ala Pro Ala Lys Gly Leu Glu Trp Leu  
 35 40 45  
 Ala Arg Thr Arg Asn Lys Ala Asn Ser Tyr Thr Thr Glu Tyr Ala Ala  
 50 55 60  
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Met Asn Ser  
 65 70 75 80  
 Leu Ser Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Ile Tyr  
 85 90 95  
 Tyr Cys Val Cys Val Arg Thr Asp Cys Ser Ser Thr Arg Cys His Gly  
 100 105 110  
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
 115 120 125

<210> 73  
 <211> 126  
 <212> PRT  
 <213> Homo sapiens

<400> 73  
 Glu Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp His  
 20 25 30  
 Tyr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Arg Asn Lys Ala Asn Ser Tyr Thr Thr Glu Tyr Ala Ala  
 50 55 60  
 Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Glu Asn Ser  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95

28/41

Tyr Cys Ala Arg Ala Glu Thr Asp Arg Gly Tyr Tyr Tyr Tyr His Gly  
 100 105 110  
 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
 115 120 125

<210> 74  
 <211> 126  
 <212> PRT  
 <213> Homo sapiens

<400> 74  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Lys Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Ser  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Arg Ser Lys Ala Asn Ser Tyr Ala Thr Ala Tyr Ala Ala  
 50 55 60  
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Arg Trp Val Leu Gly Arg Gly Ser Glu Gly His Tyr Tyr  
 100 105 110  
 Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120 125

<210> 75  
 <211> 115  
 <212> PRT  
 <213> Homo sapiens

<400> 75  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Ser  
 20 25 30  
 Ala Ile His Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly His Ile Arg Asn Lys Pro Asn Asn Tyr Ala Thr Ala Tyr Ala Ala  
 50 55 60  
 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Ala Ser Gly Ser Tyr Leu Lys Gly Gln Gly Thr Leu Val Thr  
 100 105 110  
 Val Ser Ser  
 115

<210> 76  
 <211> 125  
 <212> PRT  
 <213> Homo sapiens

<400> 76

29/41

```

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20           25           30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Lys Asp Ile Glu Asp Thr Ala Met Phe Pro Tyr Tyr Tyr Gly Met
      100          105          110
Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
      115          120          125

```

<210> 77  
 <211> 128  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> VARIANT  
 <222> (1)...(128)  
 <223> Xaa = Any Amino Acid

```

<400> 77
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1           5           10           15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20           25           30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35           40           45
Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
      50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65           70           75           80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85           90           95
Ala Lys Asp Arg Arg Asn Tyr Asp Phe Trp Ser Gly Xaa Tyr Tyr Tyr
      100          105          110
Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
      115          120          125

```

<210> 78  
 <211> 128  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> VARIANT  
 <222> (1)...(128)  
 <223> Xaa = Any Amino Acid

<400> 78

30/41

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1				5					10					15	
Ser	Gln	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Asn	Asn	Tyr
			20					25					30		
Val	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ser	Val	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
	50					55				60					
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Phe
65					70				75						80
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
			85					90					95		
Ala	Lys	Gly	Arg	Val	Cys	Ser	Gly	Gly	Arg	Cys	Tyr	Pro	Xaa	Tyr	Tyr
			100				105					110			
Tyr	Tyr	Met	Asp	Val	Trp	Gly	Lys	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser
		115					120					125			

&lt;210&gt; 79

&lt;211&gt; 128

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(128)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 79

Glu	Val	Gln	Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1				5					10					15	
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
			20					25					30		
Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			
Ser	Ala	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	Val
	50					55				60					
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
65					70				75						80
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
			85					90					95		
Ala	Lys	Asp	Arg	Arg	Asn	Tyr	Asp	Phe	Trp	Ser	Gly	Xaa	Tyr	Tyr	Tyr
			100				105					110			
Tyr	Gly	Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser
		115					120					125			

&lt;210&gt; 80

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 80

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
1				5					10					15	
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
			20					25					30		
Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
		35					40					45			

31/41

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Lys Asp Lys Gly Ser Gly Trp Tyr Trp Gly Gln Gly Thr Leu Val  
 100 105 110  
 Thr Val Ser Ser  
 115

<210> 81  
 <211> 124  
 <212> PRT  
 <213> Homo sapiens

<400> 81  
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Gly Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Asn Asp Tyr Gly Ser Gly Arg Tyr Phe Thr Tyr Ala Thr Asp  
 100 105 110  
 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
 115 120

<210> 82  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens

<400> 82  
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Ile Ser Gly Ser Gly Tyr Thr Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Lys Lys Pro Gly Asp Tyr Gly Ser Gly Ser Tyr Tyr Leu Asp Tyr  
 100 105 110  
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120



32/41

<210> 83  
 <211> 117  
 <212> PRT  
 <213> Homo sapiens

<400> 83  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr  
 20 25 30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Thr Thr Tyr Tyr Gly Asp Gly Met Asp Val Trp Gly Lys Gly Thr Met  
 100 105 110  
 Ile Thr Val Ser Ser  
 115

<210> 84  
 <211> 125  
 <212> PRT  
 <213> Homo sapiens

<400> 84  
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr  
 20 25 30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Lys Ala Val Val Arg Gly Val Ile Ser Tyr Tyr Tyr Tyr Gly Met  
 100 105 110  
 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
 115 120 125

<210> 85  
 <211> 120  
 <212> PRT  
 <213> Homo sapiens

<400> 85  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

33/41

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
           35                          40                          45  
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
           50                          55                          60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
   65                          70                          75                          80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
                           85                          90                          95  
 Ala Lys Ser Pro Asp Val Val Val Pro Ala Ala Asp Tyr Trp Gly Gln  
                           100                          105                          110  
 Gly Thr Leu Val Thr Val Ser Ser  
           115                          120

<210> 86  
 <211> 128  
 <212> PRT  
 <213> Homo sapiens

<400> 86  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
   1                          5                          10                          15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Thr Gly  
           20                          25                          30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
           35                          40                          45  
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Ile Asp Tyr Ala Glu  
   50                          55                          60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
  65                          70                          75                          80  
 Leu Phe Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
                           85                          90                          95  
 Tyr Cys Thr Thr Ala Leu Thr Arg Tyr Phe Phe Asp Ser Ser Gly Tyr  
                           100                          105                          110  
 Pro His Phe Asp His Trp Gly His Gly Thr Leu Val Thr Val Ser Ser  
           115                          120                          125

<210> 87  
 <211> 127  
 <212> PRT  
 <213> Homo sapiens

<400> 87  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
   1                          5                          10                          15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
           20                          25                          30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
           35                          40                          45  
 Ser Ala Ile Ser Gly Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
   50                          55                          60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
  65                          70                          75                          80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
                           85                          90                          95  
 Ala Lys Asp Arg Thr Pro Arg Asn Ile Val Ala Thr Lys Gly Met Asp  
                           100                          105                          110

34/41

Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser  
 115 120 125

<210> 88  
 <211> 119  
 <212> PRT  
 <213> Homo sapiens

<400> 88  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr  
 20 25 30  
 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys  
 85 90 95  
 Ala Thr His Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly  
 100 105 110  
 Thr Thr Val Thr Val Ser Ser  
 115

<210> 89  
 <211> 124  
 <212> PRT  
 <213> Homo sapiens

<400> 89  
 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met Ser Trp Val His Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ala Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Arg Gly Trp Gly Leu Arg Gly Glu Glu Gly Asp Tyr Tyr Met Asp  
 100 105 110  
 Val Trp Gly Lys Gly Thr Met Val Thr Val Ser Ser  
 115 120

<210> 90  
 <211> 124  
 <212> PRT  
 <213> Homo sapiens

<400> 90  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15

35/41

Ser. Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
 50 55 60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr Pro His Thr Phe Gly Gly Val Ile Val Ile Ser Asp  
 100 105 110  
 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 91  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens

<400> 91  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Arg Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
 50 55 60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr Ala Ser Tyr Ser Tyr Gly Arg Gly Cys Phe Asp Tyr  
 100 105 110  
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 92  
 <211> 121  
 <212> PRT  
 <213> Homo sapiens

<400> 92  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

36/41

Ala Lys Asp Ile Ser Trp Gly Asp Leu Glu Gly Leu Asp Tyr Trp Gly  
 100 105 110  
 Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 93  
 <211> 119  
 <212> PRT  
 <213> Homo sapiens

<400> 93  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
 50 55 60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr Asp Ser Leu Pro Pro His Arg Val Trp Gly Gln Gly  
 100 105 110  
 Thr Leu Val Thr Val Ser Ser  
 115

<210> 94  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens

<400> 94  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala  
 20 25 30  
 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala  
 50 55 60  
 Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr Ser Ile Pro Gly Ile Ala Val Ala Gly Thr Asp Tyr  
 100 105 110  
 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
 115 120

<210> 95  
 <211> 426  
 <212> DNA  
 <213> Mus musculus

<400> 95

37/41

atgaagttgc	ctggttaggt	gttggtgctc	tggattcggg	agacaatcgg	cgatgttggtg	60
atgacccaga	ctccactcac	tttgtcgggt	accgttggac	accagcctc	catctcttgc	120
aagtcaagtc	agagcctctt	agatagtgat	ggaaagacat	ttttgaattg	gttggttacag	180
aggccaggcc	agtctccaaa	gcgcctaate	tatctggtgt	ctaaactgga	ctctggagtc	240
cctgacaggt	tcaactggcag	tggatcaggg	acagatttca	caactgaaaat	cagcagagtg	300
gaggctgagg	atttgggagt	ttattattgc	tggcaaggta	cacattttcc	gtacacgttc	360
ggagggggga	ccaagctgga	aataaaacgg	gctgatgctg	caccaactgt	atccatcttc	420
ccacca						426

&lt;210&gt; 96

&lt;211&gt; 443

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;400&gt; 96

atggacttcg	ggtaaactt	ggttttcttt	gttggttttt	atcaagggtg	gcattgtgag	60
gtgcagcttg	ttgagtctgg	aggaggattg	gtgcagccta	aagggtcatt	gaaactctca	120
tgtgcagcct	ctggattcag	cttcaatgcc	tacgccatga	actgggtccg	ccaggctcca	180
ggaaagggtt	tggaatgggt	tgctcgcata	agaactaaaa	ataataatta	tgcaacatat	240
tatgccgatt	cagtgaaga	cagatacacc	atctccagag	atgattcaga	aagtatgctc	300
tttctgcaaa	tgaacaactt	gaaaactgag	gacacagcca	tgtattactg	tgtgaccttt	360
tacggtaacg	gtgtctgggg	cacagggacc	acggtcaccg	tctctcagc	caaaacaaca	420
gccccatccg	tctatcccct	ggt				443

&lt;210&gt; 97

&lt;211&gt; 357

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized heavy chain

&lt;400&gt; 97

gagggtgcaat	tggttgagtc	tggaggagga	ttggtgaagc	ctgggggggtc	attgagactc	60
tcatgtgcag	cctctggatt	cactttcagt	gcctacgccca	tgaactgggt	ccgccagggt	120
ccaggaaagg	gtttggaatg	ggttggccgc	ataagaacta	aaaataataa	ttatgcaaca	180
tattatgccg	attcagtga	agacagattc	accatctcca	gagatgattc	aaaaaacacg	240
ctctatctgc	aaatgaacag	cttgaaaact	gaggacacag	ccgtgtatta	ctgtaccacc	300
ttttacggta	acggtgtctg	gggccagggg	accctggtca	ccgtcagctc	agccaaa	357

&lt;210&gt; 98

&lt;211&gt; 344

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Humanized light chain

&lt;400&gt; 98

ctacgtagt	atgacccagt	ctccactctc	cttgcccgtt	acccttggac	agccagcctc	60
catctcttgc	aagtcaagtc	agagcctctt	agatagtgat	ggaaagacat	ttttgaattg	120
gtttcagcag	aggccaggcc	agtctccaa	gcgcctaate	tatctggtgt	ctaaactgga	180
ctctggagtc	cctgacaggt	tcagcggcag	tggatcaggg	acagatttca	caactgaaaat	240
cagcagagtg	gaggctgagg	atgttggagt	ttattattgc	tggcaaggta	cacattttcc	300
gtacacgttc	ggacaaggga	cccgaactgga	aataaaacgt	acgg		344

&lt;210&gt; 99

38/41

<211> 443  
 <212> DNA  
 <213> Mus musculus

<400> 99  
 accaggggat agacggatgg ggctgttggt ttggctgagg agacggtgac cgtgggtccct 60  
 gtgccccaga caccgttacc gtaaaagggt acacagtaat acatggctgt gtcctcagtt 120  
 ttcaagttgt tcatattgcag aaagagcata ctttctgaat catctctgga gatgggtgat 180  
 ctgtctttca ctgaatcggc ataatatggt gcataattat tatttttagt tcttatgcga 240  
 gcaaccatt ccaaaccctt tcttgagacc tggcggaccc agttcatggc gtaggcattg 300  
 aagctgaatc cagaggctgc acatgagagt ttcaatgacc ctttaggctg caccaatcct 360  
 cctccagact caacaagctg cacctcaca tgacacact gataaaaaac aacaaagaaa 420  
 accaagtta accgaagtc cat 443

<210> 100  
 <211> 148  
 <212> PRT  
 <213> Mus musculus

<400> 100  
 Met Asp Phe Gly Leu Asn Leu Val Phe Phe Val Val Phe Tyr Gln Gly  
 1 5 10 15  
 Val His Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln  
 20 25 30  
 Pro Lys Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe  
 35 40 45  
 Asn Ala Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu  
 50 55 60  
 Glu Trp Val Ala Arg Ile Arg Thr Lys Asn Asn Asn Tyr Ala Thr Tyr  
 65 70 75 80  
 Tyr Ala Asp Ser Val Lys Asp Arg Tyr Thr Ile Ser Arg Asp Asp Ser  
 85 90 95  
 Glu Ser Met Leu Phe Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr  
 100 105 110  
 Ala Met Tyr Tyr Cys Val Thr Phe Tyr Gly Asn Gly Val Trp Gly Thr  
 115 120 125  
 Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val  
 130 135 140  
 Tyr Pro Leu Val  
 145

<210> 101  
 <211> 426  
 <212> DNA  
 <213> Mus musculus

<400> 101  
 tgggtgggaag atggatacag ttgggtgcagc atcagcccgt tttatttcca gcttggtccc 60  
 ccctccgaac gtgtacggaa aatgtgtacc ttgccagcaa taataaactc ccaaactctc 120  
 agcctccact ctgctgattt tcagtgtgaa atctgtccct gatccactgc cagtgaacct 180  
 gtcagggact ccagagtcca gtttagacac cagatagatt aggcgcttg gagactggcc 240  
 tggcctctgt aacaaccaat tcaaaaatgt ctttccatca ctatctaaga ggctctgact 300  
 tgacttgcaa gagatggagg ctgggtgtcc aacggtaacc gacaaagtga gtggagtctg 360  
 ggtcatcaca acatcgccga ttgtctccc aatccagagc accaacagcc taacaggcaa 420  
 cttcat 426

<210> 102

39/41

<211> 142  
 <212> PRT  
 <213> Mus musculus

<400> 102  
 Met Lys Leu Pro Val Arg Leu Leu Val Leu Trp Ile Arg Glu Thr Ile  
 1 5 10 15  
 Gly Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Val  
 20 25 30  
 Gly His Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp  
 35 40 45  
 Ser Asp Gly Lys Thr Phe Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln  
 50 55 60  
 Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val  
 65 70 75 80  
 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys  
 85 90 95  
 Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln  
 100 105 110  
 Gly Thr His Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile  
 115 120 125  
 Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro  
 130 135 140

<210> 103  
 <211> 357  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Humanized heavy chain

<400> 103  
 tttggctgag ctgacgggtga ccagggtccc ctggccccag acaccggttac cgtaaaaggt 60  
 ggtacagtaa tacacggctg tgcctcagc tttcaagctg ttcatttgca gatagagcgt 120  
 gttttttgaa tcatctctgg agatgggtgaa tctgtctttc actgaatcgg cataatatgt 180  
 tgcataatta ttatttttag ttcttatgcg gccaaaccat tccaaaccct ttcttgagc 240  
 ctggcggacc cagttcatgg cgtaggcact gaaagtgaat ccagaggctg cacatgagag 300  
 tctcaatgac cccccaggct tcaccaatcc tctccagac tcaaccaatt gcacctc 357

<210> 104  
 <211> 119  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Humanized heavy chain

<400> 104  
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Tyr  
 20 25 30  
 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Gly Arg Ile Arg Thr Lys Asn Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp  
 50 55 60



40/41

Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr  
 65 70 75 80  
 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr  
 85 90 95  
 Tyr Cys Thr Thr Phe Tyr Gly Asn Gly Val Trp Gly Gln Gly Thr Leu  
 100 105 110  
 Val Thr Val Ser Ser Ala Lys  
 115

<210> 105  
 <211> 344  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Humanized light chain

<400> 105  
 ccgtacgtttt tatttccagt cgggtccctt gtccgaacgt gtacggaaaa tgtgtacctt 60  
 gccagcaata ataaactcca acatcctcag cctccactct gctgattttc agtgtgaaat 120  
 ctgtccctga tccactgccg ctgaacctgt cagggactcc agagtccagt ttagacacca 180  
 gatagattag gcgccttgga gactggcctg gcctctgctg aaaccaattc aaaaatgtct 240  
 ttccatcact atctaagagg ctctgacttg acttgcaaga gatggaggct ggctgtccaa 300  
 gggtaacggg caaggagagt ggagactggg tcatacctac gtag 344

<210> 106  
 <211> 114  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Humanized light chain

<400> 106  
 Tyr Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser  
 20 25 30  
 Asp Gly Lys Thr Phe Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly  
 85 90 95  
 Thr His Phe Pro Tyr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys  
 100 105 110  
 Arg Thr

<210> 107  
 <211> 112  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Humanized sequence

41/41

<400> 107  
 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly  
 1 5 10 15  
 His Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser  
 20 25 30  
 Asp Gly Lys Thr Phe Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser  
 35 40 45  
 Pro Arg Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly  
 85 90 95  
 Thr His Phe Pro Tyr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys  
 100 105 110

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/03537

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/62 C07K16/28 C07K16/46 C12N15/13 C12N15/63  
 C12N5/10 A61K39/395 A61P9/10 A61P19/02 A61P31/18  
 A61P37/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, CHEM ABS Data, WPI Data, PAJ, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 31949 A (PHARMACIA & UPJOHN SA ET AL.) 4 September 1997 (1997-09-04) page 8, line 27 -page 11, line 8 discussion claims	1-101
Y	WO 91 09967 A (CELLTECH LTD.) 11 July 1991 (1991-07-11) the whole document	1-101
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

13 June 2001

Date of mailing of the international search report

28/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

# INTERNATIONAL SEARCH REPORT

In International Application No

FCI/US 01/03537

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. FRADE ET AL.: "The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection." JOURNAL OF CLINICAL INVESTIGATION, vol. 100, no. 3, 1 August 1997 (1997-08-01), pages 497-502, XP002099012 New York, NY, USA the whole document	1-101
A	I. SANZ ET AL.: "VH sequence of a human anti-Sm autoantibody. Evidence that autoantibodies can be unmutated copies of germline genes." THE JOURNAL OF IMMUNOLOGY, vol. 142, no. 3, 1 February 1989 (1989-02-01), pages 883-887, XP002168811 Baltimore, MD, USA cited in the application abstract figure 3	14,21,82
A	P. CHASTAGNER ET AL.: "Cloning of a gene encoding a lupus-associated human autoantibody Vk region using the polymerase chain reaction and degenerate primers." GENE, vol. 101, no. 2, 30 May 1991 (1991-05-30), pages 305-306, XP002168812 Amsterdam, NL cited in the application abstract figure 1	13,16,82
A	C. CHOTHIA ET AL.: "Conformations of immunoglobulin hypervariable regions." NATURE, vol. 342, 21 December 1989 (1989-12-21), pages 877-883, XP002030586 London, GB cited in the application the whole document	1-17,28, 61-67, 82-91, 98,99
P,X	WO 00 05265 A (LEUKOSITE, INC.) 3 February 2000 (2000-02-03) page 17, line 23 -page 20, line 33 examples claims	1-101

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In tional Application No

101/US 01/03537

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9731949 A	04-09-1997	AU 724037 B AU 2110497 A EP 0914345 A JP 2000510685 T US 6084075 A	07-09-2000 16-09-1997 12-05-1999 22-08-2000 04-07-2000
WO 9109967 A	11-07-1991	AT 129017 T AT 124459 T AT 159299 T AU 664801 B AU 6461294 A AU 646009 B AU 6974091 A AU 649645 B AU 7033091 A AU 631481 B AU 7048691 A BG 60462 B BR 9007197 A CA 2037607 A CA 2046904 A CA 2050479 A,C DE 69020544 D DE 69020544 T DE 69022982 D DE 69022982 T DE 69031591 D DE 69031591 T DK 460167 T DK 460171 T DK 460178 T EP 0460167 A EP 0460171 A EP 0460178 A EP 0620276 A EP 0626390 A ES 2079638 T ES 2074701 T ES 2112270 T FI 990875 A WO 9109966 A WO 9109968 A GB 2246781 A,B GB 2246570 A,B GB 2268744 A,B GB 2268745 A,B GR 3017734 T GR 3025781 T HU 58372 A HU 215383 B HU 60786 A HU 58824 A,B	15-10-1995 15-07-1995 15-11-1997 30-11-1995 22-12-1994 03-02-1994 24-07-1991 02-06-1994 24-07-1991 26-11-1992 24-07-1991 28-04-1995 28-01-1992 07-09-1992 22-06-1991 22-06-1991 03-08-1995 18-01-1996 16-11-1995 28-03-1996 20-11-1997 12-03-1998 20-11-1995 28-08-1995 22-12-1997 11-12-1991 11-12-1991 11-12-1991 19-10-1994 30-11-1994 16-01-1996 16-09-1995 01-04-1998 19-04-1999 11-07-1991 11-07-1991 12-02-1992 05-02-1992 19-01-1994 19-01-1994 31-01-1996 31-03-1998 28-02-1992 28-03-2000 28-10-1992 30-03-1992
WO 0005265 A	03-02-2000	AU 5220899 A EP 1098908 A	14-02-2000 16-05-2001

**THIS PAGE BLANK (USPTO)**